

VEITH[®] SYMPOSIUM

Connecting The **Vascular** Community

41st Anniversary

Tuesday - Saturday, November 18-22, 2014

VEITH
VASCULAR ENDOVASCULAR ISSUES TECHNIQUES HORIZONS

Symposium Chairman
Frank J. Veith, MD

Symposium Co-Chairmen
Enrico Ascher, MD
Kenneth Ouriel, MD, MBA
Daniel G. Clair, MD

Sponsored by

 **Cleveland Clinic**


Hilton

www.VEITHsymposium.org

ACKNOWLEDGMENTS

The Cleveland Clinic Foundation Center for Continuing Education and VEITHsymposium acknowledge educational grants in support of this activity from:

Abbott Vascular

Aptus Endosystems, Inc.

Bard Peripheral Vascular, Inc.

Bayer HealthCare

Baylis Medical

Bolton Medical

Boston Scientific Corporation

BTG

Cardiatis

Cook Medical

Cordis Corporation

Covidien

Endologix, Inc.

Gore & Associates

Hansen Medical, Inc.

Lombard Medical Technologies, Inc.

Medtronic

Organogenesis, Inc.

Penumbra, Inc.

Proteon Therapeutics, Inc.

Shockwave Medical, Inc.

Simbionix

St. Jude Medical Inc.

TriVascular

Vascutek, a Terumo Company



SYMPOSIUM CHAIRMAN
 Frank J. Veith, MD

SYMPOSIUM CO-CHAIRMAN
 Enrico Ascher, MD
 Kenneth Ouriel, MD, MBA
 Daniel G. Clair, MD

SYMPOSIUM MANAGING DIRECTOR
 Jacqueline M. Simpson, BBA

SYMPOSIUM ASSOCIATE DIRECTOR
 Steven J. Feld, MSW

CENTER FOR CONTINUING MEDICAL EDUCATION
 William D. Carey, MD
 Steven M. Kawczak, PhD

ADVISORY COMMITTEE
 Ali F. AbuRahma, MD
 Keith D. Calligaro, MD
 Nicholas J.W. Cheshire, MD
 Timur P. Sarac, MD

SCIENTIFIC COMMITTEE
 Ali F. AbuRahma, MD
 Mark A. Adelman, MD
 Jean-Pierre Becquemin, MD
 Giancarlo Biamino, MD, PhD
 Keith D. Calligaro, MD
 Nicholas J.W. Cheshire, MD
 Jacob Cynamon, MD
 Hans-Henning Eckstein, MD, PhD
 Peter Gloviczki, MD
 Roger M. Greenhalgh, MD
 Krassi Ivancev, MD, PhD
 Michael R. Jaff, DO
 Mario Lachat, MD
 Christos D. Liapis, MD
 Evan C. Lipsitz, MD
 Frans L. Moll, MD, PhD
 Samuel R. Money, MD, MBA
 Christoph A. Nienaber, MD, PhD
 Juan C. Parodi, MD
 Vicente Riambau, MD, PhD
 Jean-Baptiste Ricco, MD, PhD
 Plinio Rossi, MD
 Timur P. Sarac, MD
 Dierk Scheinert, MD
 Carlo Setacci, MD
 Eric L. G. Verhoeven, MD, PhD
 Thomas W. Wakefield, MD
 Wayne W. Zhang, MD

CONTENTS

Acknowledgments.....	Inside Front Cover
General Information	7
Accreditation	9
Faculty Disclosure	9
Social Events	10
Hotel and Travel.....	10
Special Non-CME Activities.....	11
Program Outline At A Glance.....	12
Agenda	13–110
Faculty Listing	111–119
Registration	121–122
Save the Date.....	Inside Back Cover



19th European Vascular Course
March 8 - 10, 2015
Maastricht, The Netherlands

Special VEITHsymposium offer:
20% off registration fee
Mail us at info@vascular-course.com

Over 100 invited lectures
Interactive case discussions
Hands-on training sessions
Arterial, Venous and Access
Master Classes & textbooks
www.vascular-course.com

Learning by training



Complex Vascular Malformations and Vascular Tumors: Current Controversies and Therapies

COURSE LEADERS

Krassi Ivancev, MD, PhD
Wayne F. Yakes, MD

Endovascular Treatment of Venous Disease

COURSE LEADERS

Jose I. Almeida, MD, RVT, RPVI
Lowell S. Kabnick, MD, RPhS
Thomas W. Wakefield, MD

Hemodialysis Access

COURSE LEADERS

Larry A. Scher, MD
Anton N. Sidawy, MD, MPH

Multidisciplinary Acute Stroke Management

COURSE LEADER

Allan L. Brook, MD

WOUNDS

COURSE LEADER

Dieter O. Mayer, MD

ASSOCIATE FACULTY PODIUM/POSTER PRESENTATIONS

JUDGES

Ali F. AbuRahma, MD
Ali Amin, MD, RVT
Enrico Ascher, MD
Piergiorgio Cao, MD
Nicholas J.W. Cheshire, MD
Alan Dardik, MD, PhD
Peter Gloviczki, MD
Krassi Ivancev, MD, PhD
Christos D. Liapis, MD
Frans L. Moll, MD, PhD
Kenneth Ouriel, MD, MBA
Calogero Presti, MD
Dieter Raithel, MD, PhD
Vicente Riambau, MD, PhD
Timur P. Sarac, MD
Carlo Setacci, MD
Matt M. Thompson, MD
Ramesh K. Tripathi, MD
Eric L.G. Verhoeven, MD, PhD



CONTROVERSIES

CHALLENGES

CONSENSUS

VASCULAR & ENDOVASCULAR

Controversies Update

www.cxsymposium.com

REGISTER NOW

28 APRIL–1 MAY 2015

TUESDAY–FRIDAY

OLYMPIA GRAND, LONDON, UNITED KINGDOM

EDUCATION

INNOVATION

EVIDENCE



Download the CX App
www.bibamedical.com/apps



To join the conversation search
[@cxsymposium](https://twitter.com/cxsymposium)



Follow CX Symposium
on Facebook

NEEDS ASSESSMENT

Vascular disease in all of its manifestations is a leading cause of death and disability affecting a large percentage of Americans over the age of 50. There is a critical need for physicians who diagnose, treat and manage patients with vascular disease to receive continuing medical education in this area. The latest pharmacologic, radiologic, surgical and endovascular techniques and technologies will be presented, along with discussions of when these treatments are justified and indicated and when they are not. Updates on clinical trials and opportunities for dialogue with experts in the field provide insight along with the latest data on the results of the various treatment modalities.

There is an enormous gap between actual practice and the current state of knowledge. This gap is filled imperfectly with material in books and published articles. These sources are also often negatively influenced by the biases of authors, reviewers and editors. VEITHsymposium attempts to fill this gap more perfectly and more currently by enlisting speakers with up-to-date information and data, and also those on both sides of controversial issues. In this way, the audience gets a current view of the state-of-the-art in vascular disease management as of the date of the meeting. All important topics are covered at the meeting and for further reference in the web based library, a long-term permanent resource.

In addition, by having numerous short (5-6 minutes) talks followed by panel discussions and capturing the entire meeting on the web based library, the meeting will provide an electronic reference source to help vascular specialists in their practice decisions throughout the year. It will also provide the most up-to-date unbiased information possible to help with these decisions.

FOCUS

The VEITHsymposium provides Vascular Surgeons and other Vascular Specialists with a five-day conference on the most current information about new developments in clinical practice and relevant research. Beginning Tuesday, the symposium offers over 900 fast-paced presentations on what is new and important in the treatment of vascular disease. Important updates and reevaluations, as well as the latest significant advances, changing concepts in diagnosis and management, pressing controversies and new techniques, agents and diagnostic modalities will be presented. Video case presentations will also be included.

OBJECTIVES

Upon completion of the VEITHsymposium, the participants will, after learning about a wide array of topics, be able to:

- Explain the practical implications of clinical trial data on new technologies and techniques for endovascular repair of abdominal aortic aneurysm and thoracic aortic disease
- Summarize the impact of data on therapeutic advances for stroke and carotid disease management
- Compare the safety, efficacy, and therapeutic indications of pharmacologic agents to the management of vascular disease
- Assess data on the latest state-of-the-art for the treatment of superficial femoral and tibial artery disease and describe potential implications for clinical care
- Summarize recent data on treatment advances for venous disease and explain their clinical implications
- Provide new information about the latest developments in hemodialysis access and vascular malformations and tumors
- Explain the clinical implications of new developments in wound care

GENERAL INFORMATION

TARGET AUDIENCE

Vascular Surgeons, Interventional Radiologists, Interventional Cardiologists, Vascular Medicine Specialists and all others interested in the management of vascular disease.

TRANSLATION LANGUAGES

Translation from English to Spanish, Portuguese and Chinese will be provided in selected sessions on selected days.

ASSOCIATE FACULTY PODIUM/POSTER PRESENTATIONS

Please visit our web site (www.veithsymposium.org) for details and instructions.

GENERAL SESSIONS

General Sessions will be held in the Grand Ballroom East, Grand Ballroom West, and in the Trianon Ballroom on the 3rd floor on Tuesday, Wednesday, Thursday, Friday and Saturday.

Saturday Component Sessions will be held as follows:

Complex Vascular Malformations And Vascular Tumors: Current Controversies And Therapies

Location: Trianon Ballroom, 3rd floor

Endovascular Treatment Of Venous Disease

Location: Grand Ballroom East, 3rd floor

Hemodialysis Access

Location: Grand Ballroom West, 3rd floor

WOUNDS

Location: Gramercy Suites East and West, 2nd floor

Multidisciplinary Acute Stroke Management will be held on **Thursday, November 20, 2014** in the Murray Hill Suites East and West on the 2nd floor.

VIDEO SESSION FEATURING COMPLICATIONS AND UNUSUAL CASES

Tuesday, November 18, 2014 - 5:30 P.M. - 7:45 P.M.

Location: Gramercy Suites East and West, 2nd floor

There are some European interventionalists who are cutting edge leaders in new and better endovascular techniques and dealing with unusual complications. Some of these individuals will be included in this Tuesday evening program featuring challenging recorded live cases in these two important areas.

This program will be led by Dr. Plinio Rossi and will start at 5:30 P.M. and go until approximately 7:45 P.M., with ample time for audience discussion and questions. This program will provide a state-of-the-art update on exciting new treatment techniques. Cocktails and heavy hors d'oeuvres will be provided throughout the evening, courtesy of Cook Medical. (This is a non-CME activity.)

WEDNESDAY EVENING LINC PROGRAM WITH RECORDED LIVE CASES

Location: Trianon Ballroom, 3rd Floor

Time and agenda to be announced. Please visit www.veithsymposium.org for updates. (This is a non-CME activity.)

GENERAL INFORMATION

ACCREDITATION STATEMENT

The Cleveland Clinic Foundation Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Cleveland Clinic Foundation Center for Continuing Education designates this live activity for a maximum of 48.25 *AMA PRA Category 1 Credits*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Participants claiming CME credit from this activity may submit the credit hours to the American Osteopathic Association for Category 2 credit.

ABS MAINTENANCE OF CERTIFICATION

VEITHsymposium provides Category 1 CME and self-assessment credits toward Part 2 of the ABS MOC Program.

CME CERTIFICATES AND COURSE EVALUATION FORMS

CME certificates will be available online at www.veithsymposium.org. An e-mail will be sent to all registered attendees after the meeting with a unique password and instructions on how to obtain the certificate and complete a brief, optional course evaluation. Please note that the e-mail will be sent to the e-mail address that was used to register the attendee.

FACULTY DISCLOSURE

The Cleveland Clinic Foundation Center for Continuing Education has implemented a policy to comply with the current Accreditation Council for Continuing Medical Education Standards for Commercial Support requiring resolution of all faculty conflicts of interest. Faculty declaring a relevant commercial interest will be identified in the activity syllabus.

ADA STATEMENT

The Cleveland Clinic Foundation Center for Continuing Education complies with the legal requirements of the Americans with Disability Act. If any participant of the VEITHsymposium requires special assistance, please send written request at least one month prior to the activity to admin@veithsymposium.org, or by fax to (845) 368-2324.

ONLINE ACCESS TO ABSTRACTS

Presentation slides will be used as abstracts and will be available on the program page of the VEITHsymposium web site at www.veithsymposium.org after the meeting. Abstracts will be available on the web site for one full year.

ONLINE CONFERENCE LIBRARY

The entire program with all the talks, all the slides, all the videos - fully synchronized - and all the panels, will be available in an Online Conference Library, which can be obtained at a nominal cost. For more information on how to obtain the VEITHsymposium Online Library, please visit www.veithondemand.com or call 800-987-9314, ext. 300.

GENERAL INFORMATION

SOCIAL EVENTS

THE NEW YORK HILTON-MIDTOWN THEATER, TOUR, AND TRANSPORTATION DESK AT VEITH Symposium

Hilton Theater, Tour, and Transportation Desk Services

Our theater, tour, and transportation desk staff can assist you with many services including theater tickets, sightseeing tours, transportation to and from local airports, and more.

Broadway/Theater Entertainment Tickets

Our staff can assist with tickets to hard to get theater, sports, and entertainment, even up until a few hours before performance time. For guaranteed availability it's best to book ahead, so call or email with the show you are interested in and we can make arrangements for you ahead of time.

Sightseeing

Choose from popular double decker bus tours, Statue of Liberty, Empire State Building, harbor cruises, helicopter tours, Woodbury Commons Shopping and more. Prefer to explore museums? We can pre-arrange museum passes for MOMA, Metropolitan Museum of Art, or Museum of Natural History. Call or email us for a complete listing of available tours or to pre book.

Airport Transfers

Shuttle service and private car transfers are available between all area airports and the hotel. Shuttle service departs from the hotel once per hour and is the most economical way to travel to the airport; a private transfer can be arranged for any time and for any number of people.

To make a reservation for any items listed above please contact nicole@continentalguestservices.com or phone at 212-944-8910 x535.

HOTEL AND TRAVEL

A block of rooms has been reserved at the conference rate of \$392 plus taxes per night. This rate is available until the block is filled or until October 17, 2014. *Please request the VEITH rate when reserving your accommodations.*

New York Hilton-Midtown (Symposium Site)

1335 Avenue of the Americas
New York, NY 10019
(212) 586-7000 or
1-800-HILTONS (toll free U.S. only)

American Express Business Travel at

The Cleveland Clinic Foundation

9500 Euclid Avenue, P83
Cleveland, OH 44195
Phone: (800) 955-6111 (U.S. toll free)
(216) 444-2564 (U.S. and International)
Fax: (216) 444-2500
E-mail: Diane.M.Geneva@aexp.com

SPECIAL NON-CME ACCREDITED ACTIVITIES AT VEITHsymposium

VIDEO SESSION FEATURING COMPLICATIONS AND UNUSUAL CASES

Tuesday, November 18, 2014 | 5:30 P.M. – 7:45 P.M.

Gramercy Suites East and West, 2nd Floor

Beer, wine, soft drinks and heavy hors d'oeuvres will be served throughout the evening, courtesy of Cook Medical.

*Moderators: Plinio Rossi, MD
Carlo Setacci, MD
Frank J. Veith, MD*

- 5:45 – 5:55** Endovascular Aneurysm Repair: Managing Extreme Iliac Tortuosity
Andrew Holden, MBCHB
- 5:55 – 5:58** Discussion
- 5:58 – 6:08** Tips And Tricks In Crossing Iliac Venous Occlusions
Gerard J. O'Sullivan, MD
- 6:08 – 6:11** Discussion
- 6:12 – 6:22** Decision-Making And Techniques On Hypogastric Artery Revascularization With EVAR
Dittmar Boeckler, MD
- 6:22 – 6:25** Discussion
- 6:25 – 6:35** How To Deal With Vascular Visceral Ischemia
Fabrizio Fanelli, MD
- 6:35 – 6:38** Discussion
- 6:38 – 6:48** Ultrasound Guided Complex CLI Intervention: How Far Is The Future
Marco G. Manzi, MD
- 6:48 – 6:51** Discussion
- 6:51 – 7:01** Endovascular Treatment Of SFA Occlusions After Previous Surgery Of The Groin
Andrej Schmidt, MD
- 7:01 – 7:04** Discussion
- 7:04 – 7:14** Carbon Dioxide Guided Angioplasty: Better Than Sliced Bread?
Konstantinos Katsanos, MSc, MD, PhD
- 7:14 – 7:17** Discussion
- 7:17 – 7:30** Treatment Of A Type IV Thoracoabdominal Aneurysm With Open, Hybrid And Endovascular (Cardiatis Multilayer Stent) Procedures Over 8 Years
Luigi Inglese, MD
- 7:30 – 7:45** General Discussion And Comments From The Moderators
- 7:45** **Adjourn**

WEDNESDAY EVENING LINC PROGRAM WITH RECORDED LIVE CASES

Location: Trianon Ballroom West, 3rd Floor

Wednesday, November 19, 2014 – 5:45 P.M. – 7:45 P.M.

Time and agenda to be announced. Please visit www.veithsymposium.org for updates. (This is a non-CME activity.)

*Chairmen: Dierk Scheinert, MD
Andrej Schmidt, MD
Yvonne Bausback, MD*

PROGRAM OUTLINE AT A GLANCE

TUESDAY PROGRAMS

Program A: (Sessions 1-8)

6:49 A.M. – 5:55 P.M.

Valve And Aortic Diseases And Their Treatment; Carotid Disease And Its Treatment

Location: Grand Ballroom East, 3rd Floor

Program B: (Sessions 9-16)

6:45 A.M. – 6:08 P.M.

Lower Extremity Disease And Its Treatment

Location: Trianon Ballroom, 3rd Floor

Program C: (Sessions 17-24)

6:40 A.M. – 6:10 P.M.

Natural History, Medical Treatment, Renal Denervation, New DES, CCSVI, Complications, Endoleaks And Important Issues

Location: Grand Ballroom West, 3rd Floor

WEDNESDAY PROGRAMS

Program D: (Sessions 25-33)

6:45 A.M. – 6:08 P.M.

New Technologies, TAAAs, CHIMPS, Parallel Grafts, F/B EVAR, Military Topics, Multilayer Stent, Robotics And Guidance Systems, Laparoscopy And Ruptured Aneurysms

Location: Grand Ballroom East, 3rd Floor

Program E: (Sessions 34-41)

6:45 A.M. – 6:00 P.M.

Lower Extremity Ischemia, Popliteal Aneurysms, Aortic And Graft Infection, Vascular Disease And Medical Treatment, Technology Updates, Imaging, Thoracic Outlet, New Concepts And More On Renal Denervation

Location: Grand Ballroom West, 3rd Floor

Program F: (Sessions 42-43)

7:00 A.M. – 12:00 P.M.

New Developments In Management Options For Pulmonary Embolism

Location: Trianon Ballroom, 3rd Floor

Program F: (Sessions 44-47)

1:00 P.M. – 5:00 P.M.

Large Vein Occlusive Disease And Its Treatment

Location: Trianon Ballroom, 3rd Floor

THURSDAY PROGRAMS

Program G: (Sessions 48-55)

6:45 A.M. – 5:57 P.M.

New Developments In Treatment Of AAAs, EVAR, Aortic Branch Lesions, Laparoscopy; Natural History, Office Practice, Issues, New Techniques, More On Multilayer Stents, Open Surgery, Aortic Coarctation, Hypogastric And Visceral Arteries

Location: Grand Ballroom East, 3rd Floor

Program H: (Sessions 56-63)

6:45 A.M. – 5:30 P.M.

New And Updated Endograft Devices And Associated Technological Advances For The Aorta And Its Branches In The Abdomen, Chest And Lower Extremities; Improved Prosthetic Grafts; Endostaples

Location: Grand Ballroom West, 3rd Floor

Program I: (Sessions 64-71)

6:49 A.M. – 5:30 P.M.

Advances And New Information In Venous Disease And Its Treatment

Location: Trianon Ballroom, 3rd Floor

Program J: (Sessions 72-73)

8:00 A.M. – 5:30 P.M.

Multidisciplinary Acute Stroke Management

Location: Murray Hill Suites East and West, 2nd Floor

FRIDAY PROGRAMS

Program K: (Sessions 74-81)

6:45 A.M. – 5:45 P.M.

New Techniques And Technology; Carotid; Thoracic And Abdominal Aneurysm Disease; Carotid And Supra-Aortic Trunks; CAS vs. CEA – Bright Future For CAS; Late Breaking Information; Updates, More New Techniques And Ruptured AAA Topics

Location: Grand Ballroom East, 3rd Floor

Program L: (Sessions 82-89)

6:45 A.M. – 5:47 P.M.

New Information, Updates, New Technology And Concepts Regarding The Abdominal And Thoracic Aorta, Carotid And Lower Extremity Disease And Miscellaneous Topics

Location: Grand Ballroom West, 3rd Floor

Program M: (Sessions 90-96)

6:49 A.M. – 5:10 P.M.

More Advances And New Or Updated Information In Venous Disease And Its Treatment

Location: Trianon Ballroom, 3rd Floor

SATURDAY PROGRAMS

Program N: (Sessions 97-103)

8:00 A.M. – 5:15 P.M.

Endovascular Treatment Of Venous Disease

Location: Grand Ballroom East, 3rd Floor

Program O: (Sessions 104-108)

8:00 A.M. – 4:50 P.M.

Hemodialysis Access

Location: Grand Ballroom West, 3rd Floor

Program P: (Sessions 109-113)

7:55 A.M. – 3:05 P.M.

Complex Vascular Malformations And Vascular Tumors

Location: Trianon Ballroom, 3rd Floor

Program Q: (Sessions 114-118)

8:30 A.M. – 3:40 P.M.

Wound Care Organization, Updates, New Techniques, Debates, Science (WOUNDS)

Location: Gramercy Suites East and West, 2nd Floor

TUESDAY, NOVEMBER 18, 2014

6:00 A.M. General Registration – Rhinelander Gallery, 2nd Floor
6:00 A.M. Faculty Registration – Morgan Suite, 2nd Floor
6:15 A.M. Continental Breakfast – 2nd Floor Promenade

CONCURRENT TUESDAY PROGRAMS

PROGRAM A: SESSIONS 1-8

Valve And Aortic Disease And Their Treatment, Carotid Disease And Its Treatment

6:49 A.M. – 5:55 P.M.

Grand Ballroom East, 3rd Floor

PROGRAM B: SESSIONS 9-16

Lower Extremity Disease And Its Treatment

6:45 A.M. – 6:08 P.M.

Trianon Ballroom, 3rd Floor

PROGRAM C: SESSIONS 17-24

Natural History, Medical Treatment, CCSVI, Renal Denervation, Complications, Endoleaks And Important Issues

6:40 A.M. – 6:10 P.M.

Grand Ballroom West, 3rd Floor

PROGRAM A (SESSIONS 1-8)

VALVULAR AND AORTIC DISEASE, CAROTID DISEASE AND THEIR TREATMENT

Grand Ballroom East, 3rd Floor

6:49 – 6:53 Opening Remarks

Frank J. Veith, MD

SESSION 1 (Grand Ballroom East, 3rd Floor)

PROGRESS IN TRANSCATHETER HEART VALVES AND NEW APPROACHES TO ASCENDING AORTIC DISEASE

Moderators: Edward B. Diethrich, MD

Ali Khoynzhad, MD, PhD

6:53 – 6:58

Cerebral Protection Techniques And Devices For Use In Transcatheter Aortic Valve Replacement (TAVR) And TEVAR: The Embrella And Claret Medical Sentinal Devices And Others: How Well Do They Work

Jeffrey P. Carpenter, MD

6:59 – 7:04

Status Of Left Atrial Appendage Occlusive Devices In 2014

Ted Feldman, MD

7:05 – 7:10

Trans-Carotid Access For TAVR: Value, Technique And Limitations

Erno Ramsey-Semmelweis, MD, PhD

7:11 – 7:16

Status Of Transcatheter Mitral Valve Repair: Where Is It Heading

Ted Feldman, MD

7:17 – 7:22

Role And Value Of TAVR Today And In The Future

Mathew Williams, MD

- 7:23 – 7:28** New Simplified Concept For Constructing Branched Endografts From Standardized Components: How It Can Be Used For TAAAs, Arch Lesions And Hypogastric Revascularization
Patrick W. Kelly, MD
- 7:29 – 7:34** Endovascular Approaches To The Ascending Aorta For Repair With A Branched Endograft: Techniques And When Is It Feasible And For What Lesions
Tilo Koelbel, MD, PhD
- 7:35 – 7:40** Innovative Approaches And Future Horizons To Ascending Aortic Pathologies: What Can Be Done And What Problems Remain
Ralf R. Kolvenbach, MD
- 7:41 – 7:46** Tips, Tricks And Results With Endograft Repair Of Ascending Aortic Lesions
Grayson H. Wheatley, MD
Edward B. Diethrich, MD
- 7:47 – 7:52** Hemodynamic And Anatomical Challenges To Overcome With Endovascular Grafts In The Ascending Aorta
Robert J. Hinchliffe, MD
- 7:53 – 7:58** Experience With Ascending Aortic Endografts Using An FDA IDE Approved Device: What Has Been Done, What Lesions Can Be Treated And What Challenges Remain
Ali Khoynezhad, MD, PhD
- 7:59 – 8:05** Panel Discussion

SESSION 2 (Grand Ballroom, East 3rd Floor)

NEW DEVELOPMENTS IN THE TREATMENT OF AORTIC ARCH LESIONS AND DISSECTIONS

Moderators: *Timothy A.M. Chuter, DM*
Hazim J. Safi, MD

- 8:06 – 8:11** For Arch Lesions In Situ Fenestration Is Still Viable: New Techniques Will Facilitate This Approach
Björn Sonesson, MD, PhD
- 8:12 – 8:17** Results Of Branched Endografts For Repair Of Aortic Arch Lesions: Based On A Chinese Multicenter Study
Qingsheng Lu, MD
Zaiping Jing, MD
- 8:18 – 8:23** Mid-Term Outcomes Of A Simplified Method Of Arch Aneurysm Treatment Using A Precurved Fenestrated Aortic Endograft: Technique And Results
Yoshihiko Yokoi, MD

MEGA DEBATE

- 8:24 – 8:29** **DEBATE:** Total Endovascular Aortic Arch Repair Is Feasible And Will Be The Best Method: Technique And Early Results
Stephan Haulon, MD
- 8:30 – 8:35** **DEBATE:** Hybrid (Open And Endo) Repair Is The Best Treatment For Aortic Arch Lesions: Tips And Tricks
Germano Melissano, MD
- 8:36 – 8:41** **DEBATE:** Value And Limitations Of Chimney Grafts To Treat Arch Lesions: When Are They Best: Based On An 11-Year Experience
Nicola Mangialardi, MD

- 8:42 – 8:47** **DEBATE:** Total Endovascular Arch Replacement With Sandwich Grafts And TEVAR Is Often The Simplest And Best Treatment For Arch Lesions
Armando C. Lobato, MD, PhD
- 8:48 – 8:53** **DEBATE:** Open Repair Is Still The Best Treatment For Most Arch Lesions
Joseph S. Coselli, MD
- 8:54 – 8:59** Total Endovascular Arch Repair For Arch Aneurysms And Dissections: Comparison Of Bolton Double Branch Endograft vs. Hybrid Debranching With TEVAR
Toru Kuratani, MD, PhD
- 9:00 – 9:05** A New Classification System For Type B Aortic Dissection (TBAD): It Will Help Predict The Probability Of Visceral Malperfusion And Reverse Aortic Remodeling After TEVAR
Ali Khoynezhad, MD, PhD
- 9:06 – 9:13** Panel Discussion

SESSION 3 (Grand Ballroom East, 3rd Floor)

TYPE B AORTIC DISSECTIONS (TBADs) AND THEIR TREATMENT

Moderators: *Richard P. Cambria, MD*
Juan C. Parodi, MD

- 9:13 – 9:18** New MR Imaging Techniques (4D) To Measure Vascular Hemodynamics And Biomechanics: How Can They Help In Treating Patients With TBADs
Rachel Clough, MD, PhD
- 9:19 – 9:24** Tips And Tricks For Avoiding Pitfalls In The TEVAR Treatment Of TBADs: Based On Experience In More Than 1800 Patients
Wei Guo Fu, MD

FOUR-WAY DEBATE

- 9:25 – 9:30** **DEBATE:** All “Uncomplicated” TBADs Should Be Treated Early By TEVAR Since All Are Or Will Become Complicated: INSTEAD XL And IRAD Prove It And We Don’t Need Further Trials
Christoph A. Nienaber, MD, PhD
- 9:31 – 9:36** **DEBATE:** Why We Still Need A Randomized Controlled Trial (RCT) Of Intensive Medical Therapy vs. Early TEVAR For Uncomplicated TBAD
Frank A. Lederle, MD
- 9:37 – 9:42** **DEBATE:** Medical Therapy And Close Observation Is Best For Uncomplicated TBAD: When Complications Arise, Most Patients Are Best Treated With Open Operation: Long-Term Results (>20 Years) Justify It
Hazim J. Safi, MD
Anthony L. Estrera, MD
Ali Azizzadeh, MD
- 9:43 – 9:48** **DEBATE:** With Patients Having Uncomplicated TBAD Medical Treatment With Delayed (2-3 Months) TEVAR Is The Best Treatment: It Will Lessen Complications Including Retrograde Type A Dissections
Matt M. Thompson, MD
- 9:49 – 9:54** Current Single Center Results Of Medically Treated TBAD Patients
Mark Conrad, MD, MMSc
Richard P. Cambria, MD

- 9:55 –10:00 Why We Need A New Classification System For Patients With TBAD: What Is It
Christoph A. Nienaber, MD, PhD
Michael D. Dake, MD
- 10:01 –10:10 Panel Discussion
- 10:10 –10:30 Break – Visit Exhibits And Pavilions (2nd and 3rd Floors)

SESSION 4 (Grand Ballroom East, 3rd Floor)

NEW DEVELOPMENTS IN TEVAR AND THE MANAGEMENT OF TBAD PATIENTS

Moderators: *Christoph A. Nienaber, MD, PhD*
Michael D. Dake, MD

- 10:30 –10:35 Management Of Distal Re-entry Tears After TEVAR For TBAD: When Is It Necessary And How To Do It
Qingsheng Lu, MD
Zaiping Jing, MD
- 10:36 –10:41 In Patients With Acute TBADs When Is TEVAR Closure Of Proximal Entry Tears Sufficient And When Is Adjunctive Treatment Necessary: What Adjunctive Procedures Can Be Used
Jean-Marc Alsac, MD, PhD
- 10:42 –10:47 Endovascular Options To Obliterate The Patent False Lumen When Coverage Of The Primary Tear Does Not Do So: New Data On Safety And Efficacy Of These Options
Peter J. Mossop, MBBS
- 10:48 –10:53 Is The Petticoat Technique (Proximal Covered Stent And Distal Bare Stent) Effective In Treating Acute And Chronic TBADs: 3-Year Results Of The STABLE I And II Trials: Are Long-Term Outcomes Better
Joseph V. Lombardi, MD
- 10:54 –10:59 **DEBATE:** Value And Limitations Of Using Fenestrated And Branched Endografts (F/B EVAR) To Treat Chronic TBADs With Infradiaphragmatic AAAs: It Is The Way To Go
Eric L.G. Verhoeven, MD, PhD
Piotr M. Kasprzak, MD
- 11:00 –11:05 **DEBATE:** What Is Wrong With TEVAR To Treat Chronic TBADs
Nicholas J.W. Cheshire, MD
Richard G.J. Gibbs, FRCS
- 11:06 –11:11 When After An Acute TBAD Does The Dissection Flap Become Fixed: Based On Dynamic (4D) CTA And MRA
Alan B. Lumsden, MD
- 11:12 –11:17 Objective Assessment Of Current Endografts For TEVAR: Which Grafts For Which Lesion And Which Anatomy: It Makes A Difference
Ludovic Canaud, MD, PhD
- 11:18 – 11:25 Panel Discussion

Moderators: *Kim J. Hodgson, MD*
Jan S. Brunkwall, MD, PhD

- 11:25 – 11:30 Pathophysiological Mechanism For False Lumen Enlargement To Form An Aneurysm After A TBAD: What Can Be Done To Prevent It
Ramon Berguer, MD, PhD
- 11:31 – 11:36 Late Remodeling In Stented And Unstented Aortic Segments After TEVAR For Complex TBADs
Mark F. Conrad, MD
Richard P. Cambria, MD

- 11:37 – 11:42** Intensive Follow-up With CTA Imaging Surveillance Is Needed For TEVAR To Be Successful Treatment Of TBAD Patients
Götz M. Richter, MD, PhD
- 11:43 – 11:48** Long-Term (20-Year) Results Of Open Repair Of Chronic TBADs With Aneurysm Formation Are Good: It Should Be The Gold Standard Of Care
Hazim J. Safi, MD
- 11:49 – 11:54** Branched Endografts For Treating Chronic TBAD With Aneurysm Formation: Advantages And Limitations
Marcelo Ferreira, MD
- 11:55 – 12:00** Panel Discussion
- 12:00 – 1:00** Lunch Break – 2nd Floor Promenade
Visit Exhibits And Pavilions (2nd and 3rd Floors)

SESSION 5 (Grand Ballroom East, 3rd Floor)

IN HONOR OF JAMES A. DEWEESE, MD: NEW DEVELOPMENTS IN THE MANAGEMENT OF PATIENTS WITH CAROTID DISEASE (SEE ALSO SESSIONS 6, 76-78, 86 AND 87)

*Moderators: Wesley S. Moore, MD
Frank J. Veith, MD*

- 1:00 – 1:05** Tips And Tricks To Make CAS Safer: Lessons Learned After More Than 3000 Procedures
Klaus D. Mathias, MD
- 1:06 – 1:11** CAS Recanalization For Total ICA Occlusions: Long-Term Clinical And Image Follow-up: When Are The Procedures Worthwhile: A New Horizon
Paul H.L. Kao, MD
- 1:12 – 1:17** Diagnosis And Prophylactic Treatment Of Vulnerable Plaques: Can Their Vulnerability Be Decreased By Stenting
Gregg W. Stone, MD
- 1:18 – 1:23** What Is The Current Evidence For Decreasing The Incidence Of Strokes On Medical Treatment Alone: Don't Believe The NY Times – Statins Are Safe And Should Be Used More Widely
Richard Bulbulia, MA, MD
- 1:24 – 1:29** What Constitutes Best Medical Treatment (BMRx) Currently In Asymptomatic Carotid Stenosis: What Happens To Carotid Plaques On BMRx
J. David Spence, MD
- 1:30 – 1:35** Long-Term Results Of SAMMPRIS Trial In Patients With Intracranial Stenoses: What Does It Tell Us About The Feasibility And Value Of BMRx
*Colin P. Derdeyn, MD
Marc I. Chimowitz, MBChB*
- 1:36 – 1:41** Increased Cardiovascular Mortality In Patients With Asymptomatic Carotid Stenosis Who Are Not On Statins: What Should Optimal Medical Therapy Be And Can It Decrease Plaque Size And Danger
*Andrew N. Nicolaides, MS
Stavros Kakkos, MD, PhD
George Geroulakos, MD, PhD*
- 1:42 – 1:48** Panel Discussion

*Moderators: Daniel G. Clair, MD
Jean-Pierre Becquemin, MD*

- 1:48 – 1:53** Update On The ACT I Trial: A RCT Comparing CAS vs. CEA In Patients With Asymptomatic High-Grade Carotid Stenosis
Jon S. Matsumura, MD
- 1:54 – 1:59** **DEBATE:** Medical Treatment Is Best For Patients With High-Grade Asymptomatic Carotid Stenosis (Asx CS)
Anne L. Abbott, MD, PhD
- 2:00 – 2:05** **DEBATE:** Carotid Endarterectomy (CEA) Is The Best Treatment For Most Patients With High-Grade Asx CS
Richard P. Cambria, MD
- 2:06 – 2:11** **DEBATE:** Carotid Stenting (CAS) Is The Best Treatment For Most Patients With High-Grade Asx CS
William A. Gray, MD
- 2:12 – 2:17** Early Results From The ACST-2 Trial: In >1500 Patients CAS And CEA Appear To Be Equivalent Treatments For Asx CS
Alison Halliday, MS
- 2:18 – 2:23** What Will CREST 2 Tell Us And When: We Must Compare CAS And CEA vs. Current Medical Treatment In Patients With Asx CS In A RCT
Thomas G. Brott, MD
- 2:24 – 2:29** What Will SPACE 2 Tell Us And When: We Must Compare CAS And CEA vs. Current Medical Treatment In Patients With Asx CS In A RCT
Hans-Henning Eckstein, MD, PhD
- 2:30 – 2:35** **DEBATE:** Based On The CREST RCT And Other Data, CEA Seems To Be The Best Treatment For Symptomatic Carotid Stenosis (Sx CS) In Most Patients
Wesley S. Moore, MD
- 2:36 – 2:41** **DEBATE:** Based On The CREST RCT And Other Data, CAS Is The Best Treatment For Most Patients With Sx CS If The Right Techniques Are Used In Experienced Centers
Horst Sievert, MD
- 2:42 – 2:50** Panel Discussion
- 2:50 – 3:05** Break – Visit Exhibits And Pavilions (2nd and 3rd Floors)

SESSION 6 (Grand Ballroom East, 3rd Floor)

MORE ON THE MANAGEMENT OF PATIENTS WITH CAROTID DISEASE (SEE ALSO SESSIONS 5, 76-78, 86 AND 87)

*Moderators: Glenn M. LaMuraglia, MD
Thomas S. Riles, MD*

- 3:05 – 3:10** Resolving The Differences Between Various CAS/CEA Guidelines – All Based On The Same Data: How Could They Be So Different
Anne L. Abbott, MD, PhD
- 3:11 – 3:16** How To Optimize Brain Safety With CAS And CEA: What Is The Significance Of Silent MRI Defects
Laura Capoccia, MD, PhD
- 3:17 – 3:22** Microemboli And DW MRI Defects After Carotid Interventions: Do They Impair Cognitive Function
Wei Zhou, MD
- 3:23 – 3:28** Can Asx CS Lead To Cognitive Impairment: Does Carotid Revascularization Produce Cognitive Improvement
Brajesh K. Lal, MD

- 3:29 – 3:34** Proximal Brain Protection With Flow Reversal vs. Filter Protection For CAS: Which Is Better And How Best To Achieve Flow Reversal
Claudio J. Schonholz, MD
- 3:35 – 3:40** Flow Reversal Brain Protection Can Be Achieved During CAS With A Modified Mo.Ma Device: How To Do It
Juan C. Parodi, MD

EARLY TREATMENT OF SX CS

- 3:41 – 3:46** Is CEA Within 48 Hours Of Acute Symptom Onset Safe: The Evidence Is Mixed
Martin Björck, MD, PhD
- 3:47 – 3:52** CEA Early After Symptom Onset Does Not Increase Risk: Not So With CAS
Gustav Fraedrich, MD
- 3:53 – 3:58** **DEBATE:** Expedited CEA In Symptomatic CS Patients: How Long Post Symptom Onset Can Patients Safely Undergo CEA
Ross Naylor, MD
- 3:59 – 4:04** **DEBATE:** Early CAS After Symptom Onset Is Safe In Younger Patients Under Certain Conditions
Klaus D. Mathias, MD
- 4:05 – 4:12** Panel Discussion

SESSION 7 (Grand Ballroom East, 3rd Floor)

MORE ON THORACIC AND THORACO-ABDOMINAL ANEURYSMS (TAAAs); PREVENTING SPINAL CORD ISCHEMIA (SCI)

Moderators: *Larry H. Hollier, MD*

Timothy A.M. Chuter, DM

- 4:12 – 4:17** Paraplegia Following Fenestrated And Branched Aortic Endografts (F/B EVAR): Incidence, Severity And Ways To Prevent
Richard G. McWilliams, FRCR, EBIR
- 4:18 – 4:23** Incidence And Treatment Of SCI After TEVAR: Role Of Pressure Controlled Automatic Spinal Fluid Drainage (Liquo Guard System)
Germano Melissano, MD
- 4:24 – 4:29** Value Of Neuromonitoring During Open And Endo TAAA Repairs: How To Do It
Michael J. Jacobs, MD
- 4:30 – 4:35** Vascular Specialists Doing TEVAR May Be Underestimating The Paraplegia Risk: Pearls To Keep In Mind From A Senior TAAA Surgeon
Charles W. Acher, MD
- 4:36 – 4:41** Incidence, Clinical Features Of SCI Associated With Endovascular Repair Of TAAAs: How To Treat And Prevent This Complication
Matthew Eagleton, MD
- 4:42 – 4:47** Best Approaches To Preventing SCI During TEVAR And Open Repair Of TAAAs: Pearls Regarding Etiology, Monitoring And Treating
Hamdy Awad, MD
Patrick Vaccaro, MD
- 4:48 – 4:53** Panel Discussion

SESSION 8 (Grand Ballroom East, 3rd Floor)

MORE ON THORACIC AORTIC DISEASE, TEVAR AND TBADs

Moderators: *Rodney A. White, MD*
ShenMing Wang, MD, PhD

- 4:54 – 4:59** Ascending Aortic Complications Following TEVAR: How Can They Be Diagnosed And Treated Successfully
Roberto Chiesa, MD
- 5:00 – 5:05** Periscope Endografts To Revascularize The Left Subclavian Artery (LSA) During TEVARs Covering Its Origin: Technique And Advantages
Mario Lachat, MD
- 5:06 – 5:11** Can PET-CT Help To Indicate Which Uncomplicated TBAD Will Become Complicated: Should This Be An Indication For TEVAR
Natzi Sakalihassan, MD, PhD
- 5:12 – 5:17** How To Manage Complications Of Malperfusion After Coverage Of The TBAD Primary Tear By TEVAR: Tips And Tricks
Ali Azizzadeh, MD
Anthony L. Estrera, MD
Hazim J. Safi, MD
- 5:18 – 5:23** Why The INSTEAD Trials Are Not Enough To Justify TEVAR For All Uncomplicated TBADs And Why We Need Additional Trials
Firas F. Mussa, MD
- 5:24 – 5:29** Evaluation Of Dynamic Intimal Flap Movement In TBAD Patients: Effect Of TEVAR And How Important Is Time After Onset In Determining Flap Mobility
Frank R. Arko, MD
- 5:30 – 5:35** Adjunctive False Lumen Techniques For Endovascular Repair Of Chronic TBADs: When Are They Needed
Eric E. Roselli, MD
- 5:36 – 5:41** Relationship Between Aortic Morphology After TEVAR And Clinical Outcomes With TBADs
Matt M. Thompson, MD
- 5:41 – 5:46** Tricks And Pitfalls For Antegrade Endograft Delivery During Open Repair Of Acute Type A Aortic Dissections
Ourania Preventza, MD
Joseph S. Coselli, MD
- 5:47 – 5:55** Panel Discussion
End of Program A

PROGRAM B (SESSIONS 9-16)

LOWER EXTREMITY DISEASE AND ITS TREATMENT

Trianon Ballroom, 3rd Floor

- 6:45 – 6:48** Opening Remarks
Frank J. Veith, MD

SESSION 9 (Trianon Ballroom, 3rd Floor)

LOWER EXTREMITY OCCLUSIVE DISEASE MANAGEMENT HOT TOPICS – NEW TECHNIQUES AND NEW DEVICES

Moderators: *Enrico Ascher, MD*
Frank B. Pomposelli, MD

- 6:48 – 6:53** Ultrasound Guidance To Decrease Access Site Complications: An Essential Tool Even For Experienced Interventionalists
Peter A. Schneider, MD

- 6:54 – 6:59** Role Of Directional Atherectomy For Treatment Of Lower Extremity Occlusive Disease: Is There A Gender Effect
Lawrence A. Garcia, MD
- 7:00 – 7:05** Advantages And Limitations Of The Tack-It Device System For Minimizing Dissection After Plain Old Balloon Angioplasty (POBA) And Leaving Minimal Metal Behind: The TOBA Study
Marianne Brodmann, MD
- 7:06 – 7:11** Technical Tips And Tricks To Optimize The Performance And Outcomes With The Supera Stent And Probably All Stents: Proper Sizing, Avoiding Elongation And Adequate Predilation Matter In Producing Good 3-Year Results
D. Christopher Metzger, MD
- 7:12 – 7:17** How To Use Drug Eluting Stents (DES) In Infrapopliteal Bifurcations
Konstantinos Katsanos, MSc, MD, PhD
- 7:18 – 7:23** Use Of Collaterals For Access And Retrograde Wire Passage: How To Do It
Jos C. van den Berg, MD, PhD
- 7:24 – 7:29** When And How To Treat Below The Ankle Occlusive Disease: What Percent Of CLI Patients Will Require It
Roberto Ferraresi, MD
- 7:30 – 7:35** With Below Knee (BK) Chronic Total Occlusions (CTOs), Success Depends On Choosing The Right Tools And Techniques: What New Tools And Techniques Exist To Help With Pedal And Tibial Access Like 3 French Sheaths And Systems
Andrej Schmidt, MD
- 7:36 – 7:42** Panel Discussion

SESSION 10 (Trianon Ballroom, 3rd Floor)

LOWER EXTREMITY HOT TOPICS – MORE NEW TECHNOLOGIES AND THE IMPORTANCE OF TECHNIQUE; DEBATES

Moderators: *Kenneth Ouriel, MD, MBA*
Gregg S. Landis, MD

- 7:42 – 7:47** **DEBATE:** For CLI: Endovascular Treatments Should Be Used First In 100% Of Patients
Marc Bosiers, MD
Koen Deloose, MD
- 7:48 – 7:53** **DEBATE:** For CLI: Open Surgery Should Be Used First In Some Patients: Which Ones
Firas F. Mussa, MD
- 7:54 – 7:59** Value Of Ultrasound Guided Pedal Access To Treat CLI: How Can It Facilitate Use Of The Diamond Back Atherectomy Device: How Best To Close The Puncture Site
Jihad A. Mustapha, MD
- 8:00 – 8:05** How Do Stent Characteristics/Details And Technical Details Of PTA Balloon Usage Affect Outcomes And Incidence Of Restenosis: Oversizing Matters And Is Bad
Dierk Scheinert, MD
- 8:06 – 8:11** How To Optimize Outcomes With SFA Interventions: Details Of Stent Design And Deployment Techniques Are Important In Determining Restenosis And Failure As Is Predilatation With An Uncoated Balloon Before DEBs
Stefan Müller-Hülsbeck, MD

- 8:12 – 8:17** **DEBATE:** Why In Treating BK CTOs It Is Best To Stay Intraluminal
Marco G. Manzi, MD
- 8:18 – 8:23** **DEBATE:** Subintimal Angioplasty Is Very Useful And Often Unavoidable In Treating BK CTOs
Amman Bolia, MD
- 8:24 – 8:29** 15-Year Trends In CLI Treatment And Major Amputation: Better Care Is Making A Difference: Is It Due To Better Interventional And Bypass Treatment: Does Increased CLI Spending Increase Limb Salvage And Decrease Amputation Rates
Philip P. Goodney, MD, MS
- 8:30 – 8:37** Panel Discussion

SESSION 11 (Trianon Ballroom, 3rd Floor)

MORE LOWER EXTREMITY HOT TOPICS – NEW STENT AND DRUG ELUTING BALLOON (DEB) DATA; IMPACT AND COST ISSUES

Moderators: *Joseph L. Mills, MD*

Giancarlo Biamino, MD, PhD

- 8:38 – 8:43** Is There A Negative Effect Of Endovascular Failure On Bypass Outcomes: Is It Reality Or A Myth
Michael S. Conte, MD
- 8:44 – 8:49** What Is The Effect Of Extensive Lesion Calcification On The Outcome Of DEB Treatment
Gunnar Tepe, MD
- 8:50 – 8:55** Why Are DEBs Cost Effective For Treating CLI Patients
Thomas Zeller, MD
- 8:56 – 9:01** How To Align Financial Incentives For The Doctor, The Hospital And The Payer (Insurance Company) To Provide The Best And Most Effective Care In The Least Costly Manner: Impact Of Expensive New Technologies And Reintervention Rates
W. Charles Sternbergh III, MD
- 9:02 – 9:07** Tips And Tricks For Tibial Interventions For CLI
Roberto Ferraresi, MD
- 9:08 – 9:13** What's New With US Approved Drug Eluting Stents (DESs) In The SFA And Below
Ron Waksman, MD
- 9:14 – 9:19** 5-Year Results And New Findings From The Zilver PTX RCT And Registry: Benefits Of DESs Are Durable And Value With In Stent Restenosis (ISR), Long Lesions And Diabetics
Michael D. Dake, MD
- 9:20 – 9:25** 2-3-Year Results With EverFlex Helical Nitinol Stent In The SFA And The Popliteal Artery: Are The Benefits Durable
Marc Bosiers, MD
Patrick Peeters, MD
- 9:26 – 9:33** Panel Discussion
- 9:33 – 9:48** Break – Visit Exhibits And Pavilions (2nd and 3rd Floors)

SESSION 12 (Trianon Ballroom, 3rd Floor)

IN HONOR OF ROBERT B. RUTHERFORD, MD: NEW DEVELOPMENTS IN THE TREATMENT OF LOWER EXTREMITY ISCHEMIA; CLI, STENTS AND DEBs

Moderators: *Ali F. AbuRahma, MD*

Dierk Scheinert, MD

FOR SFA AND POPLITEAL LESIONS

- 9:48 – 9:53** Update On The Efficacy Of DEBs For SFA And Popliteal Artery Lesions: Why Some Trials Are Positive And Some Negative: Are Good Results Holding Up: GLOBAL IN.PACT Registry Results In >1400 Patients
Gunnar Tepe, MD
Dierk Scheinert, MD
- 9:54 – 9:59** POBA And “Vanella” Bare Metal Stents (BMS) Have Merit In Some AK And BK Occlusive Lesions Reserving The Fancy And Costly Stuff For Special Situations
Iris Baumgartner, MD
- 10:00 – 10:05** What Have We In The US Learned From Our European Colleagues About CLI Treatment That Can Be Used To Improve Patient Care In The US
Craig M. Walker, MD
- 10:06 – 10:11** Stenting For Femoral And Popliteal Artery Lesions: Where Do We Currently Stand And What Problems Remain
Erich Minar, MD
- 10:12 – 10:17** Role Of DEBs vs. DESs For SFA Lesions And Value Of Paclitaxel DEBs For Long SFA Lesions: Is There Level 1 Proof Of Benefit
Thomas Zeller, MD
- 10:18 – 10:23** Paclitaxel Coated DEBs Are Better Than Uncoated Balloons In The SFA: 1-Year Results From The IN.PACT SFA I/II RCTs
Peter A. Schneider, MD
John R. Laird, MD
Gunnar Tepe, MD
- 10:24 – 10:29** DEBs Are Effective For SFA Lesions: 1-Year Results From The LEVANT II RCT Show It To Be So With The Bard Lutonix DEB: Stents Were Rarely Needed
Kenneth Rosenfield, MD
Dierk Scheinert, MD
- 10:30 – 10:35** Durability Of Paclitaxel Coated DEBs In The SFA: Long-Term (3-Year) Results Of The PACIFIER Trial
Michael Werk, MD
- 10:36 – 10:41** Mid-Term Results From The Belgian IN.PACT Trial Of Paclitaxel Coated DEBs vs. POBA: What Is Special About This Trial
Erik E. Debing, MD, PhD
- 10:42 – 10:50** Panel Discussion

FOR BK AND INFRAPOPLITEAL LESIONS

Moderators: *Michael S. Conte, MD*
George H. Meier III, MD

- 10:50 – 10:55** How Often After Tibial Interventions For CLI Are Reinterventions Required: We Need Better Primary Treatments: What Are The Cost Implications
Nicolas A. Diehm, MD
Iris Baumgartner, MD
- 10:56 – 11:01** Single Center RCT Of IN.PACT Deep Paclitaxel Coated DEBs vs. Uncoated Balloons Shows Benefit For BK Lesions Causing CLI: 3-Year Results Of The DEBATE Trial
Francesco Liistro, MD
- 11:02 – 11:07** Single Center Results With Paclitaxel Coated DEBs For Infrapopliteal Lesions Shows Benefits: What Are They
Andrej Schmidt, MD
Dierk Scheinert, MD

- 11:08 – 11:13** A Multicenter RCT (IN.PACT DEEP) Comparing Paclitaxel Coated DEBs With Uncoated Balloons Fails To Show Benefit For The DEBs
Thomas Zeller, MD
- 11:14 – 11:19** Why Do The SINGLE CENTER Trial And Other BK DEB Results Differ From The Multicenter Trial Results: All DEBs Are Not Equal Or Used Equally: A Critical Analysis Of All Data And Some 3-Year Results
Francesco Liistro, MD
- 11:20 – 11:25** How To Explain Differing Results Of RCTs Of DEBs In BK And Infrapopliteal Lesions: When Will We Get DEBs For BK Lesions In The US
Krishna J. Rocha-Singh, MD
- 11:26 – 11:31** DEBs: Are They A Breakthrough Technology Or Another Tool In The Box: Why Is There Still Uncertainty: Do The PACUBA Trial Results With SFA/POP In Stent Restenosis (ISR) Help
Johannes Lammer, MD
- 11:32 – 11:37** How Long Is Restored Patency Needed In CLI Patients; What Leads To Increased Limb Salvage With Poor Patency: Importance Of Reintervention, DESs And DEBs
Frank E.G. Vermassen, MD, PhD
- 11:38 – 11:43** How Important To Interventional Outcomes Is Leaving No Foreign Body Or Metal Behind In The Artery: How Can It Be Achieved
Giancarlo Biamino, MD, PhD
Dierk Scheinert, MD
- 11:44 – 11:49** Variable And High Total Costs For Caring For CLI Patients: What Can Be Done To Cut Costs Without Impairing Patient Care
Timothy M. Sullivan, MD
- 11:50 – 12:00** Panel Discussion
- 12:00 – 1:00** Lunch Break – 2nd Floor Promenade
Visit Exhibits And Pavilions (2nd and 3rd Floors)

SESSION 13 (Trianon Ballroom, 3rd Floor)

IN HONOR OF JOHN J. BERGAN, MD: MORE LOWER EXTREMITY ISCHEMIA TREATMENT – ROLE OF OPEN SURGERY; IN STENT RESTENOSIS (ISR) MANAGEMENT – DEBs, DESs, ATHERECTOMY

Moderators: Samuel R. Money, MD, MBA
Barry T. Katzen, MD

ROLE OF OPEN SURGERY

- 1:00 – 1:05** Extreme Distal Vein Bypasses After Failed Endovascular Treatments
Giustino Marcucci, MD
- 1:06 – 1:11** Pedal Bypass With Deep Venous Arterialization: Long-Term Results And Hemodynamic Changes Are Surprisingly Good: Is It An Option After Failed Arterial Bypasses And Endovascular Treatments
Pramook Mutirangura, FRCS (Edinberg)
- 1:12 – 1:17** Endovascular vs. Open Treatments For Lower And Upper Extremity CLI: How To Avoid Failure And Bad Outcomes
Francesco Spinelli, MD
- 1:18 – 1:23** **DEBATE:** Endovascular Treatment First In All Patients With CLI Is Best
Craig M. Walker, MD
- 1:24 – 1:29** **DEBATE:** Open Surgical Treatment First Is Best For Some CLI Patients: Which Ones And Why
Michael S. Conte, MD

1:30 – 1:35 What Is The Best Treatment Strategy For CLI Patients In Terms Of Outcomes And Cost: When Open First, When Endo First
Timothy M. Sullivan, MD

1:36 – 1:42 Panel Discussion

Moderators: *Giancarlo Biamino, MD, PhD*
Michael B. Silva, Jr., MD

DEBs AND TREATMENT OF ISR

1:43 – 1:48 Importance Of Technique In Avoiding Dissection With PTA Using DEBs And Standard Balloons: Does Good Flow Matter: How To Know: When Are Stents Really Necessary
Fabrizio Fanelli, MD

1:49 – 1:54 How To Cross And Recanalize Chronically Occluded Stents: Stent Puncture And The Radiofrequency PowerWire Can Be Helpful: Technical Tips
Marcelo Guimaraes, MD

1:55 – 2:00 Treatment Of ISR: DEBs Are OK If The Lesion Is Just Intimal Hyperplasia: A Stent Is Required If The Lesion Is Severely Calcified
Dierk Scheinert, MD

2:01 – 2:06 **DEBATE:** Laser Atherectomy And Stent Graft vs. Laser Atherectomy And DEB For ISR: Which Is Best And Why Debulking Is Essential
Jos C. van den Berg, MD, PhD

2:07 – 2:12 **DEBATE:** For ISR, POBA vs. DEB vs. DES vs. Covered Stent: 1-Year Results Of The FAIR Trial With The IN.PACT Admiral DEB: Debulking Is Not Necessary
Hans Krankenberg, MD

2:13 – 2:18 The Ocelot OCT Catheter For Crossing CTOs And The Next Generation Atherectomy Device (Phoenix): How Are They Better And In Which Arteries
James F. McKinsey, MD

2:19 – 2:24 How Well Do Paclitaxel Coated DEBs Work For ISR In CLI Patients With Diabetes: 3-Year Results From The DEBATE RCT
Francesco Liistro, MD

2:25 – 2:30 In Memoriam And Recognition Of 5 Giants In Vascular Surgery Who Are No Longer With Us: **John Bergan, James DeWeese, Roy Greenberg, Robert Rutherford And David Sumner**
Jerry Goldstone, MD

2:31 – 2:38 Panel Discussion

SESSION 14 (Trianon Ballroom, 3rd Floor)

NEW DEVELOPMENTS WITH STENT-GRAFTS FOR OCCLUSIVE DISEASE AND ISR

Moderators: *Luis A. Sanchez, MD*
Gary Giangola, MD

2:38 – 2:43 Use Of Stent-Grafts To Avoid Rupture And Embolization In Endovascular Treatment Of Complex Iliac Artery Occlusive Disease
Maria Antonella Ruffino, MD

2:44 – 2:49 **DEBATE:** For Long SFA Occlusions DEBs Or Viabahn Propaten Stent-Grafts Are The Best Treatment With The Best Outcomes: Will Drug Coating Tips To Stent-Grafts Improve Results: Will They Be Available
Thomas Zeller, MD

2:50 – 2:55 **DEBATE:** For Long SFA Occlusions Zilver PTX DESs Are The Best Treatment With The Best Results
Michael D. Dake, MD

- 2:56 – 3:01** Technical Considerations For Optimal Use Of Viabahn Covered Stents For Long SFA Occlusive Lesions: Lessons Learned From The VIPER And VIASTAR Trials
Dennis R. Gable, MD
- 3:02 – 3:07** 2-Year Results Of The RELINE Trial Comparing Viabahn Stent-Grafts To POBA For ISR Show Durable Benefits To Endograft Treatment
Marc Bosiers, MD
Koen Deloose, MD
- 3:08 – 3:13** Interim Analysis Of The SUPER B Trial Comparing Heparin Bonded Viabahn Endografts To Vein Bypasses For SFA Occlusive Disease
Michael M.P. Reijnen, MD, PhD
- 3:14 – 3:19** Covered Balloon Expandable Endovascular Graft Reconstruction Of The Aortic Bifurcation (CERAB Procedure) For Aorto-Iliac Occlusive Disease: 2-Year Results And Hemodynamic And Other Advantages
Peter C.J. Goverde, MD
- 3:20 – 3:26** Panel Discussion
- 3:26 – 3:38** Break – Visit Exhibits And Pavilions (2nd and 3rd Floors)

SESSION 15 (Trianon Ballroom, 3rd Floor)

NEW DEVELOPMENTS IN THE TREATMENT OF ACUTE LOWER EXTREMITY ISCHEMIA (ALI) AND INTERMITTENT CLAUDICATION (SEE ALSO SESSION 64)

Moderators: *John B. Chang, MD*

Patrick J. Lamparello, MD

ACUTE LOWER EXTREMITY ISCHEMIA

- 3:38 – 3:43** How To Avoid Groin Incisions In Hostile Groins When Performing Femoral Embolectomy
Rajiv Parakh, MBBS, MS
- 3:44 – 3:49** Percutaneous Endovascular Thrombosuction: Devices, Techniques, Indications And Results
Athanasios Katsargyris, MD
Eric L.G. Verhoeven, MD, PhD
- 3:50 – 3:55** Advantages To Indigo Mechanical Thrombectomy For ALI: Device And Technique
Claudio J. Schonholz, MD
- 3:56 – 4:01** **DEBATE:** Endovascular Treatments Can Treat Almost All Patients With ALI
Mehdi H. Shishehbor, DO, MPH, PhD
- 4:02 – 4:07** **DEBATE:** Some Patients With ALI Require Open Surgical Treatment – Either A Bypass Or Open Thrombectomy: Which Patients
Joseph L. Mills, MD
- 4:08 – 4:13** Young Athletes With ALI Should Have An Endovascular First Approach: What Are The Causes Of The ALI
Werner Lang, MD
- 4:14 – 4:19** Cancer And ALI: A Deadly Combination: Why
Cynthia K. Shortell, MD
- 4:20 – 4:25** With ALI: When Endo; When Open: What Are The Mid-Term Outcomes
Rabih A. Chaer, MD

NEW DATA REGARDING INTERMITTENT CLAUDICATION AND ITS TREATMENT

- 4:26 – 4:31** Current Drug And Non-Interventional Treatments For Intermittent Claudication: Are They Effective
Jeffrey S. Berger, MD, MS

- 4:32 – 4:37** For Intermittent Claudication: Immediate Treatment vs. Delayed Treatment vs. No Treatment: Which Is Best
Gregory L. Moneta, MD
- 4:38 – 4:43** Endovascular vs. Exercise Treatment For Intermittent Claudication: Which Is Best
Jonathan D. Beard, ChM, MEd
- 4:44 – 4:50** Panel Discussion

SESSION 16 (Trianon Ballroom, 3rd Floor)

NEW DEVELOPMENTS IN CHRONIC CLI AND ITS TREATMENTS: THE ANGIOSOME CONCEPT – PROS AND CONS

Moderators: Keith D. Calligaro, MD
Peter F. Lawrence, MD

- 4:50 – 4:55** Advantages Of New SVS Lower Extremity Threatened Limb Classification System For Risk Stratification Based On Wound, Ischemia And Foot Infection
Joseph L. Mills, MD
Michael S. Conte, MD
- 4:56 – 5:01** Advantages Of And Indications For The Supera Stent – A Vascular Mimetic Implant With Special Properties: High Radial Strength, Low Chronic Outward Force: Tips And Tricks For Implanting And Using
Peter C.J. Goverde, MD
- 5:02 – 5:07** 3-Year Results With The Supera Interwoven Biomimetic Stent For Femoro-Popliteal Lesions Based On The SUPER B Trial: Why Is This Stent Better Than Others
Lawrence A. Garcia, MD
Kenneth Rosenfield, MD
Dierk Scheinert, MD
- 5:08 – 5:13** Is Directional Atherectomy (Silverhawk Or Turbohawk) With DEB, Better Than DEB Alone: Based On The DEFINITIVE AR RCT: 1-Year Results
Gunnar Tepe, MD
Thomas Zeller, MD
- 5:14 – 5:19** Lower Extremity Outcomes With Fancy Endovascular Devices: We Should Remain Skeptical And Look At The Data
Scott L. Stevens, MD
- 5:20 – 5:25** How To Measure Success And Failure With Interventional Treatments For Lower Extremity Ischemia: The Difference Between Thrombosis And Occlusion
Kenneth Ouriel, MD, MBA

PROS AND CONS OF THE ANGIOSOME CONCEPT

- 5:26 – 5:31** **DEBATE:** The Angiosome Concept Is Necessary And Critical In Diabetic/CLI Patients
Richard F. Neville, MD
Anton N. Sidawy, MD, MPH
- 5:32 – 5:37** **DEBATE:** The Angiosome Concept Need Not Be Followed In Diabetic Patients With CLI
Ignacio Escotto, MD
- 5:38 – 5:43** Is The Angiosome Concept Real In Determining Limb Salvage: Results Of A 2-Center Study
Jean-Baptiste Ricco, MD, MPH
- 5:44 – 5:49** Perfusion Measurements Before And After Tibial PTA Do Not Support The Angiosome Concept
Werner Lang, MD

5:50 – 5:55 Assessing Pedal Microcirculation With An Angiographic Wound Blush: Successful Revascularization And Wound Healing Can Occur Beyond Angiosomes And Beyond Pedal Loop Patency: Angiosomes Differ In Various Patients And Are Not The Holy Grail

John H. Rundback, MD

5:56 – 6:01 There Is Still A Role For Primary Major Amputation For CLI: When Is It Indicated

Jonathan D. Beard, MD

6:02 – 6:10 Panel Discussion

End of Program B

PROGRAM C (SESSIONS 17-24)

NATURAL HISTORY, MEDICAL TREATMENT, INTERVENTION FOR MEDICAL DISEASES, RENAL DENERVATIONS, COMPLICATIONS, ENDOLEAKS, CCSVI, ISSUES, RCTs, GUIDELINES, GOVERNMENT REIMBURSEMENT, BOARDS, CERTIFICATION, TRAINING, SIMULATION

Grand Ballroom West, 3rd Floor

6:40 – 6:43 Opening Remarks

Frank J. Veith, MD

SESSION 17 (Grand Ballroom West, 3rd Floor)

NATURAL HISTORY, BEST MEDICAL TREATMENT, PREVENTION OF ARTERIOSCLEROSIS AND ITS COMPLICATIONS

Moderators: *Bruce A. Perler, MD, MBA*

Keith D. Calligaro, MD

6:43 – 6:48 Can Medical Treatment Slow The Growth Of Small AAAs
Frank A. Lederle, MD

6:49 – 6:54 Are There New Medical Techniques For Limiting AAA Growth With Drugs (Telmisartan) And Cell Therapy: How Can They Work

Ronald L. Dalman, MD

6:55 – 7:00 Are Statins Decreasing The AAA Rupture Rate: Results From A Danish Nationwide Population-Based Study

Jes S. Lindholt, MD

7:01 – 7:06 A New Agent PCSK9 To Lower LDL: How Low Can LDL Go And Is It Safe

Ron Waksman, MD

7:07 – 7:12 What Is The Association Between The A/B Index And MI And Stroke Risk: Can It Be Altered; What Is The Association Between Obesity And Vascular Disease In Various Vascular Beds: When Is Being Fat Good

Caron B. Rockman, MD

7:13 – 7:18 **DEBATE:** Statins Have No Role To Play In Primary Prevention And Should Be Avoided In Most Patients

Sherif Sultan, MD

7:19 – 7:24 **DEBATE:** Nonsense: Statins Are A Game Changer, A Miracle Drug: They Should Be Used More Widely In Primary Prevention: Optimal Dosage Of Which Drug

Bruce A. Perler, MD, MBA

7:25 – 7:30 Statins In Vascular Patients: Are There Non-Responders And Responders – How To Tell And What To Do With Non-Responders: What To Do When Patients Have “Apparent Toxicity”: How To Load Preop And Preprocedurally

Don Poldermans, MD

7:31 – 7:36 Optimal Beta Blocker Management In Patients Requiring Vascular Surgery Or Intervention: Current Facts And Optimal Dosing And Drug
Jan M.M. Heyligers, MD, PhD

7:37 – 7:45 Panel Discussion

SESSION 18 (Grand Ballroom West, 3rd Floor)

INTERVENTIONAL TREATMENT OF HYPERTENSION AND OTHER MEDICAL DISEASES – RENAL DENERVATION (SEE ALSO SESSION 41)

Moderators: *Horst Sievert, MD*

Frank J. Veith, MD

7:45 – 7:50 Role Of Sympathetic Nervous System In Cardiovascular Function And Hypertension: How Does Renal Artery Denervation Produce A Drop In Blood Pressure
John W. Osborn, PhD

7:51 – 7:56 Renal Denervation For Drug Resistant Hypertension: Does It Work: Many Trials And Registries Say It Does And Yet SIMPLICITY III Says It Does Not: Does The Emperor Have No Clothes
Ron Waksman, MD

7:57 – 8:02 Collateral Benefits Of Renal Denervation: Reasons Why SIMPLICITY III Did Not Meet Its Goals: Will Renal Denervation And Other Techniques To Decrease Sympathetic Tone And Blood Pressure Work: How About Barostimulation (Rheos Device) And A-V Fistula (With ROX Device)
Krishna J. Rocha-Singh, MD

8:03 – 8:08 Unanswered Questions About Renal Denervation After SIMPLICITY III: What Other Devices Are Being Evaluated And Will They Be Effective (Northwind, Paradise, Ultrasound, Etc.)
Horst Sievert, MD

8:09 – 8:14 Where Do We Go After SIMPLICITY III: Is There Evidence That Renal Denervation Will Work: Are There Other Devices And Technology And What Do They Offer
Yvonne Bausback, MD
Dierk Scheinert, MD

8:15 – 8:20 What Is Required To Support A Renal Denervation Practice For Resistant Hypertension And Other Devices: Should Vascular Surgeons Consider Setting Up Such A Program Before Everyone Else Jumps On The Bandwagon
Christoph A. Nienaber, MD, PhD

8:21 – 8:26 Defining Real Resistant Hypertension: Are There Responders And Non-Responders To Renal Denervation And Can RF (Radiofrequency) Treatment Injure The Renal Arteries
Melvin D. Lobo, MBChB, PhD

8:27 – 8:32 Failure Of SIMPLICITY III To Demonstrate Efficacy Of Renal Denervation By Endovascular RF Could Be Due To Nerve Distribution Far From The Renal Artery Lumen: Is Surgical Perirenal Neurolysis Possible And What Is Its Effect
Juan C. Parodi, MD

8:33 – 8:39 Panel Discussion

SESSION 19 (Grand Ballroom West, 3rd Floor)

TREATMENT AND AVOIDANCE OF COMPLICATIONS; ENDOLEAKS AND THEIR MANAGEMENT

*Moderators: Timur P. Sarac, MD
Frans L. Moll, MD, PhD*

MANAGEMENT OF COMPLICATIONS

- 8:39 – 8:44** Access Site Complications After Non-Cardiac Interventions: Incidence, Predictive Factors, How To Prevent And Outcomes: Value Of Routine Ultrasound Guidance
Mark W. Mewissen, MD
- 8:45 – 8:50** Endovascular Treatment Of Anastomotic Complications After Open Surgery – Including False Aneurysms And Infections
Jos C. van den Berg, MD, PhD
- 8:51 – 8:56** Endovascular Treatment Of Tracheo-Innominate Artery Fistulas: How To Do It Successfully
Gabriel Szendro, MD
- 8:57 – 9:02** Successful Treatment Of An Innominate Artery-Tracheal Fistula With A Modified Endograft
Evan C. Lipsitz, MD

NEW DEVELOPMENTS IN ENDOLEAK MANAGEMENT

- 9:03 – 9:08** What Is Currently The Best Information About The Significance Of Type 2 Endoleaks: How Are They Best Diagnosed And Treated
Kim J. Hodgson, MD
- 9:09 – 9:14** Conservative (Observational) Management Is Appropriate For Some Primary Type 1A Endoleaks After EVAR And TEVAR Procedures: Which Ones
Frans L. Moll, MD, PhD
- 9:15 – 9:20** What Are The Real Causes Of Endotension: Can A Hypervascular AAA Sac Wall Cause It: How To Diagnose And Treat It
Timur P. Sarac, MD
- 9:21 – 9:26** Type 1 Endoleaks After EVAR: Role Of Onyx In Fixing Them: Tips And Tricks For Its Use And How To Diagnose And Treat Those That Masquerade As Type 2 Endoleaks
Robert A. Morgan, MD
- 9:27 – 9:32** What Is The Real Long-Term Outcome Of Type 2 Endoleaks: Based On A Single Center And The OVER Trial Experience
Wei Zhou, MD
- 9:33 – 9:38** Open Aortic Wrap For Persistent Type 1A Endoleak: Technical Tips And Results
Ross Milner, MD
- 9:39 – 9:44** Accurate Endoleak Detection And Characterization Using Temporal Information From Contrast Enhanced Ultrasound
S. Rao Vallabhaneni, MD
- 9:45 – 9:52** Panel Discussion
- 9:52 – 10:05** Break – Visit Exhibits And Pavilions (2nd and 3rd Floors)

SESSION 20: (Grand Ballroom West, 3rd Floor)
**OPTIMAL PERIPROCEDURAL MEDICAL
MANAGEMENT IN VASCULAR PATIENTS; SOME
INTERESTING HISTORY AND TECHNOLOGY;
THE CCSVI FOR MULTIPLE SCLEROSIS (MS)
CONTROVERSY**

Moderators: *Caron B. Rockman, MD*
K. Craig Kent, MD

**PERIPROCEDURAL MANAGEMENT,
INTERESTING HISTORY AND TECHNOLOGY**

- 10:05 – 10:10** Periop And Periprocedural Care Is Key For Vascular Patients: What Is Optimal Antiplatelet Treatment; Statin Dosage, Drugs And Loading; And Beta Blockade
Caron B. Rockman, MD
Jeffrey S. Berger, MD, MS
- 10:11 – 10:16** Scandalous High Long-Term Mortality After EVAR: It Is Due To MD Ignorance Regarding Statins And Other Medical Treatment: The AAA Is Fixed But MIs Kill: Statins Should Be In The Drinking Water
Matt M. Thompson, MD
- 10:17 – 10:22** Heparin Management During Open AAA Repair: Is Heparin Necessary For Elective Or Ruptured AAA Repair
Arno M. Wiersema, MD
- 10:23 – 10:28** How Do Statins Influence Long-Term Restenosis And Cardiovascular Events (Stroke And MI) After CEA And After CAS
Christos D. Liapis, MD
- 10:29 – 10:34** Tales From The Crypt: 5000-Year-Old History Of Atherosclerosis (ASO): What It Tells Us About ASO Today
Christopher K. Zarins, MD
- 10:35 – 10:40** What Andreas Gruntzig Said 30 Years Ago And Its Relevance Today
Sigrid Nikol, MD
- 10:41 – 10:46** Shock Wave Lithoplasty For Treating Severely Calcified Occlusive Lesions: Theory And 30-Day CE Mark Study Results
Andrew Holden, MBChB
- 10:47 – 10:53** Panel Discussion

THE CCSVI FOR MS CONTROVERSY

Moderators: *Lindsay Machan, MD*
Manish Mehta, MD, MPH

- 10:53 – 10:58** What Is New In CCSVI For MS: The Positive Evidence Mounts: How To Select Patients: Can Brain Perfusion Be Improved: Is Open Vein Repair Ever Needed
Paolo Zamboni, MD
- 10:59 – 11:04** Vein PTA Helps Selected MS Patients With CCSVI: There Is No Doubt: Stem Cell Therapy May Also Be Beneficial
Ivo Petrov, MD, PhD
- 11:05 – 11:10** The Omohyoid Muscle Can Be A Cause Of Venous Compression Leading To CCSVI: Documentation And Relief By Resection
Alberto Lomeo, MD
- 11:11 – 11:16** Regarding CCSVI And MS, A Skeptic's View
J. David Spence, MD
- 11:17 – 11:22** Despite Some Questions, There Is Still A Relationship Between CCSVI And MS And An Opportunity For A Positive Effect From Endovascular Treatment
Michael D. Dake, MD

- 11:23 – 11:28** The Proper Technique For Venoplasty For CCSVI As A Contributory Cause Of MS: Variability In Technique May Account For Variable Results
Donald B. Reid, MD
- 11:29 – 11:34** Is The CCSVI Concept In MS Valid: Results Of A Meta-Analysis
Jean-Baptiste Ricco, MD, PhD
- 11:35 – 11:40** The Presence Of Extracranial Venous Narrowing Is The Same In MS Patients And Normal Controls
Lindsay Machan, MD
- 11:41 – 11:46** Update On The RCT Of Venous Balloon Angioplasty vs. Venography Placebo: What Does It Tell Us
L. Nelson Hopkins, MD
Robert Zivadinov, MD, PhD
- 11:47 – 12:00** Panel Discussion
- 12:00 – 1:00** Lunch Break – 2nd Floor Promenade
Visit Exhibits And Pavilions (2nd and 3rd Floors)

SESSION 21 (Grand Ballroom West, 3rd Floor)

ISSUES: VARIABLE VASCULAR CARE, GOVERNMENT, FDA, HEALTH CARE REFORM, ETHICS

Moderators: Kenneth Ouriel, MD, MBA

Robert M. Zwolak, MD, PhD

- 1:00 – 1:05** How To Increase Public Awareness Of Vascular Disease And The Role Of The Specialty Of Vascular Surgery
Robert B. McLafferty, MD
- 1:06 – 1:11** Disparity Of Vascular Care: Variations Of Index Vascular Procedures In Different Hospitals And Different Locations: Why
Mohammad H. Eslami, MD, RVT
- 1:12 – 1:17** **DEBATE:** The Changes In The FDA Process For Cardiovascular Device Evaluation And Approval Will Increase US Access To Safe And Effective Devices – And Make It More Like Other Civilized Countries
Dorothy B. Abel, BSBME
J. Pablo Morales, MD
- 1:18 – 1:23** **DEBATE:** Are The FDA Changes Really Going To Facilitate New Device Evaluation And Availability In The US: The Difficulty Lies With Congress, Not The FDA
Ron Waksman, MD
- 1:24 – 1:29** Template For An IDE For Physician Modified Endografts
Patrick W. Kelly, MD
Rodney A. White, MD
Dorothy B. Abel, BSBME
- 1:30 – 1:35** Perverse Incentives To Perform Vascular Procedures, And Pay For Performance Measurements Are Bad: How To Fix The Problems
Timothy F. Kresowik, MD
- 1:36 – 1:41** Panel Discussion

IMPACT OF OBAMACARE

- 1:42 – 1:47** Impact Of Obamacare (ACA) On American Medicine And Our Country: I Thought It Was Bad But I Never Realized How Bad
Clifford J. Buckley, MD
- 1:48 – 1:53** The Train Is Coming At You: What Will The Cost Of Obamacare Be To Vascular Patients And Vascular Surgeons
James H. Black III, MD

- 1:54 – 1:59** Detrimental Effects Of The ACA And ACOs On The Work Environment Of Vascular Surgeons And Their Freedom To Provide The Best Care: Are Doctors-Unions A Legal And Inevitable Solution
Timothy M. Sullivan, MD
- 2:00 – 2:05** The Impact Of The ACA On The Medical Device Industry: What Harm Or Benefit Will It Cause: How Are Things Working Out
Kem Hawkins, MBA
- 2:06 – 2:11** Impact Of Obamacare On Vascular Surgery In 2014 And 2015
Robert M. Zwolak, MD, PhD
- 2:12 – 2:17** Heart And Vascular Care In The Era Of Health Reform And The ACA: Where Are We Headed And How To Survive
John H. Furtek, BS, RT(r)
- 2:18 – 2:23** The ACA Says It's Willing To Pay For Disease Prevention: Why That Is Not True
Clifford M. Sales, MD, MBA
Patricia Davidson, RN
- 2:24 – 2:30** Panel Discussion

SESSION 22 (Grand Ballroom West, 3rd Floor)

ISSUES RELATED TO INDEPENDENCE FOR VASCULAR SURGERY, RESIDENCY TRAINING, BUSINESS, REIMBURSEMENT, COST/BENEFIT, CONFLICT OF INTEREST (COI)

Moderators: *Michel Makaroun, MD*

Karl A. Illig, MD

INDEPENDENCE AND GOVERNANCE ISSUES FOR VASCULAR SURGERY

- 2:30 – 2:35** What Have Been The Beneficial Effects For Patients And Vascular Surgeons Of Vascular Surgery Being Recognized As An Independent Specialty In Switzerland
Jürg Schmidli, MD
- 2:36 – 2:41** How Has Independence Helped Vascular Surgery And Its Patients In Sweden
Anders Wanhainen, MD, PhD
- 2:42 – 2:47** How Has Independence For Its Governing Bodies Helped Vascular Surgery And Its Patients In The UK
George Hamilton, MD
- 2:48 – 2:53** How Has The European Vascular Surgery FEBVS Exam Contributed To Vascular Surgery's Independence In Europe And Improved Patient Care
David McLain, FEBVS
- 2:54 – 2:59** The American Board of Vascular Surgery (ABVS) And The Vascular Surgery Board of The American Board of Surgery (VSB of ABS): Is There More
James C. Stanley, MD

RESIDENCY TRAINING IN VASCULAR SURGERY

- 3:00 – 3:05** Update On The Current Status Of 0+5 Vascular Surgery Residency Training
Murray L. Shames, MD
Karl A. Illig, MD
- 3:06 – 3:11** The New Residency Review Committee-Surgery (RRC-S) Vascular Criteria For Training In General And Vascular Surgery: What Will The Case Requirements Be: Is It Good For Vascular Surgery
Ronald L. Dalman, MD

BUSINESS, REIMBURSEMENT AND COST ISSUES

- 3:12 – 3:17** What Is Happening With Vascular Procedural Reimbursement In 2015: How Bad Will It Be
Sean P. Roddy, MD
- 3:18 – 3:23** Current Business Considerations In Medicine And Reimbursement: How Can We Deal With Them
Glenn Jacobowitz, MD
Mark A. Adelman, MD
- 3:24 – 3:29** What Vascular Specialists Can Do To Protect Their Assets From Frivolous Law Suits Related To Malpractice And Other Issues
Hillel L. Presser, Esq., MBA
- 3:30 – 3:35** Heart And Vascular Institutes: Boons Or Busts For Vascular Surgeons: What Are The Dangers
Timur P. Sarac, MD
- 3:36 – 3:41** The FAST Vascular Concept: A Method To Reduce Resource Utilization With EVAR And Open Repair Of AAAs
Sebastian E. Debus, MD, PhD
- 3:42 – 3:47** What Are The Drivers Of Cost For Treating SFA Occlusive Disease And AAAs: How Can These Costs Be Decreased
Richard J. Powell, MD
- 3:48 – 3:53** Setting Up A Functional Hybrid Room Involves More Than You Think: What Resources, Personnel And Costs Must Be Involved
Rodney A. White, MD
- 3:54 – 4:04** Panel Discussion And Break
Visit Exhibits And Pavilions (2nd and 3rd Floors)

SESSION 23 (Grand Ballroom West, 3rd Floor)

OUTPATIENT TREATMENT, IMPROVING CARE, RCTs, REGISTRIES

Moderators: Mark A. Adelman, MD

Jack L. Cronenwett, MD

- 4:04 – 4:09** Advantages Of An Outpatient Endovascular Center To An Academic Vascular Surgery Department
Mark A. Adelman, MD
- 4:10 – 4:15** What Organization(s) Should Set Standards, Accredite And Regulate Outpatient Vascular And Vein Diagnostic And Treatment Centers – Toward What Goals
Lowell S. Kabnick, MD, RPhS
- 4:16 – 4:21** The Importance Of Patient Reported Outcome Measures (PROMs) To Vascular Surgeons
Mark J.W. Koelemay, MD, PhD
- 4:22 – 4:27** Relationship Between Patient Satisfaction And Favorable Surgical Outcomes
K. Craig Kent, MD
- 4:28 – 4:33** Income vs. Outcomes In Vascular Patients: Low Income Is An Independent Risk Factor For Outcomes: Why
Hence J.M. Verhagen, MD, PhD
- 4:34 – 4:39** Access To Health Care Does Not Correlate With Limb Salvage In CLI: Race And Socioeconomic Status Do
Michael C. Stoner, MD
- 4:40 – 4:45** LEAN Principles And Their Application To Vascular Surgery: What Can Toyota Teach Us About Providing Better Vascular Health Care
Tej M. Singh, MD, MBA

EVIDENCE BASED MEDICINE AND RCTs

- 4:46 – 4:51** Commentary On Evidence Based Medicine And RCTs In Cardiovascular Surgery And Medicine; Not All RCTs Are Holy
Peter Samek, MD, PhD
- 4:52 – 4:57** RCTs Can Be Underpowered And Futile To Detect Small Effects In Many Instances: Some Examples
Charles C. Miller, PhD
- 4:58 – 5:03** In The Treatment Of Asymptomatic Carotid Stenosis: How Do RCTs Relate To The Real World: What Are The Pitfalls Of RCTs
Hans-Henning Eckstein, MD, PhD

IMPROVED TECHNOLOGY AND VASCULAR SPECIALISTS' PRACTICES

- 5:04 – 5:09** How Can Social Media Help Vascular Specialists
Ido Weinberg, MD, MSc
- 5:10 – 5:15** How A Smart Phone Can Change Your Practice For The Better: How A Computer Analysis Of EKGs Can Give You Ejection Fractions And Ventricular Wall Motion And Do Away With Many Cardiac Echo Studies
Lindsay Machan, MD
- 5:16 – 5:21** Update On The Status Of The SVS VQI Registry And What It Can Offer Clinically And For Research
Larry W. Kraiss, MD
Jack L. Cronenwett, MD
- 5:22 – 5:27** Are There Disadvantages To VQI Initiatives: Do They Give Rise To Conflicts
Kenneth Ouriel, MD, MBA
- 5:28 – 5:34** Panel Discussion

SESSION 24 (Grand Ballroom West, 3rd Floor)

ISSUES RELATING TO SIMULATION, TRAINING AND EDUCATION

Moderators: Jason T. Lee, MD
Mario Lachat, MD

SIMULATION, TRAINING AND EDUCATION

- 5:34 – 5:39** Advantages And Limitations Of Patient Specific Simulator Rehearsal Prior To EVAR And Other Procedures
Isabelle van Herzele, MD, PhD
- 5:40 – 5:45** Simulator Training vs. Clinical Invasive Experience: A RCT Showing Benefits Of Case Specific Simulator Training Even With Experienced Operators
Lars B. Lönn, MD, PhD
- 5:46 – 5:51** New Pathways And Technology To Improve Efficiency And Resource Use In Vascular Practice
Nicholas J.W. Cheshire, MD
- 5:52 – 5:57** VESAP 3: Where Is It And How Can It Help In MOC And Review For The Vascular Surgery Board Exams
John F. Eidt, MD
- 5:58 – 6:03** Advances In The Education Of Vascular Surgeons In Complex Endovascular Techniques: The Boot Camp Initiative And Regional Video Conferencing
Mark G. Davies, MD
Alan B. Lumsden, MD
- 6:04 – 6:10** Panel Discussion
End of Program C

WEDNESDAY, NOVEMBER 19, 2014

6:00 A.M. General Registration – Rhinelander Gallery, 2nd Floor

6:00 A.M. Faculty Registration – Morgan Suite, 2nd Floor

6:15 A.M. Continental Breakfast – 2nd Floor Promenade

CONCURRENT ARTERIAL AND VENOUS WEDNESDAY PROGRAMS

PROGRAM D: SESSIONS 25-33

New Technologies, TAAAs, CHIMPS, Parallel Grafts, F/B EVAR, Military Topics, Multilayer Stents, Robotics And Guidance Systems, Laparoscopy And Ruptured Aneurysms

6:45 A.M. – 6:08 P.M.

Grand Ballroom East, 3rd Floor

PROGRAM E: SESSIONS 34-41

Lower Extremity Ischemia, Popliteal Aneurysms, Aortic And Graft Infection, Vascular Disease And Medical Treatment, Technology Updates, Imaging, Thoracic Outlet, New Concepts And More On Renal Denervation

6:45 A.M. – 6:00 P.M.

Grand Ballroom West, 3rd Floor

PROGRAM F: SESSIONS 42-43

New Developments In Management Options For Pulmonary Embolism

Course Leader: Michael R. Jaff, DO

7:00 A.M. – 12:00 P.M.

Trianon Ballroom, 3rd Floor

SESSIONS 44-47

Large Vein Occlusive Disease And Its Treatment

Course Leader: Kenneth Ouriel, MD, MBA

1:00 P.M. – 5:00 P.M.

Trianon Ballroom, 3rd Floor

PROGRAM D (SESSIONS 25-33)

NEW TECHNOLOGIES, TAAAs, CHIMPS, PARALLEL GRAFTS, F/B EVAR, MILITARY TOPICS, MULTILAYER STENTS, ROBOTICS AND GUIDANCE SYSTEMS, LAPAROSCOPY AND RUPTURED ANEURYSM TREATMENT DISEASE AND THEIR TREATMENT

Grand Ballroom East, 3rd Floor

SESSION 25 (Grand Ballroom East, 3rd Floor)

EXCITING NEW TECHNOLOGY AND TECHNIQUES

Moderators: Ronald L. Dalman, MD

Kenneth Ouriel, MD, MBA

6:45 – 6:50

4 French Instrumentation For Lower Extremity Disease Treatment As An Outpatient: Experience In >2000 Patients Over 10 Years: How To Do It
Jos C. van den Berg, MD, PhD

6:51 – 6:56

Role Of Endovascular Adventitial Drug Delivery To Prevent Restenosis: The Bullfrog Catheter System
Christopher D. Owens, MD

6:57 – 7:02

A New Endovascular Balloon And A New Temporary Vascular Shunt To Help Treat Vascular Injury, Hemorrhage And Shock
Todd E. Rasmussen, MD

- 7:03 – 7:08** TAVR For Pure Aortic Insufficiency: How To Make It Work And What Is Left For Surgical Valve Repair
Dietmar H. Koschyk, MD
- 7:09 – 7:14** Percussion Crossing Device For Calcified CTOs: How Does It Work And Early Results Of Piculet Hammer Device
Max Amor, MD
- 7:15 – 7:20** Will Drug-Eluting Fully Bioabsorbable Scaffolds Prove Advantageous In The Coronary Arteries
Gregg W. Stone, MD
- 7:21 – 7:26** Some Innovative New Devices From Tim Chuter: The Inch Worm Balloon; The Shapeshifter Catheter And Microstents
Timothy A.M. Chuter, DM
- 7:27 – 7:32** Panel Discussion

SESSION 26 (Grand Ballroom East, 3rd Floor)

NEW INFORMATION ABOUT PARALLEL GRAFTS – CHIMNEYS, PERISCOPES AND SANDWICH GRAFTS (CHIMPS) FOR TAAAs

Moderators: *Timur P. Sarac, MD*
Giovanni Torsello, MD

- 7:32 – 7:37** Current Role Of Chimneys And Parallel Grafts For The Treatment Of Complex Aortic Aneurysms
Frank J. Criado, MD
- 7:38 – 7:43** Value And Limitations Of Periscope Grafts For Distal TAAAs
Jason T. Lee, MD
- 7:44 – 7:49** Brazilian Registry Of Sandwich Technique Repairs For TAAAs: Mid-Term Results And How Do They Compare With Results Of Fenestrated And Branched Repairs
Armando C. Lobato, MD, PhD
- 7:50 – 7:55** The Eye Of The Tiger Technique To Eliminate Gutter Endoleaks With Parallel Grafts
David J. Minion, MD
- 7:56 – 8:01** Late Outcomes Of Thoracic And Visceral Chimney Grafts: Are They Durable
Martin Malina, MD, PhD
- 8:02 – 8:07** **DEBATE:** Mid-Term Results Of Sandwich Grafts For TAAAs Equal Those Of Branched Endografts
Ralf R. Kolvenbach, MD
- 8:08 – 8:13** **DEBATE:** Branched Endografts Are Better Treatment For TAAAs Than Sandwich Grafts Or Other Parallel Grafts
Stephan Haulon, MD
- 8:14 – 8:20** Panel Discussion

SESSION 27 (Grand Ballroom East, 3rd Floor)

IN HONOR OF ROY K. GREENBERG, MD: MORE ABOUT TAAAs: OPEN SURGERY, CHIMPS, FENESTRATED AND BRANCHED (F/B) ENDOGRAFTS

Moderators: *Frank J. Veith, MD*
Piergiorgio Cao, MD

- 8:20 – 8:25** New Strategies For Open Treatment Of TAAAs Including Sutureless Revascularization Of Renal Arteries Using A Novel Hybrid Graft And Other Techniques
Roberto Chiesa, MD
Germano Melissano, MD

- 8:26 – 8:31** Why Do TAAAs In Young Patients With Connective Tissue Disorders Still Require Open Surgery And Are There Differences Between Degenerative And Post Dissection TAAAs That Should Influence Treatment
Michael J. Jacobs, MD
Geert Willem H. Schurink, MD, PhD
- 8:32 – 8:37** **DEBATE:** Fenestrated And Branched F/B EVAR Is The Best And Most Durable Treatment For Pararenal And Thoracoabdominal Aneurysms
Matthew J. Eagleton, MD
- 8:38 – 8:43** **DEBATE:** Outcomes Of Multiple Chimney And Periscope Grafts For Pararenal And Thoracoabdominal Aneurysms Are Equal To F/B Endografts And More Versatile
Mario Lachat, MD
- 8:44 – 8:49** Mid-Term Outcomes And Technical Tips For Sandwich Endografts To Repair Pararenal And TAAAs: Are They Competitive With F/B Endografts
Armando C. Lobato, MD, PhD
- 8:50 – 8:55** 2-Year Experience With An Off-The-Shelf Multibranched Endograft (T-Branched Graft From Cook) For TAAAs: Advantages And Limitations
Martin J. Austermann, MD
Theodosios Bisdas, MD
Konstantinos P. Donas, MD
Giovanni Torsello, MD
- 8:56 – 9:01** **DEBATE:** Off-The-Shelf Endografts For Complex AAAs And TAAAs: They Are Up To The Job
Timothy A. Resch, MD, PhD
- 9:02 – 9:07** **DEBATE:** Off-The-Shelf Endografts For Complex AAAs And TAAAs: They Are Not Ready For Wide Usage
Colin D. Bicknell, MD
- 9:08 – 9:13** Why I No Longer Use Surgeon-Modified Endografts For Complex AAAs And TAAAs: Advantages Of Industry-Made Endografts: Does Staging Of Endograft Repair Of TAAAs Help Prevent Paraplegia
Gustavo S. Oderich, MD
- 9:14 – 9:19** Advantages And Limitations Of Internally Branched Endografts For Complex AAAs And TAAAs
Marcelo Ferreira, MD
- 9:20 – 9:28** Panel Discussion
- 9:28 – 9:40** Break – Visit Exhibits And Pavilions (2nd and 3rd Floors)

SESSION 28 (Grand Ballroom East, 3rd Floor)

MORE ABOUT PARALLEL GRAFTS AND F/B GRAFTS FOR AAAs, TAAAs AND COMPLICATIONS OF TBADs

Moderators: *Matthew J. Eagleton, MD*
James F. McKinsey, MD

- 9:40 – 9:45** The Geppetto Technique To Avoid Brachial Access In Complex Endovascular Interventions Requiring Revascularization Of Multiple Branches
David J. Minion, MD
- 9:46 – 9:51** The Nellix Endovascular Device Can Be Used With Multiple Chimneys For Juxta And Suprarenal AAAs And Ruptured AAAs: How To Do It
Ian Loftus, MD
- 9:52 – 9:57** The Nellix Device Can Be Used To Treat Juxtarenal Elective And Ruptured AAAs By Employing Parallel Grafts To The Renal Arteries
Michael M.P. Reijnen, MD, PhD

- 9:58 – 10:03** Gore Hybrid Grafts To Facilitate Visceral Debranching In Complex Hybrid Aortic Aneurysm Repairs
Sebastian E. Debus, MD, PhD
- 10:04 – 10:09** The Gutter Killer: A New Catheter For Embolization Of Gutter Endoleaks In Parallel Grafts
Martin Malina, MD, PhD
- 10:10 – 10:15** What Are Frequently Encountered Problems With F/B Endografts: How Can They Be Prevented And Corrected
Tara M. Mastracci, MD
- 10:16 – 10:23** Panel Discussion
- Moderators:** *Jerry Goldstone, MD*
Mario Lachat, MD
- 10:24 – 10:29** Mid-Term Outcomes Of Sandwich Grafts For Revascularizing Hypogastric Arteries With Common Iliac Aneurysms
Armando C. Lobato, MD, PhD
- 10:30 – 10:35** Parallel Grafts (Chimney Or Periscope Grafts) Can Be Used To Revascularize A Critical IMA During EVAR Treatment Of AAAs
Ross Milner, MD
- 10:36 – 10:41** Technique For Placing Guiding Sheaths, Stents And Stent-Grafts Into Visceral Arteries For Parallel Graft Procedures Complicated By Extreme Tortuosity Or Previous Hardware: How An Aortic Balloon Can Help
Jeffrey Y. Wang, MD
- 10:42 – 10:47** Parallel Grafts (CHIMPS) For Revascularizing Vital Aortic Branches At All Levels Are Effective: What Is Their Value And Their Limitation
Chang Shu, MD
- 10:48 – 10:53** Mid And Long-Term Results With Parallel Grafts (CHIMPS) In Complex AAA Repairs: How Good Are They
Alan M. Graham, MD
- 10:54 – 10:59** A Side-By-Side Computational Flow Dynamic Analysis Of The Various Devices Used For Thoracoabdominal Aneurysm Repair
Patrick W. Kelly, MD
Tyler Remund, PhD
Stephen Gent, PhD
- 11:00 – 11:06** Panel Discussion

SESSION 29 (Grand Ballroom East, 3rd Floor)

A TRIBUTE TO OUR MILITARY (8 AND 9-MINUTE TALKS)

Moderators: *Eric Elster, MD*
Todd E. Rasmussen, MD

- 11:07 – 11:16** The Doolittle Raiders And 30 Seconds Over Tokyo: What Did Their Skill And Courage Do For The US In World War II
Wayne F. Yakes, MD
- 11:17 – 11:25** Lessons Learned From Treating Combat Casualties In Our Operations In Iraq And Afghanistan
Todd E. Rasmussen, MD
- 11:26 – 11:34** Early Treatment Of Pediatric Vascular Injuries And Mass Casualties: Experience During Humanitarian Surgical Care During US Military Operations In Iraq And Afghanistan
Charles J. Fox, MD
- 11:35 – 11:43** Recent Progress In Treating Major Vascular War Wounds
Eric Elster, MD

- 11:44 – 11:53** What Biomedical Research That Is Important To All Of Us Is Being Conducted Aboard The International Space Station
Lee M. Morin, MD, PhD
- 11:54 – 12:00** Panel Discussion
- 12:00 – 1:00** Lunch Break – 2nd Floor Promenade
Visit Exhibits And Pavilions (2nd and 3rd Floors)

SESSION 30 (Grand Ballroom East, 3rd Floor)

NEW CONCEPTS, DIFFERING VIEWPOINTS, CONTROVERSIES IN VASCULAR DISEASE AND ITS TREATMENT

Moderators: *Enrico Ascher, MD*
Herbert Dardik, MD

- 1:00 – 1:05** Appropriate Genome-Based Antiplatelet Treatment Should Be A Prerequisite For All Interventional Treatments
Karthikeshwar Kasirajan, MD
- 1:06 – 1:11** Combined Anatomic-Functional Testing With Coronary CT Angiography And Functional Flow Dynamics Is A Game Changer In Evaluating Cardiac Status In Vascular Patients: It Will Replace All Other Diagnostic Tests
Christopher K. Zarins, MD
- 1:12 – 1:17** Value Of Biomarkers For Arteriosclerosis In Predicting Cardiac Risk In Vascular Patients
Peter Henke, MD
- 1:18 – 1:23** Monocyte Phenotyping: A Sensitive Biomarker For Predicting Adverse Vascular Events
John P. Fletcher, MD
- 1:24 – 1:29** Arrhythmias: What Other Vascular Specialists Need To Know About How Their Patients Can Be Treated
Larry Chinitz, MD
- 1:30 – 1:35** What Is SPY Technology And How Can It Help Vascular Specialists And Vascular Patients
Wei Zhou, MD
- 1:36 – 1:41** **DEBATE:** Off Label Use Of EVAR Devices Leads To Higher Failure Rates
Andres Schanzer, MD
- 1:42 – 1:47** **DEBATE:** Not So! Off-Label Use Of Newer EVAR Devices Does Not Lead To Higher Failure Rates: Why The Discrepancy
B. Patrice Mwipatayi, FRACS
- 1:48 – 1:53** Saccular AAAs Behave Differently From Fusiform AAAs Of The Same Diameter: How Should It Influence Our Treatment: Is There Proof
Jacques Busquet, MD
- 1:54 – 1:59** **DEBATE:** How Far Should We Go With Endovascular Treatment Of Challenging CTOs Causing CLI: An Interventionalist's Point Of View
Craig M. Walker, MD
- 2:00 – 2:05** **DEBATE:** How Far Should We Go With Endovascular Treatment Of Challenging CTOs Causing CLI: An Endocompetent Vascular Surgeon's View
Enrico Ascher, MD
- 2:06 – 2:13** Panel Discussion

SESSION 31 (Grand Ballroom East, 3rd Floor)

NEW DATA ON MULTILAYER FLOW MODULATING (MLFM) BARE STENTS IN THE TREATMENT OF ANEURYSMS AND DISSECTIONS (SEE ALSO SESSION 53)

Moderators: *Frank J. Veith, MD*

Edward B. Diethrich, MD

- 2:13 – 2:18** Update On The Value Of MLFM Uncovered Stents In The Treatment Of Visceral And Popliteal Aneurysms: Do They Shrink: Have Any Ruptured
Claudio Rabbia, MD
Maria Antonella Ruffino, MD
- 2:19 – 2:24** Endovascular Treatment Of Complex Thoracic Aortic Aneurysm With Multiple Overlapping Bare Stents Can Decrease Spinal Cord Ischemia (SCI) And Result In Decreased Aneurysm Size: When Is This Treatment Appropriate
Qingsheng Lu, MD
Zaiping Jing, MD
- 2:25 – 2:30** Continuing Impressions Of The Value Of MLFM Bare Stents In Treating Complex Aortic Aneurysms
Edward B. Diethrich, MD
- 2:31 – 2:36** Mechanisms Whereby MLFM Bare Stents Could Prevent Aneurysm Rupture: Do They Work
Jean-Marc Alsac, MD, PhD
- 2:37 – 2:42** Brazilian Experience With MLFM Stents In The Treatment Of Aortic Aneurysms
Daniel Benitti, MD
- 2:43 – 2:48** 3-Year Results Of The French Registry Of MLFM Stents In The Treatment Of Thoracic And Abdominal Complex Aortic Aneurysms
Claude D. Vaislic, MD
- 2:49 – 2:54** Value And Limitations Of The MLFM Stent In Treating Arch Aneurysms And Dissections
Erno Ramsey-Semmelweis, MD, PhD
- 2:55 – 3:00** Pros And Cons Of MLFM Stents For The Treatment Of Complex Aortic Aneurysms: A Balanced View And Is Sac Thrombosis Good Or Bad For Aneurysm Wall Integrity And Rupture: What Is The Mechanism
Frans L. Moll, MD, PhD
- 3:01 – 3:06** Advantages And Limitations Of MLFM Stents For Aortic Aneurysm Treatment: When Do They Work And When Don't They: Results Of The German Registry
Ralf R. Kolvenbach, MD
- 3:07 – 3:12** **DEBATE:** The MLFM Device Is A Disruptive Technology For Aortic Aneurysm And Dissection Based On The Results Of A Global Registry
Sherif Sultan, MD
- 3:13 – 3:18** **DEBATE:** MLFM Stents Are Not An Effective Treatment For Complex Aortic Aneurysm And Do Not Prevent Sac Growth And Rupture
Thomas Larzon, MD, PhD
- 3:19 – 3:29** Panel Discussion
- 3:30 – 3:40** Break – Visit Exhibits And Pavilions (2nd and 3rd Floors)

SESSION 32 (Grand Ballroom East, 3rd Floor)

**NEW DEVELOPMENTS IN ROBOTICS,
ENDOVASCULAR GUIDANCE, ENDOSCOPY
ACCESS AND OTHER IMPROVED TECHNOLOGY**

Moderators: Alan B. Lumsden, MD

Nicholas J.W. Cheshire, MD

IMPROVED ROBOTIC GUIDANCE

- 3:40 – 3:45** Experience With Improved Lower Profile Robotic Catheter Techniques: They Facilitate Many Endovascular Procedures Including Complex Embolizations
Barry T. Katzen, MD
- 3:46 – 3:51** How Can Robotic Navigation Be Combined With 3D Imaging To Make Complex Endovascular Procedures Easier, Quicker And More Predictable With Complex Anatomy: How Does The 6 French System Help
Alan B. Lumsden, MD
- 3:52 – 3:57** How Can Robotic Assistance And Guidance Be Helpful With Complex Anatomy For CAS And F/B EVAR: What About Radiation Exposure
Nicholas J.W. Cheshire, MD
Celia Riga, MD
- 3:58 – 4:03** What Does The ROVER Registry Tell Us About Advantages Of Robotic Catheter Based Procedures: Faster, Less Arterial Wall Trauma, Decreased Radiation Exposure, Improved Crossing Of Difficult CTOs
Jean Bismuth, MD
- 4:04 – 4:09** Minimally Invasive Treatment Of Paget-Schroetter Disease With EKOS Ultrasound Assisted Thrombolysis And Robot Assisted First Rib Resection: How The Robot Helps
Hans M.E. Coveliers, MD, MBA
- 4:10 – 4:15** The Truth About Endoscopic Vein Harvest: Is It Worthwhile: Based On VQI Observations
Fred A. Weaver, MD
- 4:16 – 4:21** Tips And Tricks For Radial Access For Lower Extremity And Other Remote Lesion Treatments: Equipment Required
Marcelo Guimaraes, MD
- 4:22 – 4:27** Update With New Simplified Aortic Occlusion Balloon For Ruptured AAAs And Other Hemorrhagic Emergencies: Advantages, Limitations And Clinical Experience: Scoring System To Help Tell Us Which Ruptured AAAs Should Not Be Treated
Benjamin W. Starnes, MD
- 4:28 – 4:33** When Can Improved Duplex Ultrasound Replace Contrast CTA For Post-EVAR Surveillance And Detecting Failing Lower Extremity Stent-Grafts
Keith D. Calligaro, MD
- 4:34 – 4:40** Panel Discussion

SESSION 33 (Grand Ballroom East, 3rd Floor)

NEW DEVELOPMENTS IN THE TREATMENT OF RUPTURED AAAs (SEE ALSO SESSION 81)

Moderators: *Benjamin W. Starnes, MD*
Matt M. Thompson, MD

4:40 – 4:45 100% Of Ruptured AAAs (RAAAs) Can Be Treated Endovascularly If Chimney, Periscopes And Other Adjuncts Are Used: Turn-Down Rates Are Low And Early Mortality Is Low
Dieter O. Mayer, MD
Thomas Larzon, MD, PhD
Mario Lachat, MD

THE RECENT RCTs OF RAAAs: FACTS AND FLAWS – A MEGA DEBATE

4:46 – 4:51 Results From The French ECAR RCT Results Comparing EVAR With Open Repair For RAAAs
Pascal Desgranges, MD, PhD

4:52 – 4:57 Results From The Dutch AJAX RCT Comparing EVAR With Open Repair For RAAAs
Willem Wisselink, MD

4:58 – 5:03 Early Results From The UK IMPROVE Trial Comparing An EVAR Strategy With Open Repair For RAAAs: It Shows That The EVAR Strategy Has No Lower Early Mortality Than Open Repair
Janet T. Powell, MD, PhD

WHY THE RCTs ARE MISLEADING

5:04 – 5:09 IMPROVE Trial Is A Laudable Study, But Its Conclusion Is Flawed: EVAR Is Better Than Open Repair For RAAAs
Frank J. Veith, MD

5:10 – 5:15 The 3 Recent RAAA RCTs Are Flawed And Misleading: What Are These Flaws
Nicholas J.W. Cheshire, MD

5:16 – 5:21 EVAR Is Clearly Better Than Open Repair And We Do Not Need An RCT To Prove It
Mario Lachat, MD

5:22 – 5:27 The Recent RCTs Comparing EVAR To Open Repair For RAAAs Are Misleading And We Do Not Need More RCTs To Prove EVAR Is Better
Thomas Larzon, MD, PhD

OTHER OPINIONS AND DATA

5:28 – 5:33 EVAR Clearly Should Be The First Treatment Choice For RAAAs: We Don't Need More Trials To Prove It
Edward B. Diethrich, MD
Julio A. Rodriguez, MD

5:34 – 5:39 Does A Fixed Protocol For Treating Ruptured AAAs By EVAR Improve Outcomes: Based On A Prospective Multicenter Registry Results
Kim J. Hodgson, MD

5:40 – 5:45 Meta-Analysis Of Recent RCTs Comparing EVAR With Open Repair For Ruptured AAAs: It Is Level 1A Evidence, But It May Be Misleading
Ron Balm, MD, PhD

5:46 – 5:51 Long-Term Survival Of Ruptured AAAs Is Better After EVAR Than After Open Repair: The Early Survival Benefit Of EVAR Persists Beyond 5 Years
Dieter O. Mayer, MD
Mario Lachat, MD
Frank J. Veith, MD
Zoran Rancic, MD, PhD

5:52 – 5:57 Why Are Treatment Outcomes For RAAAs Better In The US Than In The UK: Hints For Improving Results And Support For The Position That EVAR Is Better Than Open Repair
Matt M. Thompson, MD

5:58 – 6:08 Panel Discussion
End of Program D

PROGRAM E (SESSIONS 34-41)
LOWER EXTREMITY TREATMENTS, POPLITEAL ANEURYSMS, INFECTED AORTIC GRAFTS, TREATMENT OF VASCULAR DISEASES, MEDICAL TREATMENT, UPDATES, TECHNOLOGY, IMAGING, THORACIC OUTLET, NEW CONCEPTS, MORE ON RENAL DENERVATION
Grand Ballroom West, 3rd Floor

SESSION 34 (Grand Ballroom West, 3rd Floor)
NEW FINDINGS AND INFORMATION ON THE TREATMENT OF POPLITEAL ANEURYSM (SEE ALSO SESSION 62)

Moderators: Enrico Ascher, MD
Barry T. Katzen, MD

6:45 – 6:50 What Are The Real Results Of Endovascular Popliteal Aneurysm Repair: When Is It Indicated And When Contraindicated
Sonia Ronchey, MD, PhD

6:51 – 6:56 Anatomic Features That Predict Complications Of Endovascular Aneurysm Repair And When It Is Contraindicated
Thomas L. Forbes, MD

6:57 – 7:02 The Modern Treatment Of Popliteal Aneurysms Varies Widely: Why Is This So: Value Of Thrombolysis: What Is The Best Surgical Approach
Martin Björck, MD, PhD

7:03 – 7:08 Long-Term Outcomes And Sac Shrinkage After Endovascular Popliteal Aneurysm Repair: What Are The Implications
Franco Grego, MD
Giovanni Deriu, MD

7:09 – 7:14 Avoidance And Treatment Of Complications After Endografting For Popliteal Aneurysm
Irwin V. Mohan, MD, MBBS

7:15 – 7:20 Popliteal Aneurysm Treatment: When Endo, When Open: Technical Tips: Primary And Secondary Patency Results; Reintervention Is Not Always Required For Graft Failure
Neal S. Cayne, MD

THREE-PART DEBATE

7:21 – 7:26 **DEBATE:** Endovascular Treatment Is Inferior For Popliteal Aneurysms Needing Treatment
Werner Lang, MD

7:27 – 7:32 **DEBATE:** Some Popliteal Aneurysms Should Be Treated Endo; Some Open
Bauer E. Sumpio, MD, PhD

7:33 – 7:38 **DEBATE:** Almost All Popliteal Aneurysms Can Be Treated Endovascularly: Technical Considerations And Outcomes: What Was The Outcome Of The Former Vice President's Large Popliteal Aneurysm Repairs In 2004
Barry T. Katzen, MD

7:39 – 7:44 Panel Discussion

SESSION 35 (Grand Ballroom West, 3rd Floor)

NEW DEVELOPMENTS IN THE TREATMENT OF
INFECTED AORTIC GRAFTS AND ENDOGRAFTS;
VALUE OF EVAR FOR MYCOTIC ANEURYSMS

Moderators: *Dennis F. Bandyk, MD*

Keith D. Calligaro, MD

7:45 – 7:50 Update On Silver/Triclosan Synergy Prosthesis For In Situ Replacement Of Infected Aortic Prostheses: They Really Work Based On The SATIGI Registry And Other Data

Max Zegelman, MD

7:51 – 7:56 Endovascular Treatment Of Mycotic AAAs: When Does It Work And For How Long: Based On 132 Cases With Long Follow-up

Anders Wanhainen, MD, PhD

7:57 – 8:02 When Are Endografts The Best Treatment For Aortic Infection And When Are They Not

Francesco Setacci, MD

8:03 – 8:08 Conservative Treatment Of Endograft Infection After EVAR With CT Guided Drainage And Graft Preservation: When Can It Work And When Can It Not

Kamphol Laohapensang, MD

8:09 – 8:14 Treatment Of Para And Suprarenal Aortic Graft Infection: Do Endografts Play A Role

Manju Kalra, MBBS

8:15 – 8:20 Technical Tips For Removing An Infected Endograft: It Is Not Simple

Thomas C. Bower, MD

8:21 – 8:26 EVAR Can Be Effective Treatment For Infected Aneurysms In All Parts Of The Aorta With Both Simple And Complex Anatomies: Chimney Grafts May Be Needed: How To Do It Successfully And Get Long-Term Survival

Boonprasit Kritpracha, MD

8:27 – 8:32 **DEBATE:** Management Of Mycotic Aneurysms And Infected Stent-Grafts After EVAR And TEVAR: Infected Endografts Must Come Out

Piotr M. Kasprzak, MD

8:33 – 8:38 **DEBATE:** Not So: A New Treatment Paradigm For Treating Infected Endografts After EVAR And Mycotic Aneurysms May Allow Endograft Preservation

Martin Malina, MD, PhD

8:39 – 8:44 How To Treat Mycotic Thoracic Aneurysms

Roberto Chiesa, MD

Germano Melissano, MD

8:45 – 8:52 Panel Discussion

SESSION 36 (Grand Ballroom West, 3rd Floor)

EXCITING NEW DEVELOPMENTS IN THE MEDICAL
TREATMENT OF VASCULAR DISEASE

Moderators: *Russell H. Samson, MD, RVT*

Frans L. Moll, MD, PhD

8:52 – 8:57 Do Atherosclerotic Plaques Regress: How And Why: What Are The Implications For Treatment

Ralph G. DePalma, MD

- 8:58 – 9:03** How Can The Medical Treatment Of Arteriosclerosis Be Improved: Should More Patients Receive Statins: Do HDL Levels Matter: Does Elevating A Low HDL Level Help In Any Way: What Is On The Horizon For Improving Drug Or Medical Treatment For Arteriosclerosis
Don Poldermans, MD
- 9:04 – 9:09** What Do The New AHA Cholesterol Guidelines And The New Information About Beta Blockers Mean To Vascular Surgeons
Peter Henke, MD
- 9:10 – 9:15** Medical Therapy In Peripheral Artery Disease: Anything New On The Horizon: What Is The Value Of Chronic PA Pressure Monitoring With The CardioMEMS Implantable Pressure Sensor
Jeffrey S. Berger, MD, MS
- 9:16 – 9:21** Why All Vascular Patients Should Have Perioperative Or Periprocedural Troponins: How Do They Help In Patient Treatment
Jeffrey S. Berger, MD, MS
- 9:22 – 9:27** How Long Should Dual Antiplatelet Treatment Be Continued After Patients Receive A Coronary Stent (BMS Or DES): When Is It Safe To Stop Clopidogrel And Perform Non-Cardiac Surgery – An AAA, A Leg Bypass Or CEA: What To Do If Surgery Cannot Be Delayed: Based On New Findings From The OPTIMIZE Trial
Ron Waksman, MD
- 9:28 – 9:33** Vitamin D Supplementation And Tight Blood Glucose Control In Diabetics Do Not Have A Major Impact On The Progression Of Vascular Disease: Other Factors Are More Important
Erich Minar, MD
- 9:34 – 9:39** How To Prevent And Treat Postoperative Delirium After Vascular Surgery
Clark J. Zeebregts, MD, PhD
- 9:40 – 9:47** Panel Discussion
- 9:48 – 10:00** Break – Visit Exhibits And Pavilions (2nd and 3rd Floors)

SESSION 37 (Grand Ballroom West, 3rd Floor)

NEW DEVELOPMENTS IN ENDOVASCULAR TECHNOLOGY, TECHNIQUES AND THE MEDICAL TREATMENT OF VASCULAR DISEASE

Moderators: *Alan B. Lumsden, MD*
Richard J. Powell, MD

- 10:00 – 10:05** Imaging With Lower Radiation Exposure Using A Novel Fixed C-Arm System During Endovascular Procedures: The Philips Allura Clarity Hybrid OR
Olivier H.J. Koning, MD, PhD
- 10:06 – 10:11** Unusual Uses Of Re-entry Devices: They Are An Essential Tool
Konstantinos Katsanos, MSc, MD, PhD
- 10:12 – 10:17** **DEBATE:** Be Skeptical About The Need For Atherectomy Systems: The New Ones May Be No Better Than The Old Ones
Frank J. Criado, MD
- 10:18 – 10:23** **DEBATE:** Not So Fast, Leaving Nothing Behind Trumps Any Permanent Device In The SFA: Current Evidence And Clinical Utility Of Atherectomy Systems
Lawrence A. Garcia, MD

- 10:24 – 10:29** Endovenous Or Perivascular Routes For Internal Prosthetic Bypasses In The SFA And Popliteal Arteries: How Can IVUS And Robotics Help: A New Treatment Concept
Alan B. Lumsden, MD
Tony S. Das, MD
- 10:30 – 10:35** Where Do We Stand With Cell Therapy For Ischemia In The Legs; In The Heart
Alan Dardik, MD, PhD
- 10:36 – 10:41** Tips And Tricks For Endovascular Interventions In Pediatric Patients
Furuzan Numan, MD
- 10:42 – 10:47** Manifestations And Treatment Of Spontaneous Renal Artery Dissections
James C. Stanley, MD
- 10:48 – 10:57** Panel Discussion

NEW DEVELOPMENTS IN MEDICAL TREATMENT AND RISK MODIFICATION

Moderators: *Ron Waksman, MD*
Jack L. Cronenwett, MD

- 10:57 – 11:02** How To Improve 5-Year Survival After Vascular Surgery By 25% Or More: Give Proper Doses Of Statins And Antiplatelet Agents
Jack L. Cronenwett, MD
- 11:03 – 11:08** Preoperative Statin Administration Decreases The Incidence Of Contrast Induced Kidney Injury
John H. Rundback, MD
- 11:09 – 11:14** A Frailty Index And What It Can Mean For Vascular Specialists Or Surgeons Interested In Vascular Disease Patients: Is It Better Than The Eyeball Test
Gregory L. Moneta, MD
- 11:15 – 11:20** Differential Effect Of Arteriosclerotic Risk Factors In Men And Women: Why Does It Matter
Caron B. Rockman, MD
- 11:21 – 11:26** Cilostazol Is Associated With Improved Outcomes After Vascular Interventions: Should Vascular Specialists Use It And How
Richard J. Powell, MD
- 11:27 – 11:32** What Test Should We Use To Evaluate Antiplatelet Drugs In Vascular Patients – Especially Those Undergoing A Procedure
Frans L. Moll, MD, PhD
- 11:33 – 11:38** Importance Of Smoking Cessation Prior To Lower Extremity Bypasses: It Decreases The Failure Rate
Christopher J. Abularrage, MD
James H. Black III, MD
- 11:39 – 11:44** How To Prevent Cardiovascular Death In Diabetic Patients With CLI And Arteriosclerosis: It Is As Important As Saving The Limb
Francesco Liistro, MD
- 11:45 – 11:50** Characteristics Of Patients Who Currently Develop Acute Limb Ischemia And What Is Their Long-Term Prognosis
Beatrice R. Amann-Vesti, MD
- 11:51 – 12:00** Panel Discussion
- 12:00 – 1:00** Lunch Break – 2nd Floor Promenade
Visit Exhibits And Pavilions (2nd and 3rd Floors)

SESSION 38 (Grand Ballroom West, 3rd Floor)

ADVANCES IN IMAGING

Moderators: *Barry T. Katzen, MD*

Henrik Sillesen, MD, DMSc

- 1:00 – 1:05** Selective Intra-Arterial CTA For Lower Extremity Occlusive Disease In Patients With Renal Insufficiency: It Decreases Contrast Dose And Is Safe
Anders Wanhainen, MD, PhD
- 1:06 – 1:11** Advantages Of An Integrated 3-D Imaging Solution For Planning, Fusion And Assessment Of Complex Aortic Procedures
Stephan Haulon, MD
- 1:12 – 1:17** Aortic Procedures Of The Future Will Mandate 3D Imaging For Planning And Preparation, And For Performing
Dittmar Boeckler, MD
- 1:18 – 1:23** The Use Of A Computerized Patient Specific Model And MRA Data To Predict Pressure Drops Across Equivocal Stenoses
Jean-Paul de Vries, MD, PhD
- 1:24 – 1:29** Precannulation Of Visceral And Renal Arteries Using Fusion Software On The Artis Zeego System During F/B EVAR Is Fast, Simple, And Valuable: How To Do It
Neal S. Cayne, MD
- 1:30 – 1:35** Value And Implementation Of 3D Ultrasound Scans For All AAA Evaluations: What Can And Should Be Measured: What Equipment Is Needed
Henrik Sillesen, MD, DMSc
- 1:36 – 1:41** 3D Ultrasound Is The CT Scan Of The Future And Eliminates Radiation Exposure
Brajesh K. Lal, MD
- 1:42 – 1:47** What New Information Can Be Learned From 3D Ultrasound Of AAAs: How Can It Provide Finite Element Analysis
Marc R.H.M. van Sambeek, MD, PhD
- 1:48 – 1:53** Panel Discussion
- 1:54 – 1:59** What Important Information Can Be Obtained From Transcranial Doppler (TCD) If You Know How To Get It: Wider Use Of TCD Is Justified
Zolt Garami, MD
- 2:00 – 2:05** 3D Holography To Guide Endovascular Interventions: How Does It Work: Can CTA Be Avoided And MRI And 3D Ultrasound Take Its Place
Elchanan Bruckheimer, MBBS
- 2:06 – 2:11** A Complete Mobile Hybrid Room With Ziehm Vision RFD Hybrid C-Arm And Stille Imagiq2 Floating Table For Complex Endovascular Procedures: Advantages And Limitations Compared To A Fixed Hybrid Room
Peter C.J. Goverde, MD
- 2:12 – 2:17** **DEBATE:** Should Duplex Ultrasound Replace CTA For Post EVAR Surveillance: YES, In Most Cases
Michel Makaroun, MD
- 2:18 – 2:23** **DEBATE:** Should Duplex Ultrasound Replace CTA For Post EVAR Surveillance: NO, In Most Cases
S. Rao Vallabhaneni, MD
- 2:24 – 2:29** Panel Discussion

SESSION 39 (Grand Ballroom West, 3rd Floor)

ADVANCES AND UPDATES IN THE TREATMENT OF THORACIC OUTLET SYNDROMES, AN HISTORICAL VIGNETTE AND NEW DEVICES AND CONCEPTS

Moderators: *R. Clement Darling III, MD*

Julie Ann Freischlag, MD

- 2:29 – 2:34** New Thoracic Outlet Syndrome (TOS) SVS Reporting Standards: What Is New
Karl A. Illig, MD
- 2:35 – 2:40** Treatment Of TOS And Popliteal Entrapment In High Performance Athletes: What Is The Role Of Exercise, Physiotherapy And Surgery
Jason T. Lee, MD
- 2:41 – 2:46** Some Patients With Presumed Neurogenic TOS Really Have Jugular And Subclavian Venous Stenosis: Balloon Angioplasty Can Provide Symptom Relief
Sam S. Ahn, MD, MBA
- 2:47 – 2:52** Current Optimal Treatment For Arterial Compression At The Thoracic Outlet
Enrique Criado, MD
- 2:53 – 2:58** Historical Vignette: The First Endoleak And The First AAA Repair By Norman Freeman – Before Charles Dubost's
Christopher K. Zarins, MD
- 2:54 – 2:59** Infrared IVUS: A New Technique For Detecting Vulnerable Plaque
Ron Waksman, MD
- 3:00 – 3:05** Early Experience With A New Improved Digital Mobile C-Arm: The Cios Alpha System From Siemens: Advantages And Limitations
Sebastian E. Debus, MD, PhD
- 3:06 – 3:15** Panel Discussion
- 3:15 – 3:30** Break – Visit Exhibits And Pavilions (2nd and 3rd Floors)

SESSION 40 (Grand Ballroom West, 3rd Floor)

NEW CONCEPTS, TECHNIQUES, UPDATES

Moderators: *Christopher K. Zarins, MD*

Amman Bolia, MD

- 3:30 – 3:35** Value And Limitations Of Optical Coherence Tomography For Use In Lower Extremity Vascular Assessment And Treatments
Vikram S. Kashyap, MD
- 3:36 – 3:41** Sensible And Extreme Approach To Limb Preservation (The SEAL Approach): Who And What Is Involved And What Are The Benefits: Should There Be SEAL Centers
Niten Singh, MD
- 3:42 – 3:47** The Chocolate Balloon: A New Better Less Traumatic Drug Coated Balloon For Dilating Arterial Lesions With Less Dissection: Mode Of Action, Advantages And Clinical Experience
Jihad A. Mustapha, MD
- 3:48 – 3:53** Does Prostate Endovascular Embolization Work: For What Conditions: Advantages And Limitations
Jörn O. Balzer, MD, PhD
- 3:54 – 3:59** Pathophysiology Of Hand And Finger Ischemia In Hemodialysis Patients And How It Can Best Be Treated
Robert Ferraresi, MD

- 4:00 – 4:05** Update On Tissue Engineered Arterial Prostheses: Progress And Remaining Challenges
Elliot L. Chaikof, MD, PhD
- 4:06 – 4:11** For Recanalizing Lower Extremity CTOs Above And Below The Knee, Simpler And Cheaper Devices Are Better: It Does Not Matter Whether The Route Is Intraluminal Or Subintimal
Amman Bolia, MD
- 4:12 – 4:17** Will DEBs Become The Gold Standard For Dilating Bare Metal Stents (BMSs) In The SFA: Will This Strategy Be Cost Effective
Stefan Müller-Hülsbeck, MD
- 4:18 – 4:23** Current Optimal Techniques For Minimizing Contrast Induced Nephropathy After Angiographic Procedures
Jonathan R. Boyle, MD
- 4:24 – 4:29** Quantitative Determination Of Respiratory Movement Of Aorta And Side Branches In Image Fusion Guidance: How Can It Improve Branch Origin Location Accuracy And Minimize Errors
Geert Willem H. Schurink, MD, PhD
- 4:30 – 4:35** Underutilization Of Statins In CLI Patients: Statins Keep The Patient Alive Longer And Decrease Amputation Rates After Open And Endo Revascularization Procedures
Todd R. Vogel, MD, MPH
- 4:36 – 4:41** Diagnosis And Management Of Vascular Complications In Athletes
Jonathan D. Beard, MD
- 4:42 – 4:50** Panel Discussion

SESSION 41 (Grand Ballroom West, 3rd Floor)

NEW CONCEPTS IN ENDOVASCULAR TREATMENT AND MANAGEMENT OF COMPLICATIONS; MORE INFORMATION ABOUT RENAL DENERVATION AND OTHER WAYS TO TREAT RESISTANT HYPERTENSION; AMPUTATIONS

Moderators: *Mark H. Wholey, MD*

Krishna J. Rocha-Singh, MD

- 4:50 – 4:55** We Don't Need More Endovascular Treatments: Just Better Use Of The Ones We Have
Manj S. Gohel, MD
- 4:56 – 5:01** AAA Wall Microvasculature: How Does It Relate To Thrombus Formation And AAA Growth
Geert Willem H. Schurink, MD, PhD
- 5:02 – 5:07** Hypercoagulable Testing Is Far Overused In Vascular Patients Whose Revascularizations Fail Repeatedly: What Should We Do To Evaluate Such Patients And When Is Such Testing Helpful
Elna M. Masuda, MD
- 5:08 – 5:13** A New Simple Technique For Perfusing The Lower Limb To Prevent Ischemia During Prolonged Sheath Obstruction Of The Femoral Arteries During F/B EVAR
Johannes Kalder, MD
- 5:14 – 5:19** Total Percutaneous Axillary Artery Access In Complex Endovascular Aortic Repair: Technical Tips And Precautions
Barend M.E. Mees, MD, PhD

MORE TOPICS ON RESISTANT HYPERTENSION

- 5:20 – 5:25** With Respect To Renal Denervation, Where Do The Renal Sympathetic Nerves Lie With Respect To The Renal Artery: Can Radiofrequency (RF) And Ultrasound Inactivate Them And What Effect Do These Modalities Have On The Renal Artery
Renu Virmani, MD
- 5:26 – 5:31** Is An Arteriovenous Anastomosis The Way To Cure Resistant Hypertension: How Does It Work And Results Of The ROX Arteriovenous Coupler Trial
Melvin D. Lobo, MBChB, PhD
- 5:32 – 5:37** Percutaneous Creation Of An A-V Fistula With The ROX Device: Can It Treat Resistant Hypertension And Other Conditions
David H. Deaton, MD
- 5:38 – 5:43** Is There A Role For Chemoablation For Renal Denervation
Mark H. Wholey, MD
- 5:44 – 5:49** Why The Negative Results Of SIMPLICITY III Are No Surprise: It Does Not Mean The Field Is Dead: Predictions For The Future
Mehdi H. Shishehbor, DO, MPH, PhD
- 5:50 – 6:00** Panel Discussion
End of Program E

PROGRAM F (SESSIONS 42-43)

NEW DEVELOPMENTS IN MANAGEMENT OPTIONS FOR PULMONARY EMBOLISM

Course Leader: **Michael R. Jaff, DO**

Trianon Ballroom, 3rd Floor

SESSION 42 (Trianon Ballroom, 3rd Floor)

MANAGEMENT OF PULMONARY EMBOLISM: THE SPECTRUM AS IT EVOLVES – DRUGS, DEVICES AND SURGERY – PART 1

Moderator: **Michael R. Jaff, DO**

- 7:00 – 7:05** Introduction To The Symposium
Frank J. Veith, MD
- 7:05 – 7:15** Welcome And Introduction
Michael R. Jaff, DO
- 7:15 – 7:25** The Basics Of Pulmonary Embolism: What Is The Role Of The History, Exam, Biomarkers
Ido Weinberg, MD, MSc
- 7:25 – 7:35** The Basics Of Echocardiography For PE: What Must The Vascular Specialist Know, And Is An Emergent Echo Necessary
David M. Dudzinski, MD
- 7:35 – 7:50** What Is State-of-the-Art Medical Therapy For PE
Geno J. Merli, MD, MACP
- 7:50 – 8:00** Intravenous Thrombolytic Therapy For PE: Do We Know More In 2014
Christopher Kabrhel, MD, MPH
- 8:00 – 8:10** Catheter-Directed Thrombolysis For PE: A Better Lytic Alternative?
Jason T. Salsamendi, MD
- 8:10 – 8:25** Percutaneous Pharmacomechanical Intervention For PE: What Does The Data Say, And Where Must We Go From Here
Iris Baumgartner, MD

- 8:25 – 8:35** Lysis For PE: What About The Nuts And Bolts – Heparin, PTT And Fibrinogen Monitoring, And How Do You Know When You Are Done
Raghu Kolluri, MD
- 8:35 – 8:45** Technical Tips For Pharmacomechanical Intervention For PE: How Do I Do It?
Jeffrey Y. Wang, MD
- 8:45 – 9:15** Case Presentations / Panel Discussion / Questions And Answers
Panelists: *Michael R. Jaff, DO*
Iris Baumgartner, MD
Christopher Kabrhel, MD, MPH
Geno J. Merli, MD, MACP
Jason T. Salsamendi, MD
Jeffrey Y. Wang, MD
- 9:15 – 9:45** Break – Visit Exhibits And Pavilions (2nd and 3rd Floors)

SESSION 43 (Trianon Ballroom, 3rd Floor)

MANAGEMENT OF PULMONARY EMBOLISM: THE SPECTRUM AS IT EVOLVES – DRUGS, DEVICES AND SURGERY – PART 2

Moderator: *Michael R. Jaff, DO*

- 9:45 – 10:00** The SEATTLE Trial: A Breakthrough For PE Treatment?
Gregory Piazza, MD, MS
- 10:00 – 10:10** What Did The SEATTLE Trial Fail To Answer?
Clifford M. Sales, MD, MBA
- 10:10 – 10:20** Vortex Strategy For Massive PE
Christopher J. Kwolek, MD
- 10:20 – 10:35** ECMO And Surgical Thromboembolectomy For Massive PE: When, How, And Why?
Thoralf Sundt, MD
- 10:35 – 10:45** What Is The Modern Algorithm For Management Of Massive And Submassive PE
Tod C. Engelhardt, MD
- 10:45 – 11:00** Iliac Venous Stenosis: When To Look And When To Stent
John A. Kaufman, MD
- 11:00 – 11:15** The Team Approach To PE Management: The Emergence Of National PERT Centers
Kenneth Rosenfield, MD
- 11:15 – 11:45** Challenging Cases And “PERT” Decisions
Panelists: *Tod C. Engelhardt, MD*
John A. Kaufman, MD
Christopher J. Kwolek, MD
Gregory Piazza, MD, MS
Kenneth Rosenfield, MD
Thoralf Sundt, MD
- 11:45 – 12:00** Questions And Answers
- 12:00 – 1:00** Lunch Break – 2nd Floor Promenade
Visit Exhibits And Pavilions (2nd and 3rd Floors)

PROGRAM F (SESSIONS 44-47)

LARGE VEIN OCCLUSIVE DISEASE AND ITS
TREATMENT

Course Leader: **Kenneth Ouriel, MD, MBA**

Trianon Ballroom, 3rd Floor

SESSION 44 (Trianon Ballroom, 3rd Floor)

OCCLUSION OF THE DEEP VEINS OF THE LEG:
CAUSES, RISKS TO THE PATIENT, AND
OPPORTUNITIES FOR TREATMENT

Moderators: **Kenneth Ouriel, MD, MBA**

Alan Dardik, MD, PhD

- | | |
|--------------------|---|
| 1:00 – 1:05 | Large Vein Occlusive Disease: The Magnitude Of The Problem In The Population
<i>Peter Gloviczki, MD</i> |
| 1:06 – 1:11 | Physiology Of Large Vein Occlusion: A Hemodynamic Explanation For The Post-Thrombotic Syndrome
<i>Mark H. Meissner, MD</i> |
| 1:12 – 1:17 | Predictors Of Post-Thrombotic Syndrome After DVT: Which Patients Will Have Problems
<i>Susan R. Kahn, MD, MSc</i> |
| 1:18 – 1:23 | DVT In The Leg: New Modalities For Managing A Lifelong Problem For The Patient
<i>Gerard J. O’Sullivan, MD</i> |
| 1:24 – 1:29 | Venous Thrombosis: Can We Determine The Age Of The Thrombus And Does It Matter Anyway
<i>Cees H.A. Wittens, MD, PhD</i> |
| 1:30 – 1:35 | DEBATE: Chronic Femoral DVT Should Not Be Treated With Aggressive Interventions
<i>John Blebea, MD, MBA</i> |
| 1:36 – 1:41 | DEBATE: Endovascular Interventions Work For Chronic Femoral Occlusions And Should Be Considered In Most Patients
<i>Seshadri Raju, MD</i> |
| 1:42 – 1:47 | 2014: The Forefront Of New Anticoagulants For DVT
<i>Jeffrey W. Olin, DO</i> |
| 1:48 – 1:53 | Femoral Vein Excision For Vascular Reconstruction: Techniques To Minimize Post-Thrombotic Symptoms
<i>Timur P. Sarac, MD</i> |
| 1:54 – 1:59 | Panel Discussion |

SESSION 45 (Trianon Ballroom, 3rd Floor)

ACUTE LOWER EXTREMITY DVT: AVOIDING
EARLY AND LATE ADVERSE OUTCOMES

Moderators: **Samuel R. Money, MD, MBA**

Jean-Paul de Vries, MD, PhD

- | | |
|--------------------|---|
| 2:00 – 2:05 | Risk Of Pulmonary Embolism With DVT: Which Clots, Who And When
<i>Michael R. Jaff, DO</i> |
| 2:06 – 2:11 | The Bull’s Eye Sign: A New Iliac Vein Marker To Avert The Need For IVUS
<i>Enrico Ascher, MD</i> |
| 2:12 – 2:17 | Thrombolysis For Acute Deep Venous Thrombosis: Is It Safe, Is It Effective: Lessons From The 2014 Cochrane Update
<i>Cynthia K. Shortell, MD</i> |
| 2:18 – 2:23 | The EKOS System For Treatment Of Acute DVT: Theory And Practice
<i>Anil P. Hingorani, MD</i> |

- 2:24 – 2:29** Newer Methods For Treating Acute DVT: Thrombolysis, Ultrasound, And Mechanical Thrombectomy Devices
Robert A. Lookstein, MD
- 2:30 – 2:35** Update On The ATTRACT Study Of rt-PA For Acute DVT
Suresh Vedantham, MD
- 2:36 – 2:41** **DEBATE:** Early Intervention Is Best For Acute Iliofemoral DVT And Prevents Post-Thrombotic Complications
Anthony J. Comerota, MD
- 2:42 – 2:47** **DEBATE:** Antithrombotic Therapy Alone For Acute DVT: Lack Of High Level Evidence For Endovenous Interventions
Jeffrey W. Olin, DO
- 2:48 – 2:56** Panel Discussion
- 2:56 – 3:15** Break – Visit Exhibits And Pavilions (2nd and 3rd Floors)

SESSION 46 (Trianon Ballroom, 3rd Floor)

NOVEL BALLOONS, STENTS, THROMBOLYSIS, ULTRASOUND, AND MECHANICAL THROMBECTOMY DEVICES FOR LARGE VEIN OCCLUSIONS

Moderators: *Timur P. Sarac, MD*

Cees H.A. Wittens, MD, PhD

- 3:16 – 3:21** Dedicated Stents For The Venous System: Requirements And Status Of Devices In Clinical Development
Gerard J. O’Sullivan, MD
- 3:22 – 3:27** **DEBATE:** Currently Marketed Stents Are Suboptimal In The Venous System: The Need For New Devices Engineered For The Veins
Cees H.A. Wittens, MD, PhD
- 3:28 – 3:33** **DEBATE:** New Devices Are Encouraged But Stent Malfunctions Are Rare In The Venous System, Even With Older Devices
Seshadri Raju, MD
- 3:34 – 3:39** Should Drug-Eluting Balloons Be Considered For Large Vein Stenoses: Theory And Predictions For The Future
William A. Gray, MD
- 3:40 – 3:45** Iliofemoral DVT In Pregnancy: Thrombus Removal Is Safe And Avoids Long-Term Morbidity
Anthony J. Comerota, MD
- 3:46 – 3:51** Long-Term Outcomes After Trellis Thrombectomy For DVT
Rabih A. Chaer, MD
- 3:52 – 3:57** Tips And Tricks For Recanalization Of Occluded Large Veins: The Role Of The Ekosonic System
Jean-Paul de Vries, MD, PhD
- 3:58 – 4:03** **DEBATE:** Ultrasound-Enhanced Thrombolysis Yields No Benefit Over Thrombolysis Alone
Iris Baumgartner, MD
- 4:04 – 4:09** **DEBATE:** Nonsense; EKOS Thrombolysis For Acute DVT Is A Game Changer
Mark J. Garcia, MD
- 4:10 – 4:15** Panel Discussion

SESSION 47 (Trianon Ballroom, 3rd Floor)

TREATMENT OF INFERIOR VENA CAVA THROMBUS,
MALIGNANCY, INJURY AND OCCLUSION

Moderators: *Anthony J. Comerota, MD*

Jose I. Almeida, MD, RVT, RPVI

- 4:16 – 4:21** Treatment Of Chronic IVC Occlusion With Stents: Which Patients, Which Stents, And Results
Seshadri Raju, MD
- 4:22 – 4:27** IVC Resection And Reconstruction For Malignancy: Tips And Tricks
William J. Quinones-Baldrich, MD
- 4:28 – 4:33** Aggressive Management Of Acute Thrombosis Of The Inferior Vena Cava
Bo G. Eklof, MD, PhD
- 4:34 – 4:39** Robotic Removal Of Malfunctioning IVC Filters: A Case And Potential For The Future
Samuel R. Money, MD, MBA
- 4:40 – 4:45** Exsanguinating Hemorrhage From Iatrogenic IVC Injury: Presentation, Management And Outcome
Peter Glociczki, MD
- 4:46 – 4:51** Getting Paid For Inferior Vena Caval Procedures: Newer CPT Codes And When To Use Them
Sean P. Roddy, MD
- 4:52 – 5:00** Panel Discussion
End of Program F

THURSDAY, NOVEMBER 20, 2014

6:00 A.M. General Registration – Rhinelander Gallery, 2nd Floor

6:00 A.M. Faculty Registration – Morgan Suite, 2nd Floor

6:15 A.M. Continental Breakfast – 2nd Floor Promenade

CONCURRENT THURSDAY PROGRAMS

PROGRAM G: (SESSIONS 48-55) 6:45 A.M. – 5:57 P.M.

New Developments In Treatment Of AAAs, EVAR, Aortic Branch Lesions, Laparoscopy; Natural History, Office Practice, Issues, New Techniques, More On MLFM Stents, Open Surgery, Aortic Coarctation, Hypogastric And Visceral Arteries

Grand Ballroom East, 3rd Floor

PROGRAM H: (SESSIONS 56-63) 6:45 A.M. – 5:30 P.M.

New And Updated Endograft Devices And Associated Technological Advances For The Aorta And Its Branches In The Abdomen, The Chest And The Lower Extremities; Improved Prosthetic Grafts; Endostaples

Grand Ballroom West, 3rd Floor

PROGRAM I: (SESSIONS 64-71) 6:49 A.M. – 5:30 P.M.

Advances And New Information In Venous Disease And Its Treatment

Trianon Ballroom, 3rd Floor

PROGRAM J: (SESSIONS 72-73) 8:00 A.M. – 5:30 P.M.

Multidisciplinary Acute Stroke Management

Murray Hill Suites East and West, 2nd Floor

PROGRAM G (SESSIONS 48-55)

AAAs, EVAR, AORTIC BRANCHES, LAPAROSCOPY, NATURAL HISTORY, OFFICE PRACTICE, MORE ISSUES, NEW TECHNIQUES, MORE ON MLFM STENTS, OPEN SURGERY, AORTIC COARCTATION, HYPOGASTRIC AND VISCERAL ARTERIES

Grand Ballroom East, 3rd Floor

SESSION 48 (Grand Ballroom East, 3rd Floor)

NEW DEVELOPMENTS IN AAAs AND EVAR

Moderators: Juan C. Parodi, MD

Frank A. Lederle, MD

- 6:45 – 6:50** Thick Layer Of Thrombus In The Aortic Neck Should Not Be A Contraindication To EVAR: How To Size Neck Diameter With Thrombus: The Thrombus Resorbs With Time
Hence J.M. Verhagen, MD, PhD
- 6:51 – 6:56** How Does Aortic Neck Morphology And Thrombus Burden Influence AAA Sac Behavior After EVAR
Thomas S. Maldonado, MD
- 6:57 – 7:02** How Does Treatment Delay Increase The Risk Of AAA Repair With Open Surgery: With EVAR
Mahmoud B. Malas, MD, MHS
- 7:03 – 7:08** What Is The Post EVAR Syndrome: How Should It Be Treated
Qingsheng Lu, MD
Zaiping Jing, MD
- 7:09 – 7:14** Preoperative Prednisone Enhances Recovery After EVAR In A RCT: What Is The Mechanism And Optimal Dosage
Torben V. Schroeder, MD, DMSc
Lars B. Lonn, MD, PhD
- 7:15 – 7:20** **DEBATE:** Small AAAs (4.0-5.4 cm) Should Not Be Fixed
Frank A. Lederle, MD
- 7:21 – 7:26** **DEBATE:** Despite The Level I Evidence, Many Small AAAs (4.0-5.4 cm) Should Be Fixed
William D. Jordan, Jr., MD
- 7:27 – 7:32** Causes And Consequences Of Delay In Treatment Of AAAs And Why Unfit Patients With Large AAAs Should Be Treated: Without Treatment They Die Of Rupture: With Treatment They Can Survive
Katariina M. Noronen, MD
Maarit Venermo, MD
Mauri J.A. Lepantalo, MD
- 7:33 – 7:38** In Women, Indexing AAA Diameter To Body Surface Area Is A Better Predictor Of Rupture Than Diameter Alone: Not So In Men: Why And What Are The Implications
Marc L. Schermerhorn, MD
- 7:39 – 7:44** How Often Is Fenestrated EVAR Indicated In Today's EVAR Population And Can It Be Done Safely By Percutaneous Access
Carlos H. Timaran, MD
- 7:45 – 7:54** Panel Discussion

SESSION 49 (Grand Ballroom East, 3rd Floor)

NEW DEVELOPMENTS IN THE TREATMENT OF LESIONS OF THE AORTIC BRANCHES AND THE VISCERAL SEGMENT OF THE AORTA

Moderators: Marc L. Schermerhorn, MD

Thomas A. Sos, MD

RENAL ARTERY LESIONS

- 7:54 – 7:59** What Is The Role Of Renal Artery Stenting After The CORAL And ASTRAL Trials
Thomas A. Sos, MD
- 8:00 – 8:05** How Can We Predict The Success Of Renal Artery Stenting: It Is Not Just Looking At An Arteriogram
Monika L. Gloviczki, MD, PhD
- 8:06 – 8:11** Endovascular Treatment Of Renovascular Disease In Pediatric Patients Is Dangerous And Ineffective
James C. Stanley, MD
- 8:12 – 8:17** What Is The Current Data On The Natural History Of Renal Artery Aneurysms: How Should Traditional Treatment Criteria Be Changed
Peter F. Lawrence, MD
- 8:18 – 8:23** Optimal Techniques For Endovascular Treatment Of Renal And Visceral Artery Aneurysms: Is Open Surgery Ever Best
Barry T. Katzen, MD
- 8:24 – 8:29** Panel Discussion

Moderators: Edward Y. Woo, MD

Gustavo S. Oderich, MD

MESENTERIC ARTERIES

- 8:30 – 8:35** **DEBATE:** Chronic Mesenteric Ischemia Is Best Treated Endovascularly
Craig M. Walker, MD
- 8:36 – 8:41** **DEBATE:** Not So; Chronic Mesenteric Ischemia Is Best Treated By Open Surgery
Ramesh K. Tripathi, MD
- 8:42 – 8:47** Are Improved Early And Mid-Term Results With Covered Stents For Chronic Mesenteric Ischemia Durable: Technical Tips To Place Them
Gustavo S. Oderich, MD
- 8:48 – 8:53** Endovascular Treatment Of All 3 Mesenteric Arteries (CA, SMA, IMA): When Is It Necessary And Technical Tips
Furuzan Numan, MD

VISCERAL SEGMENT OF AORTA

- 8:54 – 8:59** Middle Aortic Syndrome: When Is Treatment Indicated; When Not: Is PTA Ever Of Value
William J. Quinones-Baldrich, MD
- 9:00 – 9:05** Endovascular Treatment Of Penetrating Ulcers Of The Aorta In The Infrarenal Segment; In The Visceral Segment
Afshin Assadian, MD
- 9:06 – 9:11** Endovascular Treatment Of Isolated Abdominal Aortic Dissections: When Is It Necessary And How To Do It
Konstantinos P. Donas, MD
Giovanni Torsello, MD
- 9:12 – 9:20** Panel Discussion
- 9:20 – 9:30** Break – Visit Exhibits And Pavilions (2nd and 3rd Floors)

SESSION 50 (Grand Ballroom East, 3rd Floor)

NEW DEVELOPMENTS IN LAPAROSCOPIC VASCULAR SURGERY, PRESERVATION OF OPEN SURGICAL SKILLS, AND THE NATURAL HISTORY OF AAAs WITHOUT TREATMENT AND AFTER EVAR

Moderators: Roger M. Greenhalgh, MD

Jean-Baptiste Ricco, MD, PhD

LAPAROSCOPIC VASCULAR SURGERY

- 9:30 – 9:35** Decline Of Laparoscopic And Robotic Vascular Surgery: Will The Trend Be Reversed
Willem Wisselink, MD
- 9:36 – 9:41** Short And Long-Term Results Of Laparoscopic Vascular Surgery: Will It Survive In The Endovascular Era
Jean-Baptiste Ricco, MD, PhD
- 9:42 – 9:47** Why Laparoscopic Surgery For Aorto-Iliac Occlusive Disease Still Has A Future
Bernard J. Segers, MD

AAA NATURAL HISTORY WITH AND WITHOUT TREATMENT

- 9:48 – 9:53** EVAR 1, DREAM, ACE And OVER Trials Show That Secondary Aortic Sac Rupture After EVAR Remains A Problem
Roger M. Greenhalgh, MD
- 9:54 – 9:59** The Incidence Of AAAs Is Decreasing: Why Is This So And What Does It Mean For Screening
Frank A. Lederle, MD
- 10:00 – 10:05** Better Long-Term Durability Results Can Be Achieved With EVAR Than In The EVAR, DREAM Or OVER Trials: Based On The Use Of A Third Generation Endograft Used In >200,000 Patients
Scott L. Stevens, MD
- 10:06 – 10:11** Long-Term Results With EVAR Beyond 5 Years: Why Are They Better Than In The 3 Landmark EVAR vs. Open Repair RCTs (EVAR 1, DREAM And OVER)
Timur P. Sarac, MD
- 10:12 – 10:17** Why Should All High Risk AAAs Be Treated In A High Volume Center: Will It Happen
Mahmoud B. Malas, MD, MHS
- 10:18 – 10:24** Panel Discussion

SESSION 51 (Grand Ballroom East, 3rd Floor)

HOT TOPICS IN THE TREATMENT OF JUXTARENAL AND PARARENAL AAAs, TAAAs AND RAAAs

Moderators: Jean-Pierre Becquemin, MD

Frank J. Veith, MD

- 10:24 – 10:29** Comparison Of FEVAR And Open Surgery For Juxtarenal AAAs: Why Open Surgery Is Still An Important Option
Jan S. Brunkwall, MD, PhD
- 10:30 – 10:35** **DEBATE:** Fenestrated EVAR (FEVAR) Is A Better Option Than Open Repair For Most Juxtarenal AAAs
Matthew J. Eagleton, MD
- 10:36 – 10:41** **DEBATE:** Open Repair Is Better Than FEVAR For Most Juxtarenal AAAs
Alun H. Davies, MA, DM
- 10:42 – 10:47** FEVAR Is The Treatment Of Choice For Pararenal And Paravisceral AAAs In Patients >80 Years Of Age: Based On A NSQIP Study
Anton N. Sidawy, MD, MPH

10:48 – 10:53 G-I Complications From FEVAR Procedures Involving The Celiac And Superior Mesenteric Arteries: Causes And Prevention: Dangers Of CO₂ Arteriography
Krassi Ivancev, MD, PhD

MEGA DEBATE

10:54 – 10:59 **DEBATE:** For Juxta And Pararenal AAAs Off-The-Shelf Devices Are Best For Most Patients
Mark A. Farber, MD

11:00 – 11:05 **DEBATE:** For Juxta And Pararenal AAAs Custom-Made Fenestrated Branched Endografts Are Best For Most Patients
Martin Malina, MD, PhD

11:06 – 11:11 **DEBATE:** For Juxta And Pararenal AAAs Standard Endovascular Devices With Parallel Graft Adjuncts Are Best For Most Patients
Jason T. Lee, MD

11:12 – 11:17 **DEBATE:** For Juxta And Pararenal AAAs All Types Of Endografts Are Necessary To Treat Patients Well
Giovanni Torsello, MD

11:18 – 11:24 Panel Discussion

Moderators: *Mark A. Farber, MD*
Martin Malina, MD, PhD

11:24 – 11:29 There Is Still A Place For AUI Endografts For Complex AAAs (Including Juxta And Pararenal) Although Parallel Graft And Adjuncts May Be Required
Martin R. Back, MD

11:30 – 11:35 Outcomes Of Ruptured AAAs (Both Endo And Open) Are Better If Treated By Vascular Surgeons Than If Treated By General Surgeons: A NSQIP Study
Amy B. Reed, MD

11:36 – 11:41 How Accurate Is The Diagnosis Of Rupture In AAA Patients Dying Without Treatment: An Important Parameter In Evaluating Natural History Studies
Katariina M. Noronen, MD
Maarit Venermo, MD
Mauri J.A. Lepantalo, MD

11:42 – 11:47 For Short Necked Juxtarenal AAA What Is The Best Treatment: Standard EVAR, FEVAR, Standard EVAR With Chimneys Or Open Repair: What Is The Current Role Of Open Repair
Jean-Pierre Becquemin, MD

11:48 – 11:53 Anatomic Scoring As A Predictor For The Outcome Of FEVAR For Juxtarenal AAA Repairs: How Useful Is It
Krassi Ivancev, MD, PhD

11:54 – 12:00 Panel Discussion

12:00 – 1:00 Lunch Break – 2nd Floor Promenade
Visit Exhibits And Pavilions (2nd and 3rd Floors)

SESSION 52 (Grand Ballroom East, 3rd Floor)

SOME ISSUES WITH MALPRACTICE, OFF-LABEL USE, OUTPATIENT PRACTICE, CENTRALIZATION AND TRAINING, UPDATES

Moderators: *Enrico Ascher, MD*
Michael L. Marin, MD

1:00 – 1:05 In A Malpractice Case, How Can One Resolve A Problem With A Bad Or Biased Expert Witness Or An Interventional Expert Who Considers Any Open Procedure With A Poor Result Malpractice
O. William Brown, MD, JD

1:06 – 1:11 **DEBATE:** Should We Treat Patients Outside IFUs: Yes, There Are Real Benefits And Upsides
Jason T. Lee, MD

1:12 – 1:17 **DEBATE:** Should We Treat Patients Outside IFUs: No, There Are Many Downsides And Risks Including Malpractice
O. William Brown, MD, JD

OUTPATIENT ISSUES

1:18 – 1:23 Tips And Tricks For Use Of CO₂ Arteriography And Venography In An Outpatient Facility: Advantages And Limitations
Kyung Cho, MD

1:24 – 1:29 High Quality Digital Fluoroscopy With A Motorized C-Arm Can Facilitate Complex Endovascular Procedures In An Outpatient Setting
Enrico Ascher, MD

1:30 – 1:35 Outpatient Fast Track EVAR: When Is It Feasible And Safe And Tips On How To Do It: Advantages And Risks
Zvonimir Krajcer, MD

TRAINING ISSUES

1:36 – 1:41 Operator Training For Fenestrated Devices: Is The Technique Broadly Applicable
Luis A. Sanchez, MD

1:42 – 1:47 How To Retrain And Train In The Open Surgical Skills That Vascular Surgeons Will Need In The Future
James May, MD, MS

1:48 – 1:54 Panel Discussion

SESSION 53 (Grand Ballroom East, 3rd Floor)

NEW TECHNOLOGIES, TECHNIQUES, UPDATES AND MORE ON MLFM STENTS

Moderators: *Timur P. Sarac, MD*
Ali F. AbuRahma, MD

1:54 – 1:59 Value And Technique For Aortic Balloon Control In Vascular Trauma Patients
George H. Meier III, MD

2:00 – 2:05 Almost All Aorto-Iliac Occlusions Can Be Treated Endovascularly: Tips And Tricks For Doing So Safely
Zvonimir Krajcer, MD

2:06 – 2:11 Outcomes Of Percutaneous EVAR: When Is It Contraindicated: Tips And Tricks For Doing It Safely
Ali F. AbuRahma, MD

2:12 – 2:17 Advantages Of Microbubbles To Reduce Dose Of Thrombolytics For Clot Lysis: Bleeding Risk Is Decreased: How Does It Work
Kak Khee Yeung, MD, PhD
Willem Wisselink, MD

2:18 – 2:23 New Approaches To Developing Better Arterial Grafts
George Hamilton, MD

2:24 – 2:29 US Population Based Survey Shows Surveillance After EVAR Falls Short In >50% Of Patients: What Can And Should Be Done About It
Andres Schanzer, MD

MORE ABOUT MLFM STENTS

2:30 – 2:35 Moroccan Results Of The MLFM Stent Experience For Treating Complex Aortic Aneurysms And Type B Dissections
Amira Benjelloun, MD

- 2:36 – 2:41 How The MLFM Bare Stent Can Change The Natural History And Behavior Of Aortic Aneurysms: Theoretical Considerations
Mark F. Fillinger, MD
- 2:42 – 2:47 The Phantom MLFM Aorto Bi-Iliac Device: A Fresh Perspective On The Treatment Of Aortic And Iliac Aneurysms
Sherif Sultan, MD
- 2:48 – 2:56 Panel Discussion
- 2:56 – 3:06 Break – Visit Exhibits And Pavilions (2nd and 3rd Floors)

SESSION 54 (Grand Ballroom East, 3rd Floor)

OPEN SURGERY AND AORTIC COARCTATION RELATED TOPICS

Moderators: *Larry H. Hollier, MD*
Hans-Henning Eckstein, MD, PhD

- 3:06 – 3:11 The Value Of Open Surgery Simulators In Training Of Vascular Surgeons: How Do They Work And Can They Help
Afshin Assadian, MD
- 3:12 – 3:17 Is There A Role For Open Surgical Treatment Of Renal Artery Stenosis For Renovascular Hypertension After The ASTRAL And CORAL Trials
George Hamilton, MD
- 3:18 – 3:23 Why Is Axillo-Bifemoral Bypass The New Gold Standard – Replacing Aorto-Bifemoral Bypass When Open Surgery Is Required For Aorto-Iliac Occlusive Disease: What Are The Current Indications For Not Using Endovascular Treatments
Russell H. Samson, MD, RVT
- 3:24 – 3:29 10-Year Results Of Open Repair Of Juxtarenal AAAs: How Durable Is The Procedure And Is It A Better Treatment Than FEVAR Or Chimney Grafts With EVAR
Jean-Paul de Vries, MD, PhD
- 3:30 – 3:35 How To Perform Open Conversion Safely After Failed EVAR: Tips And Tricks
Dieter Raithel, MD, PhD
- 3:36 – 3:41 When Is Open Surgical Repair Of AAAs Indicated In The Endovascular Era: In What Percentage Of Cases Will It Be Necessary
Edward Y. Woo, MD
- 3:42 – 3:47 When Is Open Surgical Repair Required And The Best Treatment For Complex Vascular Injuries In The Endovascular Era
Samy S. Nitecki, MD
- 3:48 – 3:53 How To Make Carotid Body Tumor Excision Almost Bloodless
Francesco Spinelli, MD

AORTIC COARCTATION TOPICS

- 3:54 – 3:59 **DEBATE:** Covered Balloon Expandable Stents (Advanta V12) Are The Best And Most Durable Way To Treat Aortic Coarctations: When Are They Not
Elchanan Bruckheimer, MBBS
- 4:00 – 4:05 **DEBATE:** Bare Metal Balloon Expandable Stents Are The Best Most Durable Way To Treat Most Aortic Coarctations: When Are They Not
Christoph A. Nienaber, MD, PhD
- 4:06 – 4:11 Endovascular Treatment Of Late Complications (Recurrent Stenosis And/Or Aneurysm) Of Surgically Repaired Aortic Coarctations
William J. Quinones-Baldrich, MD
- 4:12 – 4:19 Panel Discussion

SESSION 55 (Grand Ballroom East, 3rd Floor)

VISCERAL, RENAL AND HYPOGASTRIC ARTERY ISSUES

Moderators: *Ronald M. Fairman, MD*
Fabio Verzini, MD

MESENTERIC ISCHEMIA

- 4:19 – 4:24** Endovascular Treatment Of Acute Mesenteric Ischemia: Value Of First Look Laparoscopy Or Laparotomy
Joseph S. Giglia, MD
George H. Meier III, MD
- 4:25 – 4:30** Treatment Of Isolated SMA Dissection Producing Acute Mesenteric Ischemia
Robert B. McLafferty, MD

VISCERAL ARTERY ANEURYSMS

- 4:31 – 4:36** Endovascular Treatment Of Celiac Artery Branch Pseudoaneurysms With Life Threatening Hemorrhage: When To Use Covered Stents; When To Use Coil Embolization; Is Open Surgery Ever The Best Treatment
Kyung Cho, MD
- 4:37 – 4:42** When Is Endovascular Repair Indicated With Ruptured Visceral Artery Aneurysms: What Are The Outcomes Of Endovascular And Open Treatments
Rabih A. Chaer, MD
- 4:43 – 4:48** Inferior Pancreatico-Duodenal Artery Aneurysms Are Commonly Associated With Celiac Artery Occlusions: What Is The Best Option For Treatment
Ronald M. Fairman, MD
- 4:49 – 4:54** Should All Splenic Artery Aneurysms Be Managed Endovascularly: When Should They Not Be
Bauer E. Sumpio, MD, PhD

RENAL ARTERY ANEURYSMS

- 4:55 – 5:00** Natural History Of Renal Artery Aneurysms: Which Treatment (Endo vs. Open) Option Is Best And When
Neal S. Cayne, MD
- 5:01 – 5:06** Coiling vs. Covered Stenting For Renal Artery Aneurysms: When Is Open Surgery The Best Treatment
Furuzan Numan, MD

HYPOGASTRIC ARTERY AND LONG-TERM FEVAR TOPICS

- 5:07 – 5:12** How Should Isolated Iliac Artery Aneurysms Be Treated: Management Of The Hypogastric Especially When It Is Aneurysmal
Lars B. Lönn, MD, PhD
- 5:13 – 5:18** Hypogastric Artery Revascularization With EVAR: When Is Coil Or Occluder Use Acceptable: Which Branch Device Is Best: What About Sandwich Grafts
Piergiorgio Cao, MD
Fabio Verzini, MD, PhD
- 5:19 – 5:24** Clinical Trial Results With The Gore Branched Device For Hypogastric Revascularization: Are There Limitations
Darren B. Schneider, MD
- 5:25 – 5:30** Hypogastric Artery Revascularization During EVAR Using 2 Commercially Available Devices (Gore C3 And Endologix AFX) Without Need For Brachial Access: How To Do It
Brian G. DeRubertis, MD

- 5:31 – 5:36** 10-Year Experience With Iliac Branched Devices (IBDs) For Hypogastric Artery Revascularization During EVAR: Durability And Pitfalls To Avoid
Martin J. Austermann, MD
Konstantinos P. Donas, MD
Giovanni Torsello, MD
- 5:37 – 5:42** 14-Year Experience With FEVAR: The Procedure Is Durable But Reinterventions May Be Required
Michael J. Denton, FRACS
Domenic Robinson, MD
- 5:43 – 5:48** Different Techniques To Preserve The Hypogastric Arteries During EVAR: Tips And Tricks
Claudio J. Schonholz, MD
- 5:49 – 5:57** Panel Discussion
End of Program G

PROGRAM H (SESSIONS 56–63)

NEW AND UPDATED ENDOGRAFT DEVICES AND ASSOCIATED TECHNOLOGICAL ADVANCES FOR THE AORTA AND ITS BRANCHES IN THE ABDOMEN, CHEST AND LOWER EXTREMITIES; IMPROVED PROSTHETIC GRAFTS AND ENDOSTAPLES

Grand Ballroom West, 3rd Floor

SESSION 56 (Grand Ballroom West, 3rd Floor)

NEW AND UPDATED ENDOVASCULAR GRAFTS AND DEVICES FOR USE IN ABDOMINAL AORTIC DISEASE

Moderators: Daniel G. Clair, MD

Vicente Riambau, MD, PhD

- 6:45 – 6:50** Are The Outcomes And Costs Different With Current Endovascular Graft Systems For EVAR: Based On Data From The OVER Trial
Jon S. Matsumura, MD
- 6:51 – 6:56** Next Generation Endografts For AAAs: Are They Iterative Or Transformative
Robert M. Bersin, MD
- 6:57 – 7:02** Trouble In Paradise: How EVAR Advances And Pushing The Endo Envelope Can Lead To Disaster And Harm Patients
Frank J. Criado, MD
- 7:03 – 7:08** A Better Gore Excluder C3 Device That Is Not Only Repositionable But Also Has A Modifiable Body Angle That Can Adapt The Proximal Fixation And Sealing Zone With Difficult AAA Neck Anatomy
Dittmar Boeckler, MD
- 7:09 – 7:14** World Experience With The Bolton Treovance Device For EVAR: The RATIONALE Registry: What Are The Device's Advantages And Results
Vicente Riambau, MD, PhD
- 7:15 – 7:20** Use Of The Anaconda Fenestrated Endograft For EVAR In Challenging Or Hostile Anatomy: Advantages And Results
Nick J. Burfitt, BSc, MBB, BChir, MRCS
Michael P. Jenkins, MBBS, BSc, MS
- 7:21 – 7:26** How Well Does The Vascutek Anaconda Fenestrated Cuff Work To Treat Complications Of Standard EVAR: Advantages And Experience To Date
Michael P. Jenkins, MBBS, BSc, MS
Nick J. Burfitt, BSc, MBB, BChir

- 7:27 – 7:32** Results With The Nellix Device For Endovascular AAA Sealing (EVAS) In Europe: Advantages And Tips To Avoid Complications
Dittmar Boeckler, MD
- 7:33 – 7:38** The NELLIX EVAS FORWARD Global Registry: Early Results In 250 Patients: Nellix (EVAS) Device To Treat AAAs With Adverse Features: What Has Been The Need For Reinterventions And How Is It Better Than Conventional EVAR Devices
Andrew Holden, MBChB
- 7:39 – 7:44** Experience With The Nellix Device For AAAs: When Should It Be Used Preferentially And Can It Be Used To Treat Complications Of Other AAA Repairs Like Endoleaks, Anastomotic Breakdown And Ruptures
Ian Loftus, MD
Matt M. Thompson, MD
- 7:45 – 7:49** Expanding The Applicability Of EVAR Safely With The TriVascular Ovation Device
Sean P. Lyden, MD
- 7:50 – 7:58** Panel Discussion

SESSION 57 (Grand Ballroom West, 3rd Floor)

**MORE ABOUT NEW AND UPDATED
ENDOVASCULAR GRAFTS, DEVICES AND
TECHNOLOGIES FOR TREATING ABDOMINAL
AORTIC DISEASE, COMPLEX AAAs AND
INFECTIONS**

Moderators: *Michel Makaroun, MD*
Michael L. Marin, MD

- 7:58 – 8:03** 2-Year Results With The Ovation Graft From TriVascular For EVAR: Advantages Of This Low Profile Device
Dierk Scheinert, MD
- 8:04 – 8:09** How To Maximize The Benefits Of The Sealing Zone In The Ovation Endograft: Tips And Tricks
David J. Minion, MD
- 8:10 – 8:15** The Altura Endograft For EVAR: Advantages And 2-Year Results
Albrecht H. Krämer, MD
- 8:16 – 8:21** 3-Year European Results With A Lower Profile Device For EVAR: Advantages Of The Incraft From Cordis: The INNOVATION Trial
Giovanni Pratesi, MD
Giovanni Torsello, MD
- 8:22 – 8:27** US Experience With The New Cordis Incraft For EVAR: Advantages And Limitations
Michel Makaroun, MD
- 8:28 – 8:33** Results With The Aorfix EVAR Device From Lombard Are Good: How Iliac Morphology And Changes In Morphology Affect Outcomes
Brian R. Hopkinson, ChM
- 8:34 – 8:39** Good Mid-Term Outcomes With The Aorfix Endograft In The PYTHAGORAS PMA Trial: Advantages And Limitations
Mark F. Fillinger, MD
- 8:40 – 8:45** When Is A Chimney Graft Procedure Better Than A Fenestrated Graft: How To Design A Better Aortic Endograft To Conform To Chimney Or Other Parallel Grafts
Claude Mialhe, MD

- 8:46 – 8:51** Update On The Ventana Fenestrated Graft From Endologix: What Are Its Advantages And What Is Its Current Status
Daniel G. Clair, MD
- 8:52 – 8:57** Results With A New Concept And Endograft For EVAR And TEVAR: The Horizon Endograft: The Concept Can Be Used To Construct Branched Grafts In Any Location
Gioachino Coppi, MD
- 8:58 – 9:03** How Does The Endologix AFX Endograft Achieve A Seal In Irregular AAA Necks: Why Is It Better Than Other Aortic Endografts: Proof On A Dynamic CT Scan
Jean-Paul de Vries, MD, PhD
- 9:04 – 9:09** Advantages Of The Vela AFX Endograft System From Endologix: How Does It Make EVAR Better Or Easier – Particularly With Challenging AAA Necks
Julio A. Rodriguez-Lopez, MD
- 9:10 – 9:15** 1-Year Results With A New Iliac Side Branched Device From Jotec For Revascularizing Hypogastric Arteries: Advantages And Limitations
Jan S. Brunkwall, MD, PhD
- 9:16 – 9:21** Updated Experience With Treatment Of Infected Aortic Grafts Using A Neo-Aorta Constructed With Spiral Greater Saphenous Vein: Why Is It Better Than Using Deep Lower Extremity Veins Or Other Techniques
Jan M.M. Heyligers, MD, PhD
- 9:22 – 9:29** Panel Discussion
- 9:29 – 9:40** Visit Exhibits And Pavilions (2nd and 3rd Floors)

SESSION 58 (Grand Ballroom West, 3rd Floor)

NEW OR IMPROVED ENDOGRAFTS, DEVICES, TECHNOLOGIES AND INFORMATION FOR TREATING THORACIC AORTIC DISEASE AND COMPLEX ANEURYSMS

*Moderators: Eric L.G. Verhoeven, MD, PhD
Matt M. Thompson, MD*

- 9:40 – 9:45** In The UK Does TEVAR For Descending Thoracic Aortic Aneurysms Win Over Open Repair And Should We Be Looking For Asymptomatic Thoracic Aneurysms
Janet T. Powell, MD, PhD
- 9:46 – 9:51** IVUS Is A Necessary Adjunctive Technology For Adequate TEVAR Treatment Of Complicated TBADs
Ali Azizzadeh, MD
- 9:52 – 9:57** Early Experience With Newer Lower Profile Zenith Alpha Endografts For TEVAR And EVAR From Cook: How Well Do They Work
Eric L.G. Verhoeven, MD, PhD
- 9:58 – 10:03** Conformability Matters With TEVAR In Or Near The Aortic Arch: Modifications Of The C-TAG Device To Deal With Radial Fit Issues Of The Proximal Endograft: Redeployability And The Ability To Modify Proximal Graft Angles Are Also Helpful
Alan B. Lumsden, MD
- 10:04 – 10:09** Early Results With A New Off-The-Shelf Branched Gore Endograft For TAAA Repairs: Advantages And Limitations
Pierre Galvagni-Silveira, MD, PhD

- 10:10 – 10:15** The GREAT Registry Confirms That The Gore Conformable C-TAG Endograft Is Working Well Near The Aortic Arch
Fred A. Weaver, MD
- 10:16 – 10:21** A Modified Relay Endograft With A Proximal Scalloped Or Fenestrated Opening (From Bolton) To Preserve Left Subclavian Flow: A Branched Graft Is Unnecessary: How Well Does This Bolton Graft Work
Michael P. Jenkins, MBBS, BSc
- 10:22 – 10:27** Advantages, Limitations And Early Results With The JOTEC Device For F/B EVAR Repair Of TAAAs And Iliac Aneurysms
Burkhardt Zipfel, MD, PhD
- 10:28 – 10:33** Another Novel Potentially Off-The-Shelf Modular Branched Endovascular Graft From JOTEC For TAAAs: The Way It Works And Early Clinical Experience
Mario Lachat, MD
Giovanni Torsello, MD
Nicola Mangialardi, MD
- 10:34 – 10:44** Panel Discussion

SESSION 59 (Grand Ballroom West, 3rd Floor)

**MORE NEW OR IMPROVED ENDOGRAFTS,
DEVICES, TECHNOLOGIES AND INFORMATION
FOR TREATING THORACIC AORTIC DISEASE AND
COMPLEX ANEURYSMS**

Moderators: Edward B. Diethrich, MD

Vicente Riambau, MD, PhD

- 10:44 – 10:49** The Left Subclavian Artery (LSA) Can Be Covered In Most TEVAR Cases Without Revascularization: When Is Revascularization Necessary: Based On Data From The C-TAG Trial And The GREAT Registry
Dittmar Boeckler, MD
- 10:50 – 10:55** LSA Origin Coverage During TEVAR Is Safe And Can Be Performed Without Complications Except In Specific Circumstances: What Are They
Gustav Fraedrich, MD
- 10:56 – 11:01** LSA Flow Should Be Maintained During TEVAR: This Can Be Achieved With A Novel New Branched Device: The MONA LSA Device From Medtronic: How Does It Work And Early Results
Frank R. Arko, MD
- 11:02 – 11:07** Clinical Experience With The MONA LSA Branched Device From Medtronic To Revascularize The Left Subclavian Artery During TEVAR
Eric E. Roselli, MD
- 11:08 – 11:13** A Single Branched Endograft For TEVAR With Subclavian Revascularization From Gore: How Does It Work And Early Results: It Can Be Used To Treat All Arch Lesions Without Thoracotomy
Michael D. Dake, MD
- 11:14 – 11:19** Laser Fenestration For LSA Revascularization During TEVAR: Technique And 4-Year CT Documented Durability
Jean M. Panneton, MD
- 11:20 – 11:25** Advantages And Mid-Term Results With The Bolton Relay Endograft For TEVAR Extending Into Or Near The Arch
Vicente Riambau, MD, PhD
- 11:26 – 11:31** Why Low Profile Devices Are Important For TEVAR: They Are Available With The Cook Zenith Alpha System
Giovanni Torsello, MD

- 11:32 – 11:37** A New Low Profile Endovascular Device From Cook To Treat Traumatic Aortic Injuries In Young Patients: Advantages And Limitations
Benjamin W. Starnes, MD
- 11:38 – 11:43** Advantages Of New Zenith Alpha System For TEVAR And EVAR: Are There Limitations
Timothy A. Resch, MD, PhD
- 11:44 – 11:49** New Endografts From Gore For F/B EVAR: Concepts For Easier Treatment Of Juxta, Para And Thoracoabdominal Aortic Aneurysm Repairs
Wayne W. Zhang, MD
- 11:50 – 12:00** Panel Discussion
- 12:00 – 1:00** Lunch Break – 2nd Floor Promenade
Visit Exhibits And Pavilions (2nd and 3rd Floors)

SESSION 60 (Grand Ballroom West, 3rd Floor)
NEW OR IMPROVED ENDOVASCULAR DEVICES AND TECHNIQUES, STENTS, BIOABSORBABLE STENTS AND STENT-GRAFTS FOR TREATING LOWER EXTREMITY DISEASE AND ISCHEMIA

*Moderators: Kenneth Rosenfield, MD
Giancarlo Biamino, MD, PhD*

- 1:00 – 1:05** 3-Year Results Of The STROLL Trial With Smart Stents In The SFA: Patency And Quality Of Life Are Maintained
Michael R. Jaff, DO
- 1:06 – 1:11** What Will Be The Standard Of Care For Treating Primary Lesions In The SFA And Below: Update On The BIOLUX P-I And BIOLUX P-II Trial Results
*Patrick Peeters, MD
Thomas Zeller, MD*
- 1:12 – 1:17** Unique Properties Of A New Dual Component (Nitinol And PTFE) Stent: The Gore Tigris Conformable Stent: Early Results And When Should It Be Used
John R. Laird, MD
- 1:18 – 1:23** An Improved Helical 3D Stent (The Biomimics Stent) May Resist Kinking, Lead To Swirling Blood Flow, Decreased ISR And Improved Patency At 2 Years
Thomas Zeller, MD

BIOABSORBABLE STENTS

- 1:24 – 1:29** The Only Good Solution For Treatment Of Peripheral Artery Occlusive Lesions Must Avoid Permanent Implants: Bioabsorbable Scaffold Will Be The Future
Renu Virmani, MD
- 1:30 – 1:35** A Bioabsorbable Vascular Scaffolding Stent With Drug Elution: The BVM Stent With Good 1-Year Results In The SFA: The ESPRIT Trial
Johannes Lammer, MD
- 1:36 – 1:41** A Bioabsorbable Stent From Elixir Medical: How Does It Work And How Good Is It
Dierk Scheinert, MD
- 1:42 – 1:47** Third Generation Bioabsorbable Self-Expanding DES Will Improve Results In Lower Extremity Occlusive Disease: Results With The Stanza DR Stent
Andrew Holden, MBChB
- 1:48 – 1:53** Early And Mid-Term Results Of An Absorbable Stent For SFA Lesions
Gioachino Coppi, MD

1:54 – 1:59 The Belgian REMEDY Registry Of Experience With The Bioabsorbable Remedy Stent In The SFA: 1-Year Results
Peter C.J. Goverde, MD

STENT-GRAFTS

2:00 – 2:05 Endovascular Reconstruction Of Complex Aorto-Iliac Lesions: Stents vs. Covered Stents: Indications For Which And Why
B. Patrice Mwipatayi, FRACS

2:06 – 2:11 Uses For The Gore Hybrid Partially Stented PTFE Graft To Facilitate Arterial Bypasses In Multiple Locations
Edward Y. Woo, MD

2:12 – 2:20 Panel Discussion

SESSION 61 (Grand Ballroom West, 3rd Floor)

NEW AND IMPROVED TECHNIQUES, STENTS, STENT-GRAFTS AND PROSTHETIC (PTFE) VASCULAR GRAFTS FOR TREATING LOWER EXTREMITY DISEASE AND ISCHEMIA

Moderators: *Michael S. Conte, MD*
Edward Y. Woo, MD

2:20 – 2:25 How To Deal With Flush SFA Occlusions Endovascularly And Preserve Profunda Flow: Tips And Tricks
George H. Meier III, MD

2:26 – 2:31 A New More Conformable Covered Stent From Gore: Advantages, Limitations And Clinical Results
Andrew Holden, MBChB

IMPROVED PROSTHETIC VASCULAR GRAFTS

2:32 – 2:37 Is There A Role For Prosthetic Bypasses Below The Knee And To Tibial Arteries And How To Make Them Work
Richard F. Neville, MD

2:38 – 2:43 PTFE Tibial And Peroneal Bypasses When Vein Is Unavailable: They Yield Better Results Than Generally Acknowledged: An Update Based On A 30-Year Experience
Gregg S. Landis, MD
Nicholas J. Gargiulo III, MD
Frank J. Veith, MD

2:44 – 2:49 Status Of The Propaten Heparin Bonded PTFE Graft: How Do We Know That It Is Better Than Standard PTFE Grafts
Edward Y. Woo, MD

2:50 – 2:55 Final 5-Year Results Of RCT Comparing Heparin Bonded PTFE (Propaten) Grafts vs. Standard PTFE Grafts In Fem-Pop And Fem-Fem Bypasses: How Durable Are The Benefits
Jes S. Lindholt, MD

2:56 – 3:01 **DEBATE:** 5-Year Results With Heparin Bonded PTFE (Propaten) Grafts Are Better Than Standard PTFE And May Be As Good As ASV
Russell H. Samson, MD, RVT

3:02 – 3:07 **DEBATE:** I Don't Believe It: Good ASV Has To Be Better Than Any Prosthetic Graft
Michael S. Conte, MD

- 3:08 – 3:13** When Are Prosthetic PTFE Grafts In The Lower Extremity As Good As Vein Grafts: Does Warfarin Help
Jack L. Cronenwett, MD
- 3:14 – 3:19** PTFE Grafts With Heparin Bonding (Propaten) Can Have Good Patency Results Even When BK Popliteal And Crural Arteries Are Used For Outflow: Their Bad Reputation Is Undeserved
Walter Dorigo, MD
- 3:20 – 3:25** Advantages Of The Fusion Bioline 2-Element Heparin Bonded PTFE Graft: Based On The FINEST Multicenter RCT
Alan B. Lumsden, MD
- 3:26 – 3:40** Panel Discussion And Break
Visit Exhibits And Pavilions (2nd and 3rd Floors)

SESSION 62 (Grand Ballroom West, 3rd Floor)

ADDITIONAL NEW INFORMATION RELATED TO LOWER EXTREMITY ISCHEMIA AND POPLITEAL ANEURYSM MANAGEMENT

Moderators: *Darren B. Schneider, MD*
Palma M. Shaw, MD

- 3:40 – 3:45** Tips And Tricks To Make Endovascular Treatment Of Acute Limb Ischemia Effective 100% Of The Time: Are Open Procedures Ever Required
Ali Amin, MD, RVT
- 3:46 – 3:51** Ultrasound Enhanced Thrombolysis (EKOS) For The Treatment Of Infrainguinal Arterial Thrombosis: The Duet I And II Trial
Jean-Paul de Vries, MD, PhD
- 3:52 – 3:57** In Dialysis Patients With CLI How Much Can Be Achieved With Endovascular Treatments: Is Open Bypass Ever Needed
Francisco Liistro, MD
- 3:58 – 4:03** Lower Extremity Revascularization In Dialysis Patients With CLI: Is It Of Value: When Endo; When Open; When A Primary Amputation
Rabih A. Chaer, MD
- 4:04 – 4:09** What Is The Importance Of Patency After PTA-Stenting Or Bypass For Intermittent Claudication; For CLI: What Is The Mechanism For Exercise Improvement With Intermittent Claudication
Iris Baumgartner, MD
- 4:10 – 4:15** Endovascular Treatment Of Extensive Aorto-Iliac Occlusive Disease With A Bifurcated Endograft: A Potential Alternative To Kissing Stents Or Stent-Grafts
Thomas S. Maldonado, MD

POPLITEAL ANEURYSMS (SEE ALSO SESSION 34)

- 4:16 – 4:21** Evolving Treatment For Popliteal Aneurysms: When At Present Is Endovascular Treatment Contraindicated
Ali F. AbuRahma, MD
- 4:22 – 4:27** Elective And Emergent Treatment Of Popliteal Aneurysms: Can They All Be Treated Endovascularly And How Often Is Open Repair Indicated
Joseph J. Ricotta II, MD, MS
- 4:28 – 4:34** Panel Discussion

SESSION 63 (Grand Ballroom West, 3rd Floor)

**NEW AND IMPROVED DEVICES FOR
ENDOSTAPLING OR ENDOANCHORING FOR
EVAR AND TEVAR**

*Moderators: William D. Jordan, Jr., MD
Jean M. Panneton, MD*

FOR AAA ENDOGRAFT PROCEDURES

- 4:34 – 4:39** Do Aptus Heli-Fx EndoAnchors Provide Long-Term (5 Years) Fixation Of Endografts In AAA Necks After EVAR: Do They Decrease The Need For Surveillance: Do They Fix Endoleaks: Are They Worth Their Cost
David H. Deaton, MD
- 4:40 – 4:45** Can Heli-Fx EndoAnchors Resolve Type I Endoleaks And Improve Long-Term Endograft Fixation: In Short Necked AAAs Are They Equal Or Superior To FEVARs Or Chimneys: Based On The ANCHOR Registry
William D. Jordan, Jr., MD
- 4:46 – 4:51** Mid-Term Results Of The Global And Dutch EndoAnchor Registries Of The Heli-Fx Endograft Stapling Devices: Can It Fix Type I Endoleaks And Graft Migration: Can It Be Proven
Jean-Paul de Vries, MD, PhD
- 4:52 – 4:57** Large Palmaz Stents vs. EndoAnchors To Fix Type I Endoleaks: Which Is Better And When
Dittmar Boeckler, MD
- 4:58 – 5:03** Do EndoAnchors Improve Sac Regression After EVAR
Bart E. Muhs, MD, PhD
- 5:04 – 5:09** Active Aortic Endograft Fixations With A Novel New Endostapling System By Vestech/Jotec: Description And Advantages
Thierry Richard, MD

FOR THORACIC PROCEDURES

- 5:10 – 5:15** Value And Limitations Of Aptus Heli-Fx EndoAnchors In TEVAR Procedures: Can They Prevent Or Fix Type I Endoleaks From Difficult Neck Anatomy
Piotr M. Kasprzak, MD
- 5:16 – 5:21** Can Delayed Type I Endoleaks After TEVAR Be Treated Successfully With Heli-Fx EndoAnchors
Manish Mehta, MD, MPH
- 5:22 – 5:27** Value Of Heli-Fx EndoAnchors During Or After TEVAR Procedures
Jean M. Panneton, MD
- 5:28 – 5:38** Panel Discussion
End of Program H

PROGRAM I (SESSIONS 64-70)

**ADVANCES AND NEW INFORMATION IN VENOUS
DISEASE AND ITS TREATMENT**

*Course Leaders: Jose I. Almeida, MD, RVT, RPVI
Lowell S. Kabnick, MD, RPhS
Thomas W. Wakefield, MD*

Trianon Ballroom, 3rd Floor

SESSION 64 (Trianon Ballroom, 3rd Floor)

**VENOUS CLINICAL EXAMINATION AND
SELECTING PATIENTS APPROPRIATELY**

*Moderators: Jose I. Almeida, MD, RVT, RPVI
Lowell S. Kabnick, MD, RPhS*

- 6:49 – 6:54** CEAP & VCSS: Establishing The Treatment Plan Based On Clinical Findings
Jose I. Almeida, MD, RVT, RPVI
- 6:55 – 7:00** What Duplex Ultrasound Mapping Adds To The Exam
Lowell S. Kabnick, MD, RPhS
- 7:01 – 7:06** Quantifying Saphenous Reflux
Seshadri Raju, MD
- 7:07 – 7:12** Value Of A Diagnostic Score Ascribing Leg Symptoms To Chronic Venous Disorders In Patients Undergoing Surgery For Varicose Veins
Paul Pittaluga, MD
- 7:13 – 7:18** What Do The Quality Measures (QM) Measure: A Critical Analysis Of PQRS (Physician Quality Reporting System) Measures For Venous Disease
Fedor Lurie, MD, PhD
- 7:19 – 7:24** Vein Diameter Is Not The Key For Stratifying Interventional Strategies For Superficial Venous Disease
Alun H. Davies, MA, DM
- 7:25 – 7:30** Hemodynamic Approach On Superficial Venous Reflux (ASVAL): Does It Work
Sylvain Chastanet, MD
- 7:31 – 7:36** A New Look At Venous Hemodynamics: The Importance Of Measuring Both Reflux And Venous Outflow Obstruction
Andrew N. Nicolaides, MS
- 7:37 – 7:42** Hemodynamic Approach On Superficial Venous Reflux (CHIVA): Does It Work
Byung-Boong Lee, MD
- 7:43 – 7:48** Why Is Individual Risk Assessment For Thrombosis Important To Vascular Surgeons Since They Already Use Heparin For Their Procedures
Joseph A. Caprini, MD
- 7:49 – 7:54** The LET Score As A Standardized DVT Classification
Cees H.A. Wittens, MD, PhD
- 7:55 – 8:00** Panel Discussion

SESSION 65 (Trianon Ballroom, 3rd Floor)

FIRST-LINE VENOUS IMAGING TECHNIQUES AND PHYSIOLOGIC TESTING

Moderators: *Jose I. Almeida, MD, RVT, RPVI*
Lowell S. Kabnick, MD, RPhS

- 8:01 – 8:06** Duplex Mapping Done Correctly
Jose I. Almeida, MD, RVT, RPVI
- 8:07 – 8:12** What Information From Duplex Is Useful To Help Form A Treatment Plan? What Information Is Bogus But I've Seen Others Use Often
Neil M. Khilnani, MD
- 8:13 – 8:18** Duplex Scanning Sourcing For Origin Of Reflux In Venous Ulcerations
Alfred M. Obermayer, MD
- 8:19 – 8:24** Physiological Evaluation Of Venous Obstruction
Fedor Lurie, MD, PhD
- 8:25 – 8:30** The Role Of IVUS In Stenting Of The Venous System
Stephen A. Black, MD
- 8:31 – 8:36** How To Measure Iliac Vein Stenosis
Seshadri Raju, MD
- 8:37 – 8:42** Shifting Paradigm Of Diagnosis And Treatment Of Suspected DVT (Role Of Non-Invasive Testing And Availability Of New Anticoagulants)
Fedor Lurie, MD, PhD
- 8:43 – 8:48** Panel Discussion

SESSION 66 (Trianon Ballroom, 3rd Floor)

SUPERFICIAL VEIN TREATMENT STRATEGIES AND TECHNIQUES

Moderators: *Lowell S. Kabnick, MD, RPhS*
Alun H. Davies, MA, DM

- 8:49 – 8:54** Endovenous Thermal Ablation RCTs: Do We Know Enough
Bo G. Eklof, MD, PhD
- 8:55 – 9:00** Concomitant Treatment Of Truncal Reflux And Varicose Tributaries Is The Gold Standard
Alun H. Davies, MA, DM
- 9:01 – 9:06** The Argument Against Mandatory Duplex Scanning Following Vein Ablation
Lowell S. Kabnick, MD, RPhS
- 9:07 – 9:12** Clarivein Versus Radiofrequency Ablation: Results Of A RCT
Alun H. Davies, MA, DM
- 9:13 – 9:18** Go Green: Avoid Synthetic Venous Ablation
Lowell S. Kabnick, MD, RPhS
- 9:19 – 9:24** Reducing The Anxiety And Discomfort Of Patients Having Local Anesthetic Vein Treatments With Distraction Techniques And Hand Reflexology
Mark S. Whiteley, MS
- 9:25 – 9:30** How Real Are Venous Thromboembolic Complications With Endovenous Thermal Ablation (The Paradox Between Data From Randomized Controlled Trials, Large Observational Case Series, And Registry Data)
Thomas F. O'Donnell, Jr., MD
- 9:31 – 9:36** Different Options For Saphenous Vein Preservation
Paul Pittaluga, MD
- 9:37 – 9:42** Does Superficial Venous Treatment (Open Or Endovenous) Help Venous Ulcer Healing
Ian J. Franklin, MS
- 9:43 – 9:48** Perforator Ablation: What Are The Indications
Peter F. Lawrence, MD
- 9:49 – 9:54** Incidence Causes, And Treatment Of Recurrent Varicose Veins Following Endovenous Thermal Ablation
Thomas F. O'Donnell, Jr., MD
- 9:55 – 10:00** Value Of Postoperative Compression After Mini-Invasive Surgical Treatment Of Varicose Veins
Paul Pittaluga, MD
- 10:01 – 10:06** Is 1920 Nanometer Wavelength The Future Of Venous Ablation
Lowell S. Kabnick, MD, RPhS
- 10:07 – 10:12** Panel Discussion

SESSION 67 (Trianon Ballroom, 3rd Floor)

WOUNDS, COMPRESSION, NEW HORIZONS FOR VENOUS DISEASE MANAGEMENT

Moderators: *Thomas F. O'Donnell, Jr., MD*
Fedor Lurie, MD, PhD

- 10:13 – 10:18** Definition Of Venous Ulcer: Clinical Evaluation Wound Care, Compression, Surgical Treatment, Ancillary Measures And Primary Prevention
Marc A. Passman, MD
- 10:19 – 10:24** Deep Venous Valve: When And Why
Ramesh K. Tripathi, MD
- 10:25 – 10:30** DOMINATE The Wounds System
Fedor Lurie, MD, PhD

- 10:31 – 10:36** Sulodexide For Advanced Venous Disease
Joseph D. Raffetto, MD
- 10:37 – 10:42** Venous Hemodynamic Revised – Valve Function And The Role Of Gravity
Fedor Lurie, MD, PhD
- 10:43 – 10:48** The Importance Of Hemodynamics When Considering ASVAL
Sylvain Chastanet, MD
- 10:49 – 10:54** What's On The Horizon In Venous Thrombosis Research
Peter Henke, MD
- 10:55 – 11:00** Panel Discussion

SESSION 68 (Trianon Ballroom, 3rd Floor)

VENOUS SOCIETAL AND GOVERNANCE ISSUES

Moderators: *Lowell S. Kabnick, MD, RPhS*
Peter F. Lawrence, MD

- 11:01 – 11:06** A One Stop Vein Clinic: The Ideal Option?
Ian J. Franklin, MS
- 11:07 – 11:12** IAC Vein Center: Importance And Update
Lowell S. Kabnick, MD, RPhS
- 11:13 – 11:18** Comparison Of The New SVS/AVF Venous Ulcer Guidelines To Other Venous Ulcer Guidelines
Thomas F. O'Donnell, Jr., MD
- 11:19 – 11:24** Who Will Treat The Varicose Veins And Who Will Pay For It In The Future
Mark H. Meissner, MD
- 11:25 – 11:30** Update On The SVS-PSO VQI Venous Registry
Jose I. Almeida, MD, RVT, RPVI
- 11:31 – 11:36** What Is The Future Of Venous Reimbursement
Glenn Jacobowitz, MD
- 11:37 – 11:42** A National Coverage Determination Policy Is Needed
Lowell S. Kabnick, MD, RPhS
- 11:43 – 11:48** Primary CVD: Which Patients Should You Intervene On Early (GSV Ablation, Correct Hemodynamics) And If You Intervene Will It Reduce Or Prevent The Progression To Higher Clinical Class
Joseph D. Raffetto, MD
- 11:49 – 11:54** Why Standardization Is Needed With Endovenous Therapy
Alan M. Dietzek, MD, RPVI
- 11:55 – 12:00** Panel Discussion
- 12:00 – 1:00** Lunch Break – 2nd Floor Promenade
Visit Exhibits And Pavilions (2nd and 3rd Floors)

SESSION 69 (Trianon Ballroom, 3rd Floor)

MEDICAL AND INTERVENTIONAL STRATEGIES FOR THROMBOEMBOLIC DISEASE

Moderators: *Thomas W. Wakefield, MD*
Bo G. Eklof, MD, PhD

INTERVENTIONAL STRATEGIES

- 1:00 – 1:05** Benefit Of Early Thrombus Removal In DVT: How Should It Be Done; Endo Or Open
Bo G. Eklof, MD, PhD
- 1:06 – 1:11** How Many Patients Will Be Suitable For Pharmacomechanical Thrombolysis For Ilio-Femoral DVT
Alun H. Davies, MA, DM
- 1:12 – 1:17** Ward Based Catheter Directed Lysis
Stephen A. Black, MD

- 1:18 – 1:23** Early Thrombus Removal For Acute DVT: Does Tibial Access Help
Patrick E. Muck, MD
- 1:24 – 1:29** Aspirational Thrombectomy For DVT: Role Of Angiovac And How It Will Change Practice
Firas F. Mussa, MD
- 1:30 – 1:35** Catheter Directed Pulmonary Thrombolysis
Jason T. Salsamendi, MD
- 1:36 – 1:41** Experience With 15 Consecutive Massive Pulmonary Embolism Patients And The Use Of The EKOS System
Luis R. Leon, MD, RVT
- 1:42 – 1:48** Overview Of Current Role Of Lysis, Mechanical Thrombectomy And Stents For Acute And Subacute Iliofemoral And Caval DVT: What Is The Evidence In Support
Mark H. Meissner, MD
- 1:49 – 1:54** Panel Discussion

MEDICAL STRATEGIES

- 1:55 – 2:00** P-Selectin Inhibition Therapeutically Promotes Thrombus Resolution And Prevents Vein Wall Fibrosis Better Than Enoxaparin And An Inhibitor To Von Willebrand Factor
Thomas W. Wakefield, MD
- 2:01 – 2:06** How To Use The Newer Oral Anticoagulants: New Data Using Aspirin For Recurrent Venous Thromboprophylaxis
Timothy K. Liem, MD
- 2:07 – 2:12** New Drugs For DVT Will Likely Replace Coumadin Derivatives
John Blebea, MD, MBA
- 2:13 – 2:18** To Bridge Or Not To Bridge: That Is The Question
Joseph A. Caprini, MD
- 2:19 – 2:24** The Role Of Metabolomics In DVT
Thomas W. Wakefield, MD
- 2:25 – 2:30** DVT And PE In Infants And Children: Etiology, Diagnosis, Treatment And Prognosis
J. Leonel Villavicencio, MD
- 2:31 – 2:36** D-Dimer And/Or Duplex Findings To Manage DVT
Timothy K. Liem, MD
- 2:37 – 2:42** Panel Discussion

SESSION 70 (Trianon Ballroom, 3rd Floor)

CROSS-SECTIONAL VENOUS IMAGING TO CLARIFY DIFFICULT CLINICAL SCENARIOS

Moderators: *Cees H.A. Wittens, MD, PhD*

Barry Stein, MD

- 2:43 – 2:48** Dutch Approach To Magnetic Resonance Venography And Computed Tomographic Venography In Lower Extremity Chronic Venous Disease
Cees H.A. Wittens, MD, PhD
- 2:49 – 2:54** American Approach To Magnetic Resonance Venography And Computed Tomographic Venography In Lower Extremity Chronic Venous Disease
Barry Stein, MD
- 2:55 – 3:00** MR Venography And Cone Beam CT, Compared To IVUS And Conventional Venography For Deep Venous Intervention
Rick De Graaf, MD, PhD

- 3:01 – 3:06 Current Practice For MRV And CTV In Imaging Of Pelvic And Abdominal Venous Compressive Pathologies And Syndromes: Which Is Better And Why
Barry Stein, MD
- 3:07 – 3:12 A New Tool To Study The 3D Venous Anatomy Of The Human Embryo: The Computer Assisted Anatomical Dissection
Jean Francois Uhl, MD
- 3:13 – 3:18 Image Fusion With MRV For 3D Guidance Of Deep Venous Interventions
Rick De Graaf, MD, PhD
- 3:19 – 3:24 The Use Of IVUS To Document May Thurner Anatomy
Lowell S. Kabnick, MD, RPhS
- 3:25 – 3:30 Panel Discussion

SESSION 71 (Trianon Ballroom, 3rd Floor)

FEMORO-ILIOCAVAL INTERVENTIONAL STRATEGIES TO REDUCE VENOUS HYPERTENSION, HOT IDEAS FOR RECANALIZING CHRONIC TOTAL OCCLUSIONS

Moderators: *Jose I. Almeida, MD, RVT, RPVI*
Seshadri Raju, MD

- 3:31 – 3:36 Medical Treatment For Post-Thrombotic Syndrome
Thomas W. Wakefield, MD
- 3:37 – 3:42 Good, Bad, Ugly Of The New Dedicated Venous Stents
Stephen A. Black, MD
- 3:43 – 3:48 Which Is More Important: Iliac Or Femoral Vein Stenosis
Seshadri Raju, MD
- 3:49 – 3:54 Management Of In-Stent Restenosis
Seshadri Raju, MD
- 3:55 – 4:00 How Knowledge Of Venous Embryology Can Help Establish Venous Outflow In Patients With Uncrossable Iliac Vein Obstruction
Ramesh K. Tripathi, MD
- 4:01 – 4:06 **DEBATE:** Common Femoral Endovenectomy, A/V Fistula, And Endoluminal Iliac Vein Recanalization Is Best For Establishing Inflow
Cees H.A. Wittens, MD, PhD
- 4:07 – 4:12 **DEBATE:** Femoral Vein Recanalization Via Popliteal Access Establishes Better Inflow Than Common Femoral Vein Endovenectomy
Mark J. Garcia, MD
- 4:13 – 4:18 IVC Recanalization In The Presence Of A Thrombosed IVC Filter
David M. Williams, MD
- 4:19 – 4:24 Managing The Iliocaval Confluence With Interdigitating Z-Stents: Another Technique From The Mississippi Group One Must Learn
Jose I. Almeida, MD, RVT, RPVI
- 4:25 – 4:30 Value Of The Cutting Balloon In The Endovascular Treatment Of Post-Thrombotic Syndrome
David M. Williams, MD
- 4:31 – 4:36 Update On EKOS “ACCESS DVT” Trial For Post-Thrombotic Syndrome
Mark J. Garcia, MD
- 4:37 – 4:42 Achieving Inflow When The Femoral Vein And Profunda Femoris Vein Are Occluded
Seshadri Raju, MD

- 4:43 – 4:48** Crossing Femoro-Iliocaval Chronic Total Occlusions: Graduated Support And Tinkering
Jose I. Almeida, MD, RVT, RPVI
- 4:49 – 4:54** Re-Opening Occluded Femoro-Iliocaval Stents Using Aggressive Sharp Devices, Exploding Occluded Stents, Then Relining With New Stent
E. Brooke Spencer, MD
- 4:55 – 5:00** Off Label Use Of Arterial CTO Devices For Crossing Venous CTOs
Constantino Pena, MD
- 5:01 – 5:06** When Should I Stop Trying To Cross A Total Venous Occlusion
E. Brooke Spencer, MD
- 5:07 – 5:12** Deep Venous Reconstruction
Marzia Lugli, MD
- 5:13 – 5:18** What Conduit(s) And Why, Do I Chose For Deep System Reconstruction From Vena Cava To Iliac Veins
Peter Gloviczki, MD
- 5:19 – 5:24** Does Endovascular Treatment Work For Budd-Chiari Syndrome
Byung-Boong Lee, MD
- 5:25 – 5:30** Panel Discussion
End of Program I

PROGRAM J (SESSIONS 72-73)

MULTIDISCIPLINARY ACUTE STROKE
MANAGEMENT—PART 1

Course Leader: **Allan L. Brook, MD**

Murray Hill Suites East and West, 2nd Floor

SESSION 72-A (Murray Hill Suites East and West, 2nd Floor)

21st CENTURY STROKE THERAPY PERSPECTIVES

Moderators: **Joshua A. Hirsch, MD**

Allan L. Brook, MD

- 8:00 – 8:09** Emergency Room Stroke Triage Issues And Solutions
Edward C. Jauch, MD
- 8:10 – 8:19** IV vs. IA Is Not The Argument: Revascularization Needs To Occur Early! How To Make It Happen
Mayank Goyal, MD
- 8:20 – 8:29** 3 Trials Failed To Validate Acute Stroke Intra-Arterial Treatment: Why?
Don Frei, MD
- 8:30 – 8:39** Update And Relevance Of Certification Of Comprehensive Stroke Centers
Steven H. Rudolph, MD
- 8:40 – 8:49** Clinical Trials Update In Stroke Intervention
Michael D. Hill, MD
- 8:50 – 8:59** Healthcare Policy Impact On Your Practice
Joshua A. Hirsch, MD
- 9:00 – 9:10** Panel Discussion

SESSION 72-B (Murray Hill Suites East and West, 2nd Floor)

STATE-OF-THE-ART IMAGING FOR STROKE

Moderators: **Howard A. Rowley, MD**

R. Gilberto Gonzalez, MD, PhD

- 9:10 – 9:19** Magnetic Resonance Stroke Imaging Protocol Fast And Efficient
Howard A. Rowley, MD
- 9:20 – 9:29** CT And CTA Best Imaging Triage: The Calgary Way
Mayank Goyal, MD
- 9:30 – 9:39** Penumbra, Collaterals, And New Data: Let's Talk!
R. Gilberto Gonzalez, MD, PhD

- 9:40 – 9:49** Imaging And Treatment Of Patients With Acute Stroke: An Evidence Based Review
Pina C. Sanelli, MD, MPH
- 9:50 – 9:59** Pial Collaterals And The Capillary Index: Implications
Colin P. Derdeyn, MD
- 10:00 – 10:09** Collaterals, Not Clots! CT Angiography Predictors Of Recanalization, And Clinical Outcomes After Thrombectomy
David S. Liebeskind, MD
- 10:10 – 10:20** Panel Discussion
- 10:20 – 10:35** Break – Visit Exhibits And Pavilions (2nd and 3rd Floors)

SESSION 72-C (Murray Hill Suites East and West, 2nd Floor)

CLINICAL SCENARIOS OF THE POSTERIOR CIRCULATION OF INTEREST

Moderators: *Eugene S. Flamm, MD*
Lou R. Caplan, MD

- 10:35 – 10:44** The 5-Minute Neurological Exam
Daniel L. Labovitz, MD
- 10:45 – 10:54** Posterior Circulation Stroke Syndromes And Territories
Lou R. Caplan, MD
- 10:55 – 11:04** Dissections Of The Vertebral And Carotid Arteries: When To Treat And Why
Philip M. Meyers, MD
- 11:05 – 11:14** TIAs: Diagnosis And When To Treat Aggressively
David S. Liebeskind, MD
- 11:15 – 11:24** Basilar Artery Aneurysms: Endovascular Approaches
David Fiorella, MD
- 11:25 – 11:34** Posterior Fossa Aneurysms: Surgical Options
David J. Langer, MD
- 11:35 – 11:44** Panel Discussion
- 11:45 – 12:45** Luncheon Session - Lunch Available In The South Corridor Exhibit Area, 2nd Floor

SESSION 72-D (Murray Hill Suites East and West, 2nd Floor)

LUNCHEON SESSION: INTRACRANIAL HEMORRHAGE: NOVEL TECHNIQUES AND THE STANDARD OF CARE IN 2014

Moderators: *Aman B. Patel, MD*
Eugene S. Flamm, MD
Walter Koroshetz, MD

- 12:00 – 12:10** Standard Algorithm For Neurosurgical Management Of Intracranial Hemorrhage
David Gordon, MD
- 12:10 – 12:20** A Less Invasive Percutaneous Image Guided System: What Are The Possible Advantages/Disadvantages?
David Fiorella, MD
- 12:20 – 12:30** Case Presentations With Technical Issues For Discussion
David J. Altschul, MD
- 12:30 – 12:45** Discussion: Led By Panel Of Experts
Panelists: *Walter Koroshetz, MD*
Eugene S. Flamm, MD
Aman B. Patel, MD

MULTIDISCIPLINARY ACUTE STROKE MANAGEMENT—PART 2

SESSION 73-A (Murray Hill Suites East and West, 2nd Floor)
**CAROTID ARTERY REVASCULARIZATION - EYE
OPENERS**

Moderators: *Mark H. Wholey, MD*
Thomas G. Brott, MD

- 12:45 – 12:54** CREST 2 And Carotid Trials Update
Walter Koroshetz, MD
- 12:55 – 1:04** Can Patient Or Arterial Characteristics Guide The
Choice To Carotid Angioplasty Or Endarterectomy
Thomas G. Brott, MD
- 1:05 – 1:14** Carotid Artery Revascularization: Why Do We Need
More Trials?
Frank J. Veith, MD
- 1:15 – 1:24** Introduction To Robotic Catheter Techniques
Barry T. Katzen, MD
- 1:25 – 1:34** Review Of The Latest Pertinent Carotid Literature
Mark H. Wholey, MD
- 1:35 – 1:44** Stroke Origins - The Carotid vs. The Intracranial Tree:
Present Day Research
Raul G. Nogueira, MD
- 1:45 – 1:54** Imaging And Implications For Plaque Inflammation:
How Will It Affect Care?
Todd S. Miller, MD

SESSION 73-B (Murray Hill Suites East and West, 2nd Floor)
HEMORRHAGIC STROKE THERAPY

Moderators: *David Gordon, MD*
Daniel L. Labovitz, MD
Ajay K. Wakhloo, MD, PhD

- 1:55 – 2:04** Classification Of AVMs
Lou R. Caplan, MD
- 2:05 – 2:14** ARUBA Truths And Myths
Peter A. Rasmussen, MD
- 2:15 – 2:24** ARUBA: A Surgeon's Thoughts And Practice
Howard A. Riina, MD
- 2:25 – 2:34** Embolization's Key Role In AVM Therapy And
Strategies For Cure
J. Mocco, MD, MS
- 2:35 – 2:44** Convexity SAH And Other Causes Of Bleeds: My
Advice
Howard A. Rowley, MD
- 2:45 – 2:54** Anesthesia For INR Basic Concepts
Apolonia E. Abramowicz, MD
- 2:55 – 3:04** Next Generation Of Aneurysm Therapy
Ajay K. Wakhloo, MD, PhD
- 3:05 – 3:14** Flow Diversion Lessons Learned
Peter K. Nelson, MD
- 3:15 – 3:24** Large Paraophthalmic Aneurysms: Surgical Skull Base
Anatomy And Treatment Options
Aman B. Patel, MD
- 3:25 – 3:34** Dural Sinus Stenosis And Venous Hypertension: My
Paradigm
Sudhakar R. Satti, MD
- 3:35 – 3:45** Panel Discussion
- 3:45 – 4:00** Break – Visit Exhibits And Pavilions (2nd and 3rd Floors)

SESSION 73-C (Murray Hill Suites East and West, 2nd Floor)
BEST NEW STROKE REVASCLARIZATION DEVICES

*Moderators: Aquilla S. Turk, DO
J. Mocco, MD, MS*

- 4:00 – 4:09** Ultrafast Door To Groin Puncture Times
Mayank Goyal, MD
- 4:10 – 4:19** Pushing The Boundaries Of Acute Revascularization
J. Mocco, MD, MS
- 4:20 – 4:29** ADAPT: This Sucks, But It Works
Aquilla S. Turk, DO
- 4:30 – 4:39** Next Generation Stroke Devices
Osama O. Zaidat, MD
- 4:40 – 4:49** Mobile Stroke Treatment Unit: A New System Of Stroke Care Delivery?
Peter A. Rasmussen, MD
- 4:50 – 4:59** Balloon Guide Catheters And Other New Access Devices
Osama O. Zaidat, MD
- 5:00 – 5:09** Trials Comparing Devices: SWIFT And TREVO 2
Raul G. Nogueira, MD
- 5:10 – 5:19** Collecting High Quality Evidence On The Effectiveness Of Vascular Interventions: What Are The Research Options
Walter Koroshetz, MD
- 5:20 – 5:30** Panel Discussion
End of Program J

FRIDAY, NOVEMBER 21, 2014

- 6:00 A.M. General Registration – Rhinelander Gallery, 2nd Floor**
6:00 A.M. Faculty Registration – Morgan Suite, 2nd Floor
6:15 A.M. Continental Breakfast – 2nd Floor Promenade

CONCURRENT FRIDAY PROGRAMS

PROGRAM K: (SESSIONS 74-81) 6:45 A.M. – 5:45 P.M.
New Techniques And Technology; Carotid; Thoracic And Abdominal Aneurysm Disease; Carotid And Supra-Aortic Trunks; CAS vs. CEA – Bright Future For CAS; Late Breaking Information; Updates, More Angiosome And Ruptured AAA Topics
Grand Ballroom East, 3rd Floor

PROGRAM L: (SESSIONS 82-89) 6:45 A.M. – 5:47 P.M.
New Information, Updates, New Technology And Concepts Regarding The Abdominal Aorta, The Thoracic Aorta, Carotid And Lower Extremity Disease And Miscellaneous Topics
Grand Ballroom West, 3rd Floor

PROGRAM M: (SESSIONS 90-96) 6:49 A.M. – 5:10 P.M.
More Advances And New Or Updated Information In Venous Disease And Its Treatment
Trianon Ballroom, 3rd Floor

PROGRAM K (SESSIONS 74-81)
NEW TECHNIQUES AND TECHNOLOGY; CAROTID; THORACIC AND ABDOMINAL ANEURYSM DISEASE; CAROTID AND SUPRA-AORTIC TRUNKS; CAS VS. CEA – BRIGHT FUTURE FOR CAS; LATE BREAKING INFORMATION; UPDATES, MORE ON RUPTURED AAAs
Grand Ballroom East, 3rd Floor

SESSION 74 (Grand Ballroom East, 3rd Floor)

NEW OR IMPROVED TECHNIQUES OR TECHNOLOGIES; SOME HOT CAROTID AND VERTEBRAL TOPICS

Moderators: *Peter L. Faries, MD*

Jose Fernandes e Fernandes, MD, PhD

- 6:45 – 6:50** Cognitive And MRI Changes After Proximal TEVAR And TAVR Show The Need For Cerebral Protection During These Procedures: What Devices Are Available
Ian Loftus, MD
- 6:51 – 6:56** Use Of The VORTEC Technique: Another Method To Facilitate Hypogastric Revascularization During EVAR
Zoran Rancic, MD, PhD
- 6:57 – 7:02** How To Make CEA Safer And Better In 2014
Sebastian E. Debus, MD, PhD
- 7:03 – 7:08** Optimal Evaluation And Surgical Approaches To Carotid Body Tumors In 2014
John (Jeb) W. Hallett, MD
- 7:09 – 7:14** What Is New In The Treatment Of Vertebro-Basilar Disease
Klaus D. Mathias, MD
- 7:15 – 7:20** More Common Finding Of Thrombus Overlying A Carotid Plaque During CEA: What Is Its Significance Or Is It Related To The Earlier Performance Of CEA Currently Being Done In Symptomatic Patients
Domenico Valenti, DMChir, PhD
- 7:21 – 7:26** Association Between Carotid Plaque Type And Internal Carotid Artery Occlusion: Therapeutic Implications
Christos D. Liapis, MD
- 7:27 – 7:32** How Can MRI Help To Select The Best And Personalized Treatment For A Given Carotid Patient: Can It Measure Plaque Size And Activity Accurately
Rachel Clough, MD, PhD
- 7:33 – 7:38** What Can Duplex Ultrasonography Tell Us About Carotid Plaque Area And Juxtaluminal Black Area (JBA): How Do These Correlate With Stroke Risk And Do These Parameters And Stroke Risk Change With Statin Therapy
Andrew N. Nicolaidis, MS
Stavrok Kakkos, MD, PhD
- 7:39 – 7:44** How Do Ultrasound And Microbubbles Help With Carotid Plaque Evaluation And Selection Of Asymptomatic Patients For CEA Or CAS
Alun H. Davies, MA, DM
- 7:45 – 7:52** Panel Discussion

SESSION 75 (Grand Ballroom East, 3rd Floor)

MORE ABOUT THORACIC AND ABDOMINAL AORTIC DISEASE AND AORTIC DISSECTIONS; LARGE SHEATH ENDOVASCULAR ACCESS

Moderators: *Ronald M. Fairman, MD*

Nicholas J.W. Cheshire, MD

- 7:52 – 7:57** Aseal HQS Sheath To Minimize Blood Loss With Large Diameter Endovascular Devices
Claude Mialhe, MD
- 7:58 – 8:03** **DEBATE:** Large Sheath Suture Closure Devices: Why Proglide Is Better: Tips And Tricks
Carlos H. Timaran, MD

- 8:04 – 8:09** **DEBATE:** Large Sheath Suture Closure Devices: Why Prostar Is Better: Tips And Tricks
Ian Loftus, MD
- 8:10 – 8:15** Which Patients Should Not Be Treated By TEVAR For Aneurysms Or TBADs Because Their 3-Year Mortality Or Reintervention Rates Are So High
Matt M. Thompson, MD
- 8:16 – 8:21** Outcomes Of TEVAR For Complicated Acute TBADs Are Favorable: 1-Year Results From The US VALIANT (Medtronic) IDE Trial
Rodney A. White, MD
Joseph E. Bavaria, MD
- 8:22 – 8:27** Multicenter 1-Year Favorable IDE Trial Results Of Conformable Gore C-TAG Device In TEVAR For Acute Complicated TBADs
Richard P. Cambria, MD
- 8:28 – 8:33** Importance Of Biomechanical Factors For Ascending Aortic Endografts: What Can Be Done To Overcome These Factors
Rachel Clough, MD, PhD
Peter R. Taylor, MA, MChir
- 8:34 – 8:39** Cerebral Embolic Injury Silent And Symptomatic During TEVAR: Incidence And Risk Factors: Significance Of Silent MRI Defects: What Can Be Done To Protect Against These Injuries
Richard G.J. Gibbs, FRCS
- 8:40 – 8:45** Potential For Treating Type A Dissections With A Combined Transcatheter Aortic Valve Replacement And Ascending Aortic Stent-Graft: What Will And Will Not Be Possible
Christoph A. Nienaber, MD, PhD
- 8:46 – 8:53** Panel Discussion

SESSION 76 (Grand Ballroom East, 3rd Floor)

IN HONOR OF DAVID E. SUMNER, MD: CAROTID ARTERY AND SUPRA-AORTIC BRANCH TOPICS

Moderators: *Jean-Baptiste Ricco, MD, PhD*
Mark A. Adelman, MD

- 8:53 – 8:58** How To Pick The Best Stent For CAS: It Is A Patient-Anatomy And Lesion Specific-Choice
Patrick Peeters, MD
Marc Bosiers, MD
- 8:59 – 9:04** How To Improve CAS Results With Better Approaches For Access, Mesh/Membrane Covered Stents (Roadsaver, C-Guard, Scaffold) And Better Embolic Protection: What Is The Evidence
Sumaira Macdonald, MBChB (Comm), PhD
- 9:05 – 9:10** Will Robotic Assistance With The Magellan Robotic System Help To Navigate The Arch And Its Branches For CAS Less Traumatically
Nicholas J.W. Cheshire, MD
Celia Riga, MD
- 9:11 – 9:16** **DEBATE:** For Patients Who Are Undergoing CABG And Who Require Carotid Treatment CAS Is The Way To Go: Many Patients Need CAS
Mehdi H. Shishehbor, DO, MPH, PhD
- 9:17 – 9:22** **DEBATE:** Very Few Patients Need CAS Or CEA With Any Coronary Bypass Procedures
Ross Naylor, MD

- 9:23 – 9:28 Outcomes Of CAS For Radiation Induced Carotid Stenosis Are Equal To Those For Typical Arteriosclerotic Carotid Stenosis – Despite Increased Tortuosity Of Carotid Arteries: What Precautions Need To Be Taken
Peter L. Faries, MD
- 9:29 – 9:34 Behavior Of Extracranial Carotid Aneurysms: How Should They Best Be Treated: Data From An International Registry
Gerrit J. de Borst, MD
- 9:35 – 9:40 Improved Treatment Of Iatrogenic Catheter Related Brachiocephalic Artery Injuries Using Endovascular Techniques: Tips And Tricks
Mark K. Eskandari, MD
- 9:41 – 9:46 How Can Biochemical Markers CRP And BNP Be Helpful In Vascular Patient Management: Can CRP Levels Predict Progression Of Carotid Stenosis
Patrick A. Stone, MD
- 9:47 – 9:52 Diaphragm Of The Cervical Carotid Arteries: An Underdiagnosed Cause Of Cerebral Infarcts: Diagnosis And Treatment
Emmanuel M. Houdart, MD
- 9:53 – 10:00 Panel Discussion
- 10:00 – 10:10 Break – Visit Exhibits And Pavilions (2nd and 3rd Floors)

SESSION 77 (Grand Ballroom East, 3rd Floor)

CAS vs. CEA RELATED TOPICS: THE FUTURE FOR CAS IS BRIGHT (SEE ALSO SESSIONS 5 AND 6)

Moderators: *Ross Naylor, MD*

Frank J. Veith, MD

- 10:10 – 10:15 Despite Various Claims, What Is The Current Truth About The Effects Of CAS And CEA On Cognitive Function: Is There A Difference Between The Procedures
Kosmas I. Paraskevas, MD
- 10:16 – 10:21 Carotid Procedures (CEA Or CAS) For Acute Stroke: When Should They Be Done And How
Laura Capoccia, MD, PhD
- 10:22 – 10:27 Outcome Of A High Risk Plaque Study In 6100 Americans: What Does It Tell Us
Henrik Sillesen, MD, DMSc
- 10:28 – 10:33 The Truth About The High Risk Carotid Patient And Which Patients Should Be Enrolled In Future Carotid Trials
Gerrit J. de Borst, MD
- 10:34 – 10:39 Long-Term Stroke Risk After CEA Has Been Lower Than After CAS: Based On VQI And Medicare US Population-Wide Data
Philip P. Goodney, MD, MS
- 10:40 – 10:45 **DEBATE:** CMS (Medicare) Should Expand Reimbursement For CAS Indications To Include Average Risk Symptomatic And Asymptomatic Carotid Stenosis Patients
William A. Gray, MD
- 10:46 – 10:51 **DEBATE:** CMS Should Not Expand Reimbursement For CAS Indications To Include Average Risk Symptomatic And Asymptomatic Carotid Stenosis Patients
Wesley S. Moore, MD

- 10:52 – 10:57** Will Recent Improvements In Medical Therapy Lower Stroke Risk In Asymptomatic Carotid Stenosis Patients So Much That Further Treatment Will Be Unnecessary: Are The ACST And ACSRS Studies Now Obsolete And Will They Have To Be Done Again: Is There A High Risk Asymptomatic Patient Group That Will Benefit From CEA Or CAS
*Andrew N. Nicolaidis, MS
Stavrok Kakkos, MD, PhD*
- 10:58 – 11:05** Panel Discussion

Moderators: *L. Nelson Hopkins, MD
Wesley S. Moore, MD*

THE FUTURE FOR CAS IS BRIGHT

- 11:05 – 11:10** Why CAS Will Have A Renaissance And What Studies Are Needed To Justify It: The Mesh Covered Scaffold Stent (Gore) Should Help
Peter A. Schneider, MD
- 11:11 – 11:16** How To Improve CAS And Prevent Post-Procedural Strokes After CAS: Clinical Experience With The RoadSaver Micromesh Carotid Stent: How Does The Micromesh Stent Compare To Other Mesh-Covered Stents Like The MicroNet (C-Guard) Stent From InspireMD And the Scaffold Stent From Gore
Max Amor, MD
- 11:17 – 11:22** A New Development In CAS Which Will Improve Results: Is The Cervical Flow Reversal Device (Michi System) From Silk Road The Safest Way To Perform CAS: When Will We Know How Well It Works
*Christopher K. Kwolek, MD
Richard P. Cambria, MD*
- 11:23 – 11:28** What Is The Pathological And Functional Significance Of Diffusion Weighted MRI (DW MRI) Defects After CEA And CAS: Are They Irrelevant Or A Bad Thing
Emmanuel M. Houdart, MD

UPDATES ON TRIALS AND OTHER INFORMATION

- 11:29 – 11:34** Intensive Medical Therapy With Proper Statin Usage Etc. Is A Disruptive Influence In Cardiovascular Device Trials
Thomas G. Brott, MD
- 11:35 – 11:40** The CREST Trial Did Not Optimize Medical Treatment And Risk Factor Control Especially In the CEA Treated Patients: What Are The Implications
Carlos H. Timaran, MD
- 11:41 – 11:46** How Will ACST 2, SPACE 2 And CREST 2 Change The CAS vs. CEA Game
Carlo Setacci, MD
- 11:47 – 11:52** What Will The ECST-2 Trial Tell Us About CEA, CAS And Medical Treatment: What Is The Significance Of White Matter And Other MRI Lesions
Martin M. Brown, MD
- 11:53 – 12:00** Panel Discussion
- 12:00 – 1:00** Lunch Break – 2nd Floor Promenade
Visit Exhibits And Pavilions (2nd and 3rd Floors)

SESSION 78 (Grand Ballroom East, 3rd Floor)

MORE ABOUT CEA AND CAS

Moderators: *Timur P. Sarac, MD*

Alan Dardik, MD, PhD

- 1:00 – 1:05** What Were The Pathophysiological Mechanisms Leading To Intraprocedural Strokes In ICSS
Gerrit J. de Borst, MD
- 1:06 – 1:11** How To Optimize Outcomes For CAS And CEA By Appropriate Patient Selection And Having Experts In Both Procedures On The Treating Service
Carlos Saadeh, MD
- 1:12 – 1:17** Dual Antiplatelet Treatment And Tobacco Use May Increase The Rate Of Progression Of Asymptomatic Carotid Stenosis
Mahmoud B. Malas MD, MHS
Caitlin W. Hicks, MD, MS
Bruce A. Perler, MD, MBA
- 1:18 – 1:23** US National Trends In Utilization Of CAS For Carotid Bifurcation Disease: Effect Of CMS (Medicare) Decision And CREST Publications: Where Is CAS Going
Mohammad H. Eslami, MD, RVT
- 1:24 – 1:29** **DEBATE:** Treating Recently Symptomatic Carotid Stenosis Patients Rapidly By CEA Trumps All Interventions In Symptomatic Patients: CAS Should Not Be Used In This Setting
Ross Naylor, MD
- 1:30 – 1:35** **DEBATE:** Not So: Rapid CAS In Recently Symptomatic Carotid Stenosis Patients Can Be Done Safely With Results Equal To CEA
Sumaira Macdonald, MBChB (Comm), PhD
- 1:36 – 1:41** What Is The Long-Term Fate Of The External Carotid Artery After CEA: Why It Matters
Russell H. Samson, MD, RVT
- 1:42 – 1:47** Clinical And Imaging Strategies For Predicting Long-Term Stroke Risk In Asymptomatic Patients With Carotid Stenosis
Ross Naylor, MD
- 1:48 – 1:53** Tips And Techniques For Managing Intraprocedural Complications With CAS
Claudio J. Schonholz, MD
- 1:54 – 2:00** Panel Discussion

SESSION 79 (Grand Ballroom East, 3rd Floor)

LATE BREAKING AND CONTROVERSIAL TOPICS

Moderators: *Samuel R. Money, MD, MBA*

Michael B. Silva, Jr., MD

- 2:00 – 2:05** Management Of Secondary Hemorrhage From Vein Grafts In Military Extremity Wounds: In A War Setting PTFE Grafts May Be Better Than Vein Grafts
Charles J. Fox, MD
- 2:06 – 2:11** Plaque Analysis After Lower Extremity Interventional Treatments And Its Impact On Outcomes
Hany Zayed, MD
- 2:12 – 2:17** The Metabolic Syndrome And How Does It Lead To Bad Outcomes With Vascular Procedures Like EVAR And CEA
Alan Dardik, MD, PhD
- 2:18 – 2:23** How Does The Ruby Coil System (From Penumbra) Facilitate Coil Embolization
Frank R. Arko, MD

- 2:24 – 2:29** Intraluminal PTA Is Better In Diabetics With CLI: Tips To Stay Intraluminal
Marco G. Manzi, MD
- 2:30 – 2:35** Renal Artery Stenting Is Still A Useful Procedure Despite The CORAL And ASTRAL Trials: When Is This So
Irwin V. Mohan, MD, MBBS
- 2:36 – 2:41** Pearls For The Vascular Surgeon/Specialist Managing Patients With Ehlers-Danlos Syndrome
James H. Black III, MD
- 2:42 – 2:47** How To Treat Super Large AAAs 12-15 cm In Diameter: Is Open Or Endo Better
Jacques Busquet, MD
- 2:48 – 2:53** Impact Of Selection Bias In RCTs Comparing EVAR To Open Repair For Ruptured AAAs: This Is A Major Flaw In The Recent Trials Including IMPROVE
Jonathan R. Boyle, MD
- 2:54 – 2:59** A Phantom Aorta: Use Of 3D Printer Technology To Facilitate Fenestrated EVAR
Benjamin W. Starnes, MD
- 3:00 – 3:10** Panel Discussion And Break
Visit Exhibits And Pavilions (2nd and 3rd Floors)

SESSION 80 (Grand Ballroom East, 3rd Floor)

NEW TECHNOLOGIES, TECHNIQUES AND CONCEPTS: SOME HOT CAROTID TOPICS

Moderators: *Mark A. Farber, MD*
Gregg S. Landis, MD

- 3:11 – 3:16** Endovascular Limb Salvage After Many Failed Open Bypasses And Open Surgical Limb Salvage After Many Failed Endovascular Procedures: Never Give Up
Edward Y. Woo, MD
- 3:17 – 3:22** Technique For Assessing Lower Extremity (Foot) Perfusion Beyond ABI, PVRs And Toe Pressures
Mehdi H. Shishehbor, DO, MPH, PhD
- 3:23 – 3:28** Hybrid Revascularization In CLI Patients: Still An Important And Useful Option: Tips And Tricks
Hany Zayed, MD
- 3:29 – 3:34** Hybrid Revascularizations For The “No Option” CLI Patient: What Are They And What Are The Results
Hisham Rashid, FRCS (Gen)
- 3:35 – 3:40** Optimal Techniques For Endovascular Management Of AAA Patients With Small Heavily Calcified Distal Aortic Necks And Common Iliac Arteries
Ronald M. Fairman, MD
- 3:41 – 3:46** Ischemic Colitis After EVAR: What Is The Pathogenesis And Why Is The Incidence Decreasing
Benjamin W. Starnes, MD
- 3:47 – 3:52** Real Health Consequences To Interventionalists Of Radiation And Wearing Lead: It Is A Big Deal – Largely Unrecognized And What Can Be Done To Lessen These Consequences
Lindsay Machan, MD
- 3:53 – 3:58** Weightless Lead Protection System For Busy Interventionalists: The Zero Gravity Radiation Protection System From CFI Medical Solutions: Advantages And Limitations
Mark A. Farber, MD
- 3:59 – 4:04** At What Size Should Degenerative Femoral Aneurysms Be Repaired: Their Natural History Is Now Better Known And This Has Led To Changed Criteria For Repair
Peter F. Lawrence, MD

- 4:05 – 4:10** Carotid Duplex Studies Can Be Terribly Misleading And Overestimate The Percent Stenosis: What Is The Mechanism: CEA vs. CAS Should Not Be Performed Without A Confirmatory Test
Natalie A. Marks, MD, RVT, RPVI
- 4:11 – 4:16** Carotid Duplex Studies Can Be Terribly Misleading And Miss Or Underestimate A High-Grade Carotid Stenosis: What Is The Mechanism
Glenn M. LaMuraglia, MD
- 4:17 – 4:24** Panel Discussion

SESSION 81 (Grand Ballroom East, 3rd Floor)

MORE LATE BREAKING INFORMATION AND UPDATES; ADDITIONAL VITAL NEW DATA ON RUPTURED AAAs

*Moderators: James May, MD, MS
John J. Ricotta, MD*

- 4:24 – 4:29** Is There Evidence In 2014 That Inferior Mesenteric Or Lumbar Artery Embolization Before EVAR Is Beneficial And Safe
Florian Dick, MD
- 4:30 – 4:35** Interobserver Variability In Assigning TASC Or SVS Run-Off Scores: Neither Widely Quoted System Is Worth Much In Real World Usage
Steven G. Katz, MD
- 4:36 – 4:41** AAA Patients With Highly Angulated Necks Can Be Treated Successfully If Certain Adjunctive Procedures Are Used: Tips And Tricks On How To Use Them
Boonprasit Kritpracha, MD
- 4:42 – 4:47** Can Endograft Migration After EVAR Be Treated Successfully With Chimney Grafts
Ignacio Escotto, MD
- 4:48 – 4:54** Panel Discussion

VITAL NEW DATA ON RUPTURED AAAs AND THEIR TREATMENT

- 4:54 – 4:59** How Often After EVAR For Ruptured AAAs Are Type 2 Endoleaks A Problem: How Can They Be Diagnosed And Treated
Clark J. Zeebregts, MD, PhD
- 5:00 – 5:05** How Do Type 2 Endoleaks Behave Differently After Elective EVAR And EVAR For Ruptured AAAs: Implications For Treatment
Manish Mehta, MD, MPH
- 5:06 – 5:11** High Metabolic Activity By PET/CT Correlates With A High Rupture Risk In Patients With A Family History Of AAA: Such Patients Should Have A Lower Diameter Threshold For Repair Than 5.5 cm
Natzi Sakalihan, MD, PhD
- 5:12 – 5:17** Institutional Transfer Of Ruptured AAA Patients Before Definitive Repair And Its Effect On Mortality: Tips And Tricks For Doing It Right
*Matthew W. Mell, MD, MS
Ronald L. Dalman, MD*
- 5:18 – 5:23** Technique Of Aortic Balloon Control For Ruptured AAAs: The Technique Is Not Simple
*Todd Berland, MD
Neal S. Cayne, MD
Frank J. Veith, MD*
- 5:24 – 5:29** Survival After AAA Rupture X3 In The Same Patient Over Many Years; What Is The Mechanism
James May, MD, MS

5:30 – 5:35 Onyx Can Be Used Successfully To Treat Some Ruptured AAAs, Ruptured Thoracic Aneurysms And Type I Endoleaks: Tips And Tricks In Its Use And When It Will Fail

Thomas Larzon, MD, PhD

5:36 – 5:45 Panel Discussion

End of Program K

PROGRAM L (SESSIONS 82-89)

NEW INFORMATION, UPDATES, NEW TECHNOLOGY AND CONCEPTS REGARDING THE ABDOMINAL AORTA, THORACIC AORTA, CAROTID ARTERIES, LOWER EXTREMITY DISEASE AND MISCELLANEOUS TOPICS

Grand Ballroom West, 3rd Floor

SESSION 82 (Grand Ballroom West, 3rd Floor)

ABDOMINAL AORTA AND ILIAC ARTERY RELATED TOPICS

Moderators: *Kenneth Ouriel, MD, MBA*

Ramon Berguer, MD, PhD

6:45 – 6:50 Spontaneous Aortic Thrombus In The Absence Of Aortic Pathology: What Is Its Embolic Potential And How Should It Be Treated

Cynthia K. Shortell, MD

6:51 – 6:56 Renal Function Decline After EVAR: Is It Important And What Is The Etiology

Franco Grego, MD

Giovanni Deriu, MD

6:57 – 7:02 CO₂ Angiography For EVAR In Patients Intolerant To Contrast: Tips, Tricks And Precautions For Its Use

Luigi Inglese, MD

7:03 – 7:08 **DEBATE:** Current Stent-Grafts Will Allow Better Outcomes With EVAR Than Those Obtained In The RCTs: EVAR I, DREAM And OVER

Marc R.H.M. van Sambeek, MD, PhD

7:09 – 7:14 **DEBATE:** Not So: Current Outcomes For EVAR Will Be No Different From Those In The RCTs And The Conclusions Of These Trials Are Valid Today

Jan D. Blankensteijn, MD

7:15 – 7:20 Long-Term Outcomes Of EVAR And Open Repair In A US Medicare Database: How Do These Compare With The RCT (EVAR 1, DREAM And OVER) Outcomes

Marc L. Schermerhorn, MD

7:21 – 7:26 Outcomes And QOL Of EVAR In Octogenarians: The Procedure Is Worthwhile: Based On ENGAGE Registry Results

Michel M.P. Reijnen, MD, PhD

7:27 – 7:32 Internal Iliac Aneurysms: Challenges And Techniques For Open And Endovascular Repair: At What Size (Diameter) Is Repair Indicated

Manju Kalra, MBBS

7:33 – 7:38 **DEBATE:** AAAs With Straight Short Necks (8-15 mm) Should Be Treated With Standard Endografts

Hence J.M. Verhagen, MD, PhD

7:39 – 7:44 **DEBATE:** Not So: AAAs With Straight Short Necks (8-15 mm) Should Be Treated With Fenestrated Endografts

Gustavo S. Oderich, MD

7:45 – 7:53 Panel Discussion

SESSION 83 (Grand Ballroom West, 3rd Floor)

MORE ABDOMINAL AORTA RELATED TOPICS

Moderators: Thomas C. Bower, MD

John B. Chang, MD

- 7:53 – 7:58** Finite Element Analysis Is A Tool To Predict AAA Rupture Risk: How Can This Be Determined Easily And How Can It Be Combined With Other Risk Factor Data To Better Predict AAA Rupture Risk: What Is “Equivalent Diameter Rupture Risk” And The Vascops System
Dittmar Boeckler, MD
Natzi Sakalihan, MD, PhD
T. Christian Gasser, PhD
- 7:59 – 8:04** How To Prevent Gutter Endoleaks With Parallel Grafts
Willem Wisselink, MD
Kak Khee Yeung, MD, PhD
- 8:05 – 8:10** When Is AAA Repair Justified In Patients With Chronic Renal Insufficiency Or Connective Tissue Disease: By EVAR; By Open Repair
Vicente Riambau, MD, PhD
- 8:11 – 8:16** Techniques And Strategies For Renal Protection During Open Pararenal And Thoracoabdominal Aneurysm Repair
Yamune Tshomba, MD
Germano Melissano, MD
Roberto Chiesa, MD
- 8:17 – 8:22** Why Are The Rates Of AAA Sac Regression So High And Of Type 2 Endoleak So Low With The Endologix AFX Grafts: Is It Related To An Extended Proximal Seal Or Other Factors
Zachary M. Arthurs, MD
- 8:23 – 8:28** Errors In Endograft Sizing And How They Can Influence Outcomes: How To Prevent Them
Juan C. Parodi, MD
- 8:29 – 8:34** Screening For AAAs Should Be More Selective As AAA Demographics Changes And Incidence Decreases
Ian Loftus, MD
- 8:35 – 8:40** There Is Little Glory In Achieving Access But Many Adverse Consequences Result: How To Do It Safely For EVAR And Other Procedures
Scott L. Stevens, MD
- 8:41 – 8:46** Mural Thrombus Formation In The AAA Sac After EVAR: How Does It Relate To Complications And The Need For Surveillance: When Can Surveillance Protocols Be Relaxed
Hence J.M. Verhagen, MD, PhD
- 8:47 – 8:52** Is There A Difference In Type 2 Endoleak Incidence Or Behavior Between Different Endografts: What Is The Reason
Marc L. Schermerhorn, MD
- 8:53 – 8:58** Value Of Preloaded Catheters And Wires In Fenestrated Stent-Grafts: How Do They Work And How Helpful Are They
Konstantinos P. Donas, MD
- 8:59 – 9:04** How To Predict, Prevent And Treat Iliac Limb Occlusion In EVAR
Ronald M. Fairman, MD
- 9:05 – 9:13** Panel Discussion

SESSION 84 (Grand Ballroom West, 3rd Floor)

THORACIC AORTA AND ARCH BRANCH RELATED TOPICS

*Moderators: Krassi Ivancev, MD, PhD
Marcelo Ferreira, MD*

- 9:13 – 9:18** Value And Need For Secondary Interventions After TEVAR: What Factors Predict An Increased Likelihood Of A Secondary Intervention
Mark K. Eskandari, MD
- 9:19 – 9:24** Tips And Tricks To Avoid Complications And Improve TEVAR Results: How Well Do Branched Grafts Work In The Aortic Arch
Dittmar Boeckler, MD
- 9:25 – 9:30** Newer Branched Endografts And Large Proximal Scallops For Aortic Arch Lesions
*Mo S. Hamady, MD
Nicholas J. W. Cheshire, MD*
- 9:31 – 9:36** Does Endovascular Or Open Surgical Treatment Of TAAAs Yield A Survival Benefit
Florian Dick, MD
- 9:37 – 9:42** With TBADs Secondary Interventions To Get Improved False Lumen Exclusion Is Important: How To Do It With Stents, Plugs, Coils: When Should They Be Done
Joseph V. Lombardi, MD
- 9:43 – 9:48** Thoracoabdominal Aneurysm Sac Perfusion And Motor Evoked Potentials To Decrease Spinal Cord Ischemia With BEVAR Procedures: Tips And Tricks
Piotr M. Kasprzak, MD
- 9:49 – 9:54** How To Protect A Left Internal Mammary Artery Coronary Bypass In Aortic Arch Interventions
Tilo Koelbel, MD, PhD
- 9:55 – 10:00** How Durable Are Today's TEVAR Devices: What Is The Need For Secondary Interventions To Fix Device Related Problems
Ronald M. Fairman, MD
- 10:01 – 10:10** Panel Discussion
- 10:10 – 10:30** Break – Visit Exhibits And Pavilions (2nd and 3rd Floors)

SESSION 85 (Grand Ballroom West, 3rd Floor)

MORE THORACIC AORTA AND ARCH BRANCH RELATED TOPICS

*Moderators: Alan M. Dietzek, MD, RPVI
Dennis F. Bandyk, MD*

- 10:30 – 10:35** Endovascular Treatment Of Aortic And Branch Takayasu's Disease: When Does It Work And When Does It Not: Based On An Asian Experience
Ramesh K. Tripathi, MD
- 10:36 – 10:41** Endovascular Treatment Of Takayasu's Disease: What Is Its Value: Based On A 10-Year South American Experience
Arno von Ristow, MD
- 10:42 – 10:47** What Cardiac Surgeons Do Not Know About Acute Type A And Type B Aortic Dissections
Firas F. Mussa, MD
- 10:48 – 10:53** Value Of Hepatorenal Bypass To Facilitate Treatment Of TBADs And Complex AAAs
Joseph S. Giglia, MD
- 10:54 – 10:59** Retroperitoneal Access To Target Arteries: A Bailout Procedure When Prograde Branch Catheterization Does Not Work For F/B EVAR
Eric L.G. Verhoeven, MD, PhD

- 11:00 – 11:05** Treatment Of Distal Aortic Growth After TEVAR For TBADs
James H. Black III, MD
- 11:06 – 11:14** Panel Discussion
- 11:15 – 11:20** What Is The Difference Between A Penetrating Aortic Ulcer And A Saccular Aneurysm: Why It Matters
Benjamin M. Jackson, MD
- 11:21 – 11:26** Tips And Tricks For Open Repair After Failed TEVAR
Karl H. Orend, MD
- 11:27 – 11:32** Open Surgical Adjuncts To Preserve Failing Infrarenal Endografts And Creative Non-Femoral Access Options
Martin R. Back, MD
- 11:33 – 11:38** Chronic Aortic Aneurysms After TBADs: Incidence And Treatment Methods: Long-Term Outcomes Are Poor
Richard G.J. Gibbs, FRCS
- 11:39 – 11:44** How Can Patients With An Aorto-Esophageal Fistula After TEVAR Be Salvaged
Jürg Schmidli, MD
- 11:45 – 11:50** How To Identify Healthy Aorta For A Landing Zone In Endovascular Aneurysm Repairs: It May Not Always Be Possible
Matthew J. Eagleton, MD
- 11:51 – 12:00** Panel Discussion
- 12:00 – 1:00** Lunch Break – 2nd Floor Promenade
Visit Exhibits And Pavilions (2nd and 3rd Floors)

SESSION 86 (Grand Ballroom West, 3rd Floor)

CAROTID RELATED TOPICS AND RECENT ADVANCES IN ACUTE STROKE TREATMENT

Moderators: *Ali F. AbuRahma, MD*

Anthony J. Comerota, MD

- 1:00 – 1:05** Should Patients With Chronic Renal Insufficiency Undergo CAS Or CEA
Ali F. AbuRahma, MD
- 1:06 – 1:11** Gender Specific Outcomes For CEA And CAS: Results From The SVS Registry Show That CEA Is Better In Both Men And Women
Joseph J. Ricotta II, MD, MS
- 1:12 – 1:17** CAS Is Still Not As Cost Effective As CEA: But That May Change
Kosmas I. Paraskevas, MD
- 1:18 – 1:23** With Symptomatic Carotid Stenosis Are The Results Of NASCET And ECST Obsolete In View Of Advances In Medical Therapy
Alison Halliday, MS
- 1:24 – 1:29** Which Asymptomatic Carotid Stenosis Patients Should Currently Be On Statins And Medical Therapy And Which Should Get This Treatment Plus CEA Or CAS: When Will We Know For Sure And What Should We Do Now
Anthony J. Comerota, MD
- 1:30 – 1:35** How Common Are Carotid Stent Fractures After CAS And What Is Their Clinical Significance
Richard J. Powell, MD
- 1:36 – 1:42** Panel Discussion

**RECENT PROGRESS IN ACUTE STROKE
TREATMENT**

*Moderators: Allan L. Brook, MD
L. Nelson Hopkins, MD*

- 1:42 – 1:47** Recent Improvements In Acute Stroke Management: Impact Of New Clot Aspiration Techniques And Stent-Clot Retrievers
Stefan Müller-Hülsbeck, MD
- 1:48 – 1:53** New Developments In Acute Stroke Endovascular Treatment: Value Of Stent-Clot Retriever Systems (Solitaire From Covidien) Coupled With Balloon Guide Catheters To Decrease Forward Arterial Flow
L. Nelson Hopkins, MD
- 1:54 – 1:59** New Developments In Acute Stroke Management And Endovascular Devices For Clot Removal And Managing Acute Carotid Occlusions: Success And Adverse Event Rates
Klaus D. Mathias, MD
- 2:00 – 2:11** Panel Discussion

SESSION 87 (Grand Ballroom West, 3rd Floor)

MORE CAROTID RELATED TOPICS

*Moderators: R. Clement Darling III, MD
Cynthia K. Shortell, MD*

- 2:11 – 2:16** Inefficient Distal Embolic Filters A Cause Of Stroke With CAS: What Can Be Done To Offset This
Mark H. Wholey, MD
- 2:17 – 2:22** How To Make CAS In Recently Symptomatic Carotid Stenosis Patients Safe: When Can CAS Compete With CEA In Such Patients
Carlo Setacci, MD
- 2:23 – 2:28** CEA Under Local Anesthesia: Was The GALA Trial Misleading: How Can This Lower Costs In The ACA Era
Dipankar Mukherjee, MD
- 2:29 – 2:34** How To Improve The Results Of Early CEA For Stroke
R. Clement Darling III, MD
- 2:35 – 2:40** How To Perform CAS Safely In Patients With A Non-Circumferential Severely Calcified Carotid Stenosis
Gioachino Coppi, MD
- 2:41 – 2:46** The Game Is Finally Changing With Carotid Disease: When And How To Intervene Beyond Good Medical Therapy
Jose Fernandes e Fernandes, MD, PhD
- 2:47 – 2:52** Tips And Tricks For Performing CAS With Difficult Arch Anatomy
*Enrico M. Marone, MD
Germano Melissano, MD
Roberto Chiesa, MD*
- 2:53 – 2:58** CEA In Women: Still Searching For Parity In Access To Treatment: Why Does This Occur And What Is Its Impact
Cynthia K. Shortell, MD
- 2:59 – 3:04** Which Specialty Gets The Best Outcomes With CEA; With CAS
Ali F. AbuRahma, MD
- 3:05 – 3:10** Clinical Volume Correlates With Outcomes For CAS: It Is Undeniable
Carlos H. Timaran, MD
- 3:11 – 3:17** Panel Discussion
- 3:17 – 3:24** Break – Visit Exhibits And Pavilions (2nd and 3rd Floors)

SESSION 88 (Grand Ballroom West, 3rd Floor)

LOWER EXTREMITY AND MISCELLANEOUS TOPICS

Moderators: Vivian Gahtan, MD
Calogero Presti, MD

- 3:24 – 3:29** Gracilis Muscle Flap To Heal Groin Wounds With Infected Vascular Grafts: How To Do It And Results
John F. Eidt, MD
- 3:30 – 3:35** Significance And Interpretation Of TLR (Target Lesion Revascularization) And Why TLR And Primary Patency Measures In Clinical Trials Can Be Misleading
John R. Laird, MD
- 3:36 – 3:41** Why The TASC Classification Is No Longer Valid As A Treatment Guide
Klaus D. Mathias, MD
- 3:42 – 3:47** Has The Increase In Lower Extremity Interventions Led To Lower Major Amputation Rates
Manju Kalra, MBBS
- 3:48 – 3:53** Tips And Tricks For OCT Guided Crossing Of Difficult SFA And Popliteal CTOs: A Way To Decrease Radiation Exposure
Patrick E. Muck, MD
- 3:54 – 3:59** Value And Limitations Of Subintimal PTA Of Aortic And Iliac Occlusive Lesions: Tips And Tricks
George H. Meier III, MD
- 4:00 – 4:05** Optimal Strategies For Dealing With Heavily Calcified SFA Lesions
Craig M. Walker, MD
- 4:06 – 4:11** Endovascular Treatment Of Arterial Complications Of Pancreatitis: Tips And Tricks
Maria Antonella Ruffino, MD
- 4:12 – 4:17** Importance Of Distal Embolization After SFA Interventions And How To Prevent And Treat It
Nicholas J. Morrissey, MD
- 4:18 – 4:23** Hybrid Procedures In The Lower Extremity: Are They Effective And Which Are The Factors That Determine Durability
Athanasios D. Giannoukas, MSc, MD, PhD
- 4:24 – 4:31** Panel Discussion

SESSION 89 (Grand Ballroom West, 3rd Floor)

MORE LOWER EXTREMITY AND MISCELLANEOUS TOPICS

Moderators: Kenneth Ouriel, MD, MBA
Peter A. Schneider, MD

- 4:31 – 4:36** Do Anti-MRSA Agents Prophylactically Prevent Groin Infection After Vascular Procedures: A RCT: What Regimen Should We Use
Patrick A. Stone, MD
- 4:37 – 4:42** Key Technical Tips For Preventing Groin Incision Infections And Decreasing Readmissions And Hospital Costs
Peter Henke, MD
- 4:43 – 4:48** In Hemodialysis Diabetic Patients With CLI And Gangrene: When Is A Primary Amputation The Right Treatment Option And When Should Revascularization Be Attempted
Mark G. Davies, MD
- 4:49 – 4:54** How IVUS Can Be Helpful In Treating Lower Extremity Ischemia And The Lesions Causing It
Fabrizio Fanelli, MD

- 4:55 – 5:00** A Special New Technique For Spinal Artery Mapping To Aid In Preservation Of Its Flow And Decrease Cord Ischemia With Thoracic Aortic Procedures
Jeffrey Indes, MD
- 5:01 – 5:06** Tips And Tricks For Performing Optimal And Adequate Debridements Of Diabetic Foot Infections
Giustino Marcucci, MD
- 5:07 – 5:12** How Should Lower Extremity Post PTA Dissections Be Managed And Why Do “Bail Out Stenting” Rates Vary So Much
Peter A. Schneider, MD
- 5:13 – 5:18** Tips And Tricks To Make CFA Stenting Successful: When Is It Indicated
George H. Meier III, MD
- 5:19 – 5:24** Tips And Tricks To Make A Radial Artery Approach Applicable To Most Endovascular Interventions
Ali Amin, MD, RVT
- 5:25 – 5:30** Results And Cost Effectiveness Of Carbon Dioxide As Contrast Media For Revascularization Of TASC A And B Femoro-Popliteal Lesions: A Prospective RCT
Mariana Krutman, MD
- 5:31 – 5:36** Duplex Guided Angioplasty And Stenting vs. Conventional Endovascular Technique In Femoro-Popliteal Occlusive Disease: Comparative Results
Eduardo F. Rocha, MD
- 5:37 – 5:47** Panel Discussion
End of Program L

PROGRAM M (SESSIONS 90-96)
MORE ADVANCES AND NEW OR UPDATED
INFORMATION IN VENOUS DISEASE AND ITS
TREATMENT

Course Leaders: *Jose I. Almeida, MD, RVT, RPVI*
Lowell S. Kabnick, MD, RPhS
Thomas W. Wakefield, MD

Trianon Ballroom, 3rd Floor

SESSION 90 (Trianon Ballroom, 3rd Floor)
MORE STRATEGIC METHODS TO DEAL WITH
SAPHENOUS INCOMPETENCE AND VARICOSE
VEINS

Moderators: *Lowell S. Kabnick, MD, RPhS*
Alun H. Davies, MA, DM

- 6:49 – 6:54** RCT Comparing Open Surgery, Radiofrequency, Laser Or Foam Sclerotherapy For Varicose Veins
Bo G. Eklof, MD, PhD
- 6:55 – 7:00** Why Is The SVS-VQI Venous Registry Critical
Thomas W. Wakefield, MD
- 7:01 – 7:06** Thermal Ablation On Anticoagulated Patients: Is It Durable And Effective
Glenn Jacobowitz, MD
- 7:07 – 7:12** When LEED Isn't Enough: The Distribution Of Thermal Energy In The Vein Wall After Endovenous Thermal Ablation
Mark S. Whiteley, MS
- 7:13 – 7:18** Investigating The Effects Of Sclerotherapy And MOCA With Histology And Immunocytochemistry
Mark S. Whiteley, MS
- 7:19 – 7:24** Extreme C6 Cases And Endovenous Solutions
Ignacio Escotto, MD

- 7:25 – 7:30** Do The Economic Benefits Of Earlier Surgery Trump The Current Conservative Non-Operative Approach To The Healing Of Venous Ulcers
Thomas F. O'Donnell, Jr., MD
- 7:31 – 7:36** Incidence, Causes, And Treatment Of Recurrent Varicose Veins Following Endovenous Thermal Ablation
Edward G. Mackay, MD
- 7:37 – 7:42** Partial Crossectomy With Branch Preservation And Venoplasty Of Saphenous Bulb
Gioachino Coppi, MD
- 7:43 – 7:48** Use Of Mechanical Chemical Ablation In Non Saphenous Veins
Julianne Stoughton, MD
- 7:49 – 7:54** Step By Step Use Of Cyanoacrylate For Saphenous Ablation
Jose I. Almeida, MD, RVT, RPVI
- 7:55 – 8:00** Neurological Complications Of Sclerotherapy For Varicose Veins
Edward G. Mackay, MD
- 8:01 – 8:06** Radiofrequency Treatment Of Perforating Veins For Recalcitrant Venous Ulcers: How To Do It And Does It Help
Peter F. Lawrence, MD
- 8:07 – 8:12** Superficial Vein Thrombophlebitis: To Treat Or Not To Treat
Joseph D. Raffetto, MD
- 8:13 – 8:18** Saphenous Ablation Of Complex Anatomy: Tips And Tricks
Jose I. Almeida, MD, RVT, RPVI
- 8:19 – 8:24** The Role Of Truncal Ablation In Venous Ulceration: Is Timing Key
Manj S. Gohel, MD
- 8:25 – 8:30** Panel Discussion

SESSION 91 (Trianon Ballroom, 3rd Floor)

MORE STRATEGIES FOR CORRECTING SEVERE DEEP VENOUS REFLUX AND/OR OBSTRUCTION

Moderators: Anthony J. Comerota, MD
Ramesh K. Tripathi, MD

- 8:31 – 8:36** Surgical Reconstruction Of The Deep Veins
Stephen A. Black, MD
- 8:37 – 8:42** Neo-Valve Reconstruction In The Post-Thrombotic Syndrome
Marzia Lugli, MD
- 8:43 – 8:48** What Is Worse: Obstruction Or Reflux?
Mark H. Meissner, MD
- 8:49 – 8:54** There Is No Such Thing As “Chronic Thrombus”
Anthony J. Comerota, MD
- 8:55 – 9:00** What Comprises The Chronic Venous Obstruction Of Post-Thrombotic Syndrome?
Anthony J. Comerota, MD
- 9:01 – 9:06** Reduction Internal Valvuloplasty (RIVAL) - A New Technique For Deep Vein Valve Reconstruction: Early Results
Ramesh K. Tripathi, MD
- 9:07 – 9:12** Panel Discussion

SESSION 92 (Trianon Ballroom, 3rd Floor)

OTHER MISCELLANEOUS VENOUS CONDITIONS

Moderators: *Thomas F. O'Donnell, Jr. MD*

Joann Lohr, MD

- 9:13 – 9:18** Wound Care, Compression, Surgical Treatment, Ancillary Measures And Primary Prevention
Thomas F. O'Donnell, Jr., MD
- 9:19 – 9:24** Anomalous Features Of Iliac Vein Stenosis That Impact Diagnosis And Treatment
Seshadri Raju, MD
- 9:25 – 9:30** Quality Of Life Assessment After Iliac Vein Stenting For DVT From May-Thurner Syndrome
Todd Berland, MD
- 9:31 – 9:36** Optimal Management Of Isolated Gastrocnemius Or Soleal Vein Thrombosis (ISGVT)
Clifford M. Sales, MD, MBA
- 9:37 – 9:42** Non-Venous Vascular Complications Of Pregnancy
Joann Lohr, MD
- 9:43 – 9:48** Knowns And Unknowns About Popliteal Venous Aneurysms
Ido Weinberg, MD, MSc
- 9:49 – 9:54** What Is Short-Stretch Compression And Why Is That Important For Vascular Surgeons?
Joseph A. Caprini, MD
- 9:55 – 10:00** Lymphedema In Cancer Patients Is Usually Due To Venous Obstructions And Therefore Treatable
Gerard J. O'Sullivan, MD
- 10:01 – 10:06** PAVA – More Understanding Of Peri-Adventitial Venous Abnormalities
Mark S. Whiteley, MS
- 10:07 – 10:12** Venous Embryology
Jean Francois Uhl, MD
- 10:13 – 10:18** RCT Demonstrating The Efficacy And Benefits Of Sulodexide Treatment In Patients With Venous Ulcers
Joseph D. Raffetto, MD
- 10:19 – 10:24** AVM And VM Are As Different As Apple And Orange
Byung-Boong Lee, MD
- 10:25 – 10:30** Is There A Role For Percutaneous Suture Mediated Closure Systems In Venous Interventions: Tips And Tricks
Brian G. DeRubertis, MD
- 10:31 – 10:36** Update On Caprini DVT Risk Assessment Score
Joseph A. Caprini, MD
- 10:37 – 10:42** How To Properly Design And Interpret Clinical Trials
Thomas W. Wakefield, MD
- 10:43 – 10:48** Panel Discussion

SESSION 93 (Trianon Ballroom, 3rd Floor)

PELVIC INCOMPETENCE AND ITS CONSEQUENCES

Moderators: *Jose I. Almeida, MD, RVT, RPVI*

Melvin Rosenblatt, MD

- 10:49 – 10:54** Diagnosis And Treatment Paradigm For Patients With Pelvic Venous Congestion Syndrome
Melvin Rosenblatt, MD
- 10:55 – 11:00** Pelvic Congestion Syndrome: Current Principles Of Diagnostic Duplex Imaging
Melvin Rosenblatt, MD
- 11:01 – 11:06** Pelvic Congestion Syndrome: Current Principles Of Diagnostic Cross-Sectional Imaging
Barry Stein, MD

- 11:07 – 11:12** Should You Worry About The Left Renal Vein When Occluding The Left Ovarian Vein?
Jose I. Almeida, MD, RVT, RPVI
- 11:13 – 11:18** Embolization Has A Major Role In The Treatment Of Varicocele And Pelvic Congestion Syndrome
Lindsay Machan, MD
- 11:19 – 11:24** Pelvic Vein Reflux – Are Hemorrhoids The Next Target?
Mark S. Whiteley, MS
- 11:25 – 11:30** The Safety Of Coil Embolization Of Pelvic Veins And Subsequent Pregnancy
Mark S. Whiteley, MS
- 11:31 – 11:36** Ovarian Vein, Hypogastric Vein Incompetence Or Compression Syndrome: Coil, Stent, Both, Neither?
Constantino Pena, MD
- 11:37 – 11:42** Left Renal Vein Stenting Pitfalls
Constantino Pena, MD
- 11:43 – 11:48** How To Treat Vulvar Veins Before Or After Pelvic Embolization
Barrie A. Price, Mr, MD, MS
- 11:49 – 11:54** Acute Or Chronic Ovarian Vein Thrombosis: What To Do?
Mikel Sadek, MD
- 11:55 – 12:00** Panel Discussion
- 12:00 – 1:00** Lunch Break – 2nd Floor Promenade
Visit Exhibits And Pavilions (2nd and 3rd Floors)

SESSION 94 (Trianon Ballroom, 3rd Floor)

MORE STRATEGIES FOR THROMBOEMBOLIC EVENTS IN THE VENOUS SYSTEM INCLUDING THE AXILLO-SUBCLAVIAN SYSTEM

Moderators: *Thomas W. Wakefield, MD*
Gregory L. Moneta, MD

- 1:00 – 1:05** Endovascular Management Of Ilio-Femoral DVT With Percutaneous Thrombectomy And Thrombolysis: Indications, Techniques And Results
Ali Amin, MD, RVT
- 1:06 – 1:11** Pharmacomechanical Thrombolysis Of Large Volume (Extensive) DVT Using The Rapid Lysis Technique Minimizing The Need For Catheter Directed Lysis
Mark J. Garcia, MD
- 1:12 – 1:17** Methods Of Aging Of Deep Vein Thrombosis
Alun H. Davies, MA, DM
- 1:18 – 1:23** Rheolytic Thrombectomy For Deep Vein Thrombosis: Final Report Of A Prospective Multi-Center Registry
Ali Amin, MD, RVT
- 1:24 – 1:29** Appropriate Use Of D-Dimer Testing Can Minimize Over-Utilization Of Venous Duplex Ultrasound In A Contemporary High-Volume Hospital
Albeir Y. Mousa, MD
- 1:30 – 1:35** Portal Vein Thrombosis: Techniques For Treating And Recanalizing
Mark J. Garcia, MD
- 1:36 – 1:41** What's New In Thoracic Outlet Syndrome Treatment And Reporting Standards: When If Ever Should Neurologic TOS Be Treated?
Karl A. Illig, MD
- 1:42 – 1:48** **DEBATE:** Warfarin Is Still The Treatment Of Choice For VTE: The Noacs Are Not Ready For Prime Time
Joseph A. Caprini, MD

- 1:49 – 1:54** **DEBATE:** Warfarin Is NOT Still The Treatment Of Choice For VTE: The Noacs Are Ready For Prime Time
Anthony J. Comerota, MD
- 1:55 – 2:00** The Value Of Non-Invasive Diagnosis Of Venous Obstruction At The Thoracic Outlet
Enrique Criado, MD
- 2:01 – 2:06** Incidence Of Upper Extremity DVT After Central Venous Catheterization And What To Do About It
Gregory L. Moneta, MD
- 2:07 – 2:12** Venous Issues In Thoracic Outlet Syndrome: Lysis, Venoplasty, First Rib Resection: Staged Or Same Setting?
Enrique Criado, MD
- 2:13 – 2:18** Panel Discussion

SESSION 95 (Trianon Ballroom, 3rd Floor)

ENDOVASCULAR AND OPEN SOLUTIONS FOR INFERIOR VENA CAVA TUMORS

Moderators: *Peter Gloviczki, MD*

William J. Quinones-Baldrich, MD

- 2:19 – 2:24** IVC Replacement For Malignancy: How To Do It And What Is The Best Graft
Thomas C. Bower, MD
- 2:25 – 2:30** Endovascular Reconstruction Techniques For Chronic IVC Occlusions
Mark J. Garcia, MD
- 2:31 – 2:36** Role Of Z-Stent In Iliocaval And Caval Stenting
Seshadri Raju, MD
- 2:37 – 2:42** IVC Agenesis: Is This A Real Entity
David M. Williams, MD
- 2:43 – 2:48** Management Of Tumor Thrombus From Renal Cell Carcinoma Extending Into Supra Hepatic IVC And Right Heart
Ramesh K. Tripathi, MD
- 2:49 – 2:54** Patient Selection For In-Line Caval Reconstruction
William J. Quinones-Baldrich, MD
- 2:55 – 3:00** Exposure And Techniques For In-Line Caval Reconstruction
William J. Quinones-Baldrich, MD
- 3:01 – 3:06** Conduit Choices For In-Line Caval Reconstruction
Peter Gloviczki, MD
- 3:07 – 3:12** Caval Tumors
William A. Marston, MD
- 3:13 – 3:18** Catheter-Based Interventions For Caval Thrombosis: Which Is The Best
Iris Baumgartner, MD
- 3:19 – 3:24** Panel Discussion

SESSION 96 (Trianon Ballroom, 3rd Floor)

VENA CAVA FILTRATION STRATEGIES, PITFALLS, AND COMPLICATIONS AND MORE ABOUT ILIAC VEIN STENTING

Moderators: *Paul J. Foley III, MD*

Ramesh K. Tripathi, MD

VENA CAVA FILTRATION

- 3:25 – 3:30** IVC Filters In Acute DVT: Necessary Or Expensive Luxury?
Gerard J. O'Sullivan, MD

- 3:31 – 3:36** Update On The PRESERVE Vena Cava Filter Study
David L. Gillespie, MD
- 3:37 – 3:42** Remove Tilted IVC Filters Immediately: Complications Are Inevitable
Werner Lang, MD
- 3:43 – 3:48** Indications For IVC Filters – Are They Being Observed?
John E. Rectenwald, MD, MS
- 3:49 – 3:54** Successful Techniques For Challenging IVC Filter Retrieval (Permanent And Temporary IVC Filters)
Paul J. Foley III, MD
- 3:55 – 4:00** Why Aren't Retrievable IVC Filters Retrieved?
Ronald L. Dalman, MD
- 4:01 – 4:06** Major Complications After IVC Filter Placement And How To Avoid Them
Clifford M. Sales, MD, MBA

SATURDAY, NOVEMBER 22, 2014

- 7:00 A.M. General Registration – 2nd Floor Promenade**
7:00 A.M. Faculty Registration – Morgan Suite, 2nd Floor
7:30 A.M. Continental Breakfast – Promenade/Foyer, 3rd Floor

CONCURRENT SATURDAY PROGRAMS

PROGRAM N: (SESSIONS 97-103) 8:00 A.M. – 5:15 P.M.

Endovascular Treatment Of Venous Disease

Grand Ballroom East, 3rd Floor

PROGRAM O: (SESSIONS 104-108) 8:00 A.M. – 4:50 P.M.

Improving Outcomes In Hemodialysis Access

Grand Ballroom West, 3rd Floor

PROGRAM P: (SESSIONS 109-113) 7:55 A.M. – 3:15 P.M.

Complex Vascular Malformations And Vascular Tumors

Trianon Ballroom, 3rd Floor

PROGRAM Q: (SESSIONS 114-118) 8:30 A.M. – 4:00 P.M.

WOUNDS

Gramercy Suites East and West, 2nd Floor

- 4:07 – 4:12** Update On The Sentry Bioconvertible Non-Retrieval IVC Filter

David Rosenthal, MD

- 4:13 – 4:18** What Evidence Is There That IVC Filters Save Lives?

Gregory L. Moneta, MD

- 4:19 – 4:24** The Prepic Trial – Fact Or Fiction?

John E. Rectenwald, MD, MS

- 4:25 – 4:30** Panel Discussion

MORE ON STENTS

- 4:31 – 4:36** First Experiences With The Veniti And Zilver Vena Stents

Stephen A. Black, MD

- 4:37 – 4:42** Nitinol Versus Wall Stents For Iliac Vein Stenting For Lower Limb Outflow Obstruction: Does It Really Matter? What Is An Ideal Venous Stent?

Ramesh K. Tripathi, MD

- 4:43 – 4:48** VIVO Venous Stent IDE Trial Design

Anthony J. Comerota, MD

- 4:49 – 4:54** Pregnancy After Stenting For Ilio-Femoral DVT: Outcome And Complications

Gabriel Szendro, MD

4:55 – 5:00 What Is The Nature Of In-Stent Stenosis After Venous Stenting?
David M. Williams, MD

5:01 – 5:10 Panel Discussion

End of Program M

PROGRAM N (SESSIONS 97–103)

ENDOASCULAR TREATMENT OF VENOUS DISEASE

Course Leaders: *Jose I. Almeida, MD, RVT, RPVI*

Lowell S. Kabnick, MD, RPhS

Thomas W. Wakefield, MD

Grand Ballroom East, 3rd Floor

SESSION 97 (Grand Ballroom East, 3rd Floor)

BASICS OF SUPERFICIAL VENOUS DISEASE

Moderators: *Jose I. Almeida, MD, RVT, RPVI*

Lowell S. Kabnick, MD, RPhS

Thomas W. Wakefield, MD

8:00 – 8:05 Welcome: Tour Of C1 - C6 Venous Disease

Jose I. Almeida, MD, RVT, RPVI

8:06 – 8:11 Venous Embryology: Part 1

Jean Francois Uhl, MD

8:12 – 8:17 Venous Embryology: Part 2

Jean Francois Uhl, MD

8:18 – 8:23 Important Superficial Venous Anatomy

Jean Francois Uhl, MD

8:24 – 8:29 Venous Mapping: How Detailed Should This Be

Neil M. Khilnani, MD

8:30 – 8:35 Evolution Of Superficial Venous Insufficiency:
Ascending Or Descending Theory

Sylvain Chastanet, MD

8:36 – 8:41 Venous Valvular Physiology

Fedor Lurie, MD, PhD

8:42 – 8:47 Is It The Weakened Venous Wall Or The Valve That
Causes Varicose Veins

Joseph D. Raffetto, MD

8:48 – 8:53 Venous Disease Pathophysiology: Which Patients
Progress To Tissue Damage At The Ankle

Peter J. Pappas, MD

8:54 – 9:00 Panel Discussion

SESSION 98 (Grand Ballroom East, 3rd Floor)

EVALUATION AND MANAGEMENT OF SUPERFICIAL VENOUS DISEASE - PART 1

Moderators: *Jose I. Almeida, MD, RVT, RPVI*

Lowell S. Kabnick, MD, RPhS

Thomas W. Wakefield, MD

9:01 – 9:06 How To Use CEAP And VCSS Properly

William A. Marston, MD

9:07 – 9:12 What Determines The Clinical Severity Of Superficial
Venous Disease

Lowell S. Kabnick, MD, RPhS

9:13 – 9:18 What Kind Of Duplex Image Should We Expect After
Endovenous Ablation

Jean Luc Gerard, MD

9:19 – 9:24 Clinical Findings Do Not Match The Ultrasound:
What Do You Do

Edward G. Mackay, MD

9:25 – 9:30 Investigating The Effects Of Sclerotherapy And
MOCA With Histology And Immunocytochemistry

Mark S. Whiteley, MS

- 9:31 – 9:36** Step By Step Use Of 1470nm Laser To Ablate Perforators And Indications
Mark A. Adelman, MD
- 9:37 – 9:42** Step By Step Use Of Mechanical-Chemical Ablation In Non-Saphenous Veins
Julianne Stoughton, MD
- 9:43 – 9:48** Step By Step Use Of Proprietary Foam For Saphenous Ablation And Indications
Lowell S. Kabnick, MD, RPhS
- 9:49 – 9:54** Step By Step Treatment Of Recurrent Veins Following Endovenous Thermal Ablation, Incidence And Causes
Thomas F. O'Donnell, Jr., MD
- 9:55 – 10:00** Panel Discussion

SESSION 99 (Grand Ballroom East, 3rd Floor)

EVALUATION AND MANAGEMENT OF SUPERFICIAL VENOUS DISEASE - PART 2

Moderators: *Jose I. Almeida, MD, RVT, RPVI*

Lowell S. Kabnick, MD, RPhS

Thomas W. Wakefield, MD

- 10:01 – 10:06** Step By Step Use Of Sclerotherapy For Large Varicose Tributaries And Why
Neil M. Khilnani, MD
- 10:07 – 10:12** Step By Step Use Of Ambulatory Phlebectomy For Large Varicose Tributaries And Why
Alan M. Dietzek, MD, RPVI
- 10:13 – 10:18** Efficacy Of Powered Phlebectomy For Large Symptomatic Varicosities
Thomas W. Wakefield, MD
- 10:19 – 10:24** Steps To Treat The Small Saphenous Cranial Extension
Randolph Todd C. Jones III, MD
- 10:25 – 10:30** Steps To Avoid Endothermal Heat Induced Thrombosis
Mikel Sadek, MD
- 10:31 – 10:36** Steps To Avoid Complications Of Foam And Liquid Sclerotherapy
Edward G. Mackay, MD
- 10:37 – 10:42** Steps To Avoid Thermal Ablation Complications
David J. Dexter, MD
- 10:43 – 10:48** Steps To Avoid Nerve Damage
Jean Luc Gerard, MD
- 10:49 – 10:54** Steps To Avoid Thermal Skin Damage
Lowell S. Kabnick, MD, RPhS
- 10:55 – 11:00** Panel Discussion

SESSION 100 (Grand Ballroom East, 3rd Floor)

FUTURE OF VENOUS DISEASE

Moderators: *Jose I. Almeida, MD, RVT, RPVI*

Lowell S. Kabnick, MD, RPhS

Thomas W. Wakefield, MD

- 11:01 – 11:06** Who Will Treat Varicose Veins And Who Will Pay For The Treatment In The Future
Mark H. Meissner, MD
- 11:07 – 11:12** How Should Society Allocate Resources For Venous Disease
Peter F. Lawrence, MD
- 11:13 – 11:18** Future Of Venous Reimbursement: Pressures From CMS
Glenn Jacobowitz, MD
- 11:19 – 11:24** Update: Intersocietal Accreditation Commission – Vein Center
Lowell S. Kabnick, MD, RPhS

- 11:25 – 11:30** A One Stop Vein Clinic: The Ideal Option
Ian J. Franklin, MS
- 11:31 – 11:36** A Plea For A National Coverage Determination Policy
Lowell S. Kabnick, MD, RPhS
- 11:37 – 11:42** Why Is The SVS-VQI Venous Registry Critical
Thomas W. Wakefield, MD
- 11:43 – 11:48** Update On The Management Of Lymphedema
Raghu Kolluri, MD
- 11:49 – 11:54** Partial Crossectomy With “Branch” Preservation And Venoplasty Of Saphenous Bulb
Gioachino Coppi, MD
- 11:55 – 12:00** Panel Discussion
- 12:00 – 1:00** Lunch Break – 3rd Floor Foyer and Promenade
Visit Exhibits And Pavilions (3rd Floor)

SESSION 101 (Grand Ballroom East, 3rd Floor)

EVIDENCE AND RESEARCH NEEDED FOR ENDOVENOUS TREATMENT

Moderators: *Thomas W. Wakefield, MD*
Jose I. Almeida, MD, RVT, RPVI
Lowell S. Kabnick, MD, RPhS

- 1:00 – 1:05** Endovenous Thermal Ablation RCTs: Do We Know Enough
Bo G. Eklof, MD, PhD
- 1:06 – 1:11** Should The UK Nice Guidelines Be The Same As The SVS/AVF
Alun H. Davies, MA, DM
- 1:12 – 1:17** What Do The Quality Measures (QM) Measure: Analysis Of PQRS (Physician Quality Reporting System) For Venous Disease
Fedor Lurie, MD, PhD
- 1:18 – 1:23** Venous Ulcers - An Algorithm For Management
Peter F. Lawrence, MD
- 1:24 – 1:29** **DEBATE:** Ultrasound Is Mandatory After Saphenous Ablation
Mark S. Whiteley, MS
- 1:30 – 1:35** **DEBATE:** Ultrasound Is Not Mandantory After Saphenous Ablation
Lowell S. Kabnick, MD, RPhS
- 1:36 – 1:41** Extreme C6 Cases And Endovenous Solutions
Ignacio Escotto, MD
- 1:42 – 1:47** Not All Skin Ulcers Are Venous
Raghu Kolluri, MD
- 1:48 – 1:53** Thermal Ablation On Anticoagulated Patients: Is It Durable And Effective
Glenn Jacobowitz, MD
- 1:54 – 2:00** Panel Discussion

SESSION 102 (Grand Ballroom East, 3rd Floor)

MORE TOPICS REGARDING TRUNCAL REFLUX, CLUSTERS AND SPIDER TELANGIECTASIA

Moderators: *Thomas W. Wakefield, MD*
Jose I. Almeida, MD, RVT, RPVI
Lowell S. Kabnick, MD, RPhS

- 2:01 – 2:06** A Prospective Observational Study Comparing 810nm And 1470nm Wavelength For Great Saphenous Laser Ablation
Ian C. Chetter, MD
- 2:07 – 2:12** Is 1920nm Wavelength The Future Of Venous Ablation
Lowell S. Kabnick, MD, RPhS

- 2:13 – 2:18** Primary CVD: Which Patients Should You Intervene On Early (GSV Ablation, Correct Hemodynamics) And If You Intervene Will It Reduce Or Prevent The Progression To Higher Clinical Class
Joseph D. Raffetto, MD
- 2:19 – 2:24** Homemade Foam Versus FDA Approved Manufactured Foam: Risks And Rewards
Lowell S. Kabnick, MD, RPhS
- 2:25 – 2:30** 5-Year Results Of A Randomized Clinical Trial Comparing Concomitant And Sequential Phlebectomy Following Endovenous Laser Ablation
Ian C. Chetter, MD
- 2:31 – 2:36** How Real Are Venous Thromboembolic Complications With Endovenous Thermal Ablation: Paradox Between RCTs, Large Observational Case Series, And Registry Data
Thomas F. O'Donnell, Jr., MD
- 2:37 – 2:42** Radiofrequency Ablation Treatment Pearls
Alan M. Dietzek, MD, RPVI
- 2:43 – 2:48** Laser Ablation Treatment Pearls
Lowell S. Kabnick, MD, RPhS
- 2:49 – 2:54** Sclerotherapy Pearls
Julianne Stoughton, MD
- 2:55 – 3:00** Cutaneous Laser Pearls: When And How To Use For Spider Veins
Ian J. Franklin, MS
- 3:01 – 3:06** Mechanico-Chemical Ablation Pearls
Steve Elias, MD
- 3:07 – 3:12** New Vascular Occlusion Device
Lowell S. Kabnick, MD, RPhS
- 3:13 – 3:18** Panel Discussion

SESSION 103 (Grand Ballroom East, 3rd Floor)

ENDOVENOUS CASE PRESENTATION, PRE-RECORDED VIDEO, EVIDENCE AND MORE

Moderators: *Lowell S. Kabnick, MD, RPhS*

Thomas W. Wakefield, MD

Jose I. Almeida, MD, RVT, RPVI

- 3:19 – 3:29** Saphenous Ablation
Jose I. Almeida, MD, RVT, RPVI
- 3:29 – 3:33** Discussion/Q&A
- 3:34 – 3:44** Pelvic Congestion Syndrome
Neil M. Khilnani, MD
- 3:44 – 3:48** Discussion/Q&A
- 3:49 – 3:59** Predictive Value Of A Preoperative Test For The Reversibility Of The Reflux After Phlebectomy With Preservation Of The Great Saphenous Vein
Sylvain Chastanet, MD
- 3:59 – 4:03** Discussion/Q&A
- 4:04 – 4:14** A New Look At Venous Hemodynamics: Importance Of Measuring Both Reflux And Venous Outflow Obstruction
Andrew N. Nicolaidis, MS
- 4:14 – 4:18** Discussion/Q&A
- 4:19 – 4:29** How To Treat Exotic Veins – Hand, Foot, And Vulvar Veins
Barrie A. Price, Mr, MD, MS
- 4:29 – 4:33** Discussion/Q&A
- 4:34 – 4:44** Phlebectomy: How, When, And Why
Paul Pittaluga, MD
- 4:44 – 4:48** Discussion/Q&A

- 4:49 – 4:59** Proper Application Of Bandages –Short Stretch And Why Is That Important For Vascular Surgeons
Joseph A. Caprini, MD
- 4:59 – 5:03** Discussion/Q&A
- 5:04 – 5:15** Panel Discussion
End of Program N

PROGRAM O (SESSIONS 104–108)

IMPROVING OUTCOMES IN HEMODIALYSIS ACCESS

- Course Directors: **Anton N. Sidawy, MD, MPH**
Larry A. Scher, MD
- Course Co-Directors: **John E. Aruny, MD**
Haimanot (Monnie) Wasse, MD, MPH

Grand Ballroom West, 3rd Floor

SESSION 104 (Grand Ballroom West, 3rd Floor)

PREOPERATIVE PLANNING FOR HEMODIALYSIS ACCESS

- Moderators: **Larry A. Scher, MD**
Anton N. Sidawy, MD, MPH

- 8:00 – 8:07** Review Of The SVS Guidelines For Hemodialysis Access
Robyn A. Macsata, MD
- 8:08 – 8:15** Predialysis Planning To Optimize The Management Of The Patient With CKD
Prabir Roy-Chaudhury, MD, PhD
- 8:16 – 8:23** Update On The Fistula First/Catheter Last Initiative
Lawrence M. Spergel, MD
- 8:24 – 8:31** Algorithms To Avoid Central Venous Catheters At Dialysis Initiation
Charmaine Lok, MD
- 8:32 – 8:39** Quality Benchmarks Of A Vascular Access Program
David L. Cull, MD
- 8:40 – 8:50** Discussion
- 8:51 – 8:58** Use Of The Noninvasive Vascular Laboratory In Dialysis Access
Russell H. Samson, MD, RVT
- 8:59 – 9:06** Impact Of Transvenous Cardiac Devices On Vascular Access Placement And Patency
Haimanot (Monnie) Wasse, MD, MPH
- 9:07 – 9:14** The Implications Of Transradial Approach For Cardiovascular Interventions On Hemodialysis Access
Theodore F. Saad, MD
- 9:15 – 9:22** Anesthesia For Office Based Vascular Access Interventions
David Fox, MD
- 9:23 – 9:30** Dialysis Access Cannulation: A Lost Art?
Deborah Brouwer-Maier, RN, CNN
- 9:31 – 9:41** Panel Discussion
- 9:42 – 10:00** Break – Visit Exhibits And Pavilions (3rd Floor)

SESSION 105 (Grand Ballroom West, 3rd Floor)

OPTIMIZING OUTCOMES IN HEMODIALYSIS ACCESS

- Moderators: **Haimanot (Monnie) Wasse, MD, MPH**
Theodore F. Saad, MD

- 10:00 – 10:07** Optimization Of Risk Factors To Maximize Vascular Access Patency
Charmaine Lok, MD
- 10:08 – 10:15** How Do Cell Biology And Hemodynamics Impact AV Access Outcomes
Prabir Roy-Chaudhury, MD, PhD

- 10:16 – 10:23** Medical Factors Affecting Patency Of AV Access Procedures
Robyn A. Macsata, MD
- 10:24 – 10:31** Management Of Hypercoagulable States In Patients With End Stage Renal Disease
Jeffrey H. Lawson, MD, PhD
- 10:32 – 10:39** Role Of Surveillance And Preemptive Intervention In Optimizing Hemodialysis Access Outcomes
Jack Work, MD
- 10:40 – 10:47** The Role Of BAM In Autogenous Access Maturation
Gregg A. Miller, MD
- 10:48 – 10:58** Panel Discussion
- 10:59 – 11:06** Challenges Of Vascular Access In The Elderly Patient
David L. Cull, MD
- 11:07 – 11:14** Challenges Of Vascular Access In The Obese Patient
William Jennings, MD
- 11:15 – 11:22** Challenges Of Vascular Access In The Patient With Lupus
Mitchell L. Henry, MD
- 11:23 – 11:30** Update On The Results Of The REVISE, RESCUE And RENOVA Trials
John E. Aruny, MD
- 11:31 – 11:38** Management Of Complications In An Office Based Practice
Gregg A. Miller, MD
- 11:39 – 11:49** Panel Discussion
- 11:50 – 12:30** Lunch Break – 3rd Floor Foyer and Promenade
Visit Exhibits And Pavilions (3rd Floor)

SESSION 106 (Grand Ballroom West, 3rd Floor)

POLITICAL, ETHICAL AND LEGAL ISSUES IN HEMODIALYSIS

Moderators: *John E. Aruny, MD*
Mitchell L. Henry, MD

- 12:30 – 12:40** Challenges And Opportunities In Hemodialysis Access In The Current Economic Climate
Robert Provenzano, MD
- 12:41 – 12:48** The Affordable Care Act, Capitation, And Other Factors That Affect Our Hemodialysis Access Practice
Robert M. Zwolak, MD, PhD
- 12:49 – 12:56** Medicolegal Risk Reduction In Hemodialysis Access Surgery
O. William Brown, MD, JD
- 12:57 – 1:04** Ethical Issues In Hemodialysis Access
James W. Jones, MD, PhD, MHA
- 1:05 – 1:12** Coding For Hemodialysis Access Procedures: What's New And What Lies Ahead
Sean P. Roddy, MD
- 1:13 – 1:20** How The FDA Is Working To Improve The Quality Of Vascular Access For Dialysis Patients
Kenneth J. Cavanaugh, Jr., PhD
- 1:21 – 1:28** Office Based Access Centers And Financial Impact On Practice
Clifford M. Sales, MD, MBA
- 1:29 – 1:39** Panel Discussion

SESSION 107 (Grand Ballroom West, 3rd Floor)

NEW TECHNOLOGIES AND CONCEPTS IN HEMODIALYSIS ACCESS

*Moderators: Clifford M. Sales, MD, MBA
Eric Chemla, MD*

- 1:40 – 1:47** Endoluminal Anastomosis: Results With The Gore Hybrid Graft
John R. Ross, Sr., MD
- 1:48 – 1:55** VWing™ Vascular Needle Guide For Improved AV Fistula Access
Marc H. Glickman, MD
- 1:56 – 2:03** Clinical Experience With Tissue Engineered Grafts In Hemodialysis Access
Jeffrey H. Lawson, MD, PhD
- 2:04 – 2:11** Spiral Laminar Flow Grafts In Hemodialysis Access
Richard F. Neville, MD
- 2:12 – 2:19** Optiflow™ Device For Percutaneous AV Fistula Anastomosis
Prabir Roy-Chaudhury, MD, PhD
- 2:20 – 2:27** NexSite™ Catheter For Hemodialysis Access
John R. Ross, Sr., MD
- 2:28 – 2:44** Panel Discussion
- 2:45 – 3:10** Break

SESSION 108 (Grand Ballroom West, 3rd Floor)

UPDATE ON CLINICAL ISSUES IN HEMODIALYSIS ACCESS

*Moderators: A. Frederick Schild, MD
Marc H. Glickman, MD*

- 3:10 – 3:17** The Role Of Peritoneal Dialysis In Patients With Difficult Hemodialysis Access
Jack Work, MD
 - 3:18 – 3:25** Current Status Of Biologic Grafts In Hemodialysis Access
Matthew J. Dougherty, MD
 - 3:26 – 3:33** Strategies For Use Of Early Access Grafts For Hemodialysis Access
Eric Chemla, MD
 - 3:34 – 3:41** Basilic Vein Transposition Using One Stage Or Two Stage Techniques
Mitchell L. Henry, MD
 - 3:42 – 3:49** Management Of The Massively Dilated AV Fistula
Surendra Shenoy, MD, PhD
 - 3:50 – 4:00** Panel Discussion
 - 4:01 – 4:08** Use Of Stent Grafts To Treat Cephalic Arch Stenosis
David Shemesh, MD, RVT
 - 4:09 – 4:16** Innovative Approaches To Treatment Of Central Venous Stenosis
Karl A. Illig, MD
 - 4:17 – 4:24** Role Of The HeRo Graft In Hemodialysis Access
Marc H. Glickman, MD
 - 4:25 – 4:32** An Individualized Approach To The Management Of Hand Ischemia Associated With Dialysis Access
Lawrence M. Spergel, MD
 - 4:33 – 4:40** Creating Access In A Patient With A History Of Steal Syndrome
William Jennings, MD
 - 4:41 – 4:50** Panel Discussion
- End of Program O**

PROGRAM P (SESSIONS 109-113)

COMPLEX VASCULAR MALFORMATIONS AND VASCULAR TUMORS

Course Leaders: **Wayne F. Yakes, MD**
Krassi Ivancev, MD, PhD

Trianon Ballroom, 3rd Floor

SESSION 109 (Trianon Ballroom, 3rd Floor)

CLASSIFICATION, IMAGING, AND EMBOLIC AGENTS FOR VASCULAR ANOMALIES

Moderators: **Wayne F. Yakes, MD**
Krassi Ivancev, MD, PhD

- 7:55 – 8:00** Introduction
Krassi Ivancev, MD, PhD
- 8:00 – 8:10** Current Classification And Nomenclature Of Vascular Malformations
Ziv J. Haskal, MD
- 8:10 – 8:20** Vascular Tumors Confused With Vascular Malformations: Pediatric Hemangioma, RICH, NICH, KPH Of Liver, KPH Of Trunk With Kassabach-Merritt Syndrome
Francine Blei, MD
- 8:20 – 8:30** New Imaging Modalities Essential For Accurate Diagnosis Of Vascular Malformations
Cynthia K. Shortell, MD
- 8:30 – 8:40** 2014 ISSVA Classification Of Vascular Anomalies: Update
Francine Blei, MD
- 8:40 – 8:50** Techniques For Treating Vascular Malformations Of The Extremities
Cynthia K. Shortell, MD
- 8:50 – 9:00** Old Things About Arterio-Venous Lesions And Personal Classification
Emmanuel M. Houdart, MD
- 9:00 – 9:10** The Houdart AVM Classification, The Cho-Do AVM Classification, And The Yakes AVM Classification And Its Therapeutic Implications
Wayne F. Yakes, MD
- 9:10 – 9:20** Use Of Polymerizing Agents In The Endovascular Treatments Of AVMs
Robert J. Rosen, MD
- 9:20 – 9:30** Onyx AVM Embolotherapy: The Histologic Tissue Changes, The Tissue Inflammatory Response, And The Fluoroscopy Issues With Its Use
Mollie Meek, MD
- 9:30 – 9:40** Sclerogel: A New Ethanol Based Embolic Agent To Treat Low-Flow Vascular Malformations
Iris Baumgartner, MD
- 9:40 – 10:00** Break – Visit Exhibits And Pavilions (3rd Floor)

SESSION 110 (Trianon Ballroom, 3rd Floor)

MANAGEMENT OF HEAD AND NECK VASCULAR ANOMALIES

Moderators: **Krassi Ivancev, MD, PhD**
Wayne F. Yakes, MD

- 10:00 – 10:10** The Role Of Medical Therapies For Hemangiomas And Vascular Malformations
Francine Blei, MD
- 10:10 – 10:20** Surgical Management Of Head And Neck Pediatric Hemangioma
Milton Waner, MD

- 10:20 – 10:30** Dangerous Arterial Corrections In The Head And Neck: Avoiding Neurological Complications And The Judicious Use Of Embolic Agents
Guilherme Dabus, MD
- 10:30 – 10:40** Surgical Options In Head And Neck Vascular Malformation Management
Milton Waner, MD
- 10:40 – 10:50** Head And Neck Vascular Malformation Management: UAMS Experience
Mollie Meek, MD
- 10:50 – 11:00** Liquid Embolic Agents In The Treatment Of Cranio-Facial AVMs and AVFs: Techniques And Results
Guilherme Dabus, MD
- 11:00 – 11:10** Curative Endovascular Management Of Complex Multiple High-Flow Vascular Malformations Of The Head And Neck
Wayne F. Yakes, MD
- 11:10 – 11:20** Endovascular Treatment Of Yakes Type IV AVMs
Krassi Ivancev, MD, PhD
- 11:20 – 11:30** Intra-Arterial Chemotherapy For Retinoblastoma: Lessons Learned After 1000 Infusions
Pierre Gobin, MD
- 11:30 – 11:40** Ethanol Endovascular Management Of Low-Flow Venous And Lymphatic Vascular Malformations Of The Head, Neck, And Tongue
Wayne F. Yakes, MD

SESSION 111 (Trianon Ballroom, 3rd Floor)

UPPER AND LOWER EXTREMITY VASCULAR MALFORMATION MANAGEMENT – PART 1

Moderators: *Wayne F. Yakes, MD*
Krassi Ivancev, MD, PhD

- 11:40 – 11:50** Surgical Approaches To Vascular Malformation Management: Triumphs And Pitfalls
Christopher J. Morin, MD
- 11:50 – 12:00** Step Table Venography In Venous Malformation Of The Lower Extremities
Patricia E. Burrows, MD
- 12:00 – 12:10** Surgical Concepts To Treat The Lateral Marginal Vein Of The Servelle Of The Lower Extremity
Byung-Boong Lee, MD
- 12:10 – 1:15** Lunch Break – Visit Exhibits And Pavilions (3rd Floor)

SESSION 112 (Trianon Ballroom, 3rd Floor)

UPPER AND LOWER EXTREMITY VASCULAR MALFORMATION MANAGEMENT – PART 2

Moderators: *Wayne F. Yakes, MD*
Krassi Ivancev, MD, PhD

- 1:15 – 1:25** Common Femoral And Iliac Arterial Sparing Endovascular Techniques In Neonates
Patricia E. Burrows, MD
- 1:25 – 1:35** Treatment Of Intramuscular Venous Malformations Of The Extremities
Robert J. Rosen, MD
- 1:35 – 1:45** Treatment Of AVMs Of The Upper And Lower Extremities
Wayne F. Yakes, MD
- 1:45 – 1:55** Long-Term Outcomes For The Treatment Of Vascular Malformations: The Northwestern Experience
Robert L. Vogelzang, MD

1:55 – 2:05 Endovascular Curative Management Of AVMs Of Bone
Wayne F. Yakes, MD

SESSION 113 (Trianon Ballroom, 3rd Floor)
**CHEST, ABDOMEN, PELVIS AND BUTTOCK
VASCULAR MALFORMATIONS**

Moderators: Krassi Ivancev, MD, PhD
Wayne F. Yakes, MD

- 2:05 – 2:15** Ethanol Ablation Of Venous Malformations Of The Chest, Abdomen And Buttocks
Krassi Ivancev, MD, PhD
- 2:15 – 2:25** Endovascular Management Of Mesenteric, Small Bowel, Hepatic, And Colo-Rectal High Flow And Low Flow Vascular Malformations
Wayne F. Yakes, MD
- 2:25 – 2:35** Staged Management Of Pelvic AVMs With nBCA
Robert J. Rosen, MD
- 2:35 – 2:45** Management Of Malformations Of The Vulva And External Genitalia
George Hamilton, MD
- 2:45 – 2:55** Endovascular Management Of Strategies For Inoperable Thoracic And Shoulder AVMs
Wayne F. Yakes, MD
- 2:55 – 3:05** Large Complex Pelvic AVMs: The Retrograde Vein Approach For Curative Treatment
Robert L. Vogelzang, MD
- 3:05 – 3:15** Combined Antegrade Arterial And Retrograde Vein Approaches To Cure Complex AVMs Of The Chest, Abdomen, Paraspinal And Spinal Areas
Wayne F. Yakes, MD
- 3:15** **End of Program P**

PROGRAM Q (SESSIONS 114-118)
WOUND CARE ISSUES, DEBATES, UPDATE

Course Leader: Dieter O. Mayer, MD
Gramercy Suites East and West, 2nd Floor

8:30 – 8:40 Opening Remarks
Dieter O. Mayer, MD

SESSION 114 (Gramercy Suites East and West, 2nd Floor)
UPDATES AND NEW CONCEPTS IN WOUND CARE

Moderator: Elizabeth A. Ayello, PhD, RN

- 8:40 – 8:50** Systematic Management Approach To Chronic Wounds – “DOMINATE The Wounds” System
Fedor Lurie, MD, PhD
- 8:50 – 8:55** Discussion
- 8:55 – 9:05** Pharmacological Agents In Promoting Leg Ulcer Healing
Alun H. Davies, MA, DM
- 9:05 – 9:10** Discussion
- 9:10 – 9:20** The Role Of TNF Alfa Inhibitors In Lower Leg Ulcers
Marco Romanelli, MD, PhD
- 9:20 – 9:25** Discussion
- 9:25 – 9:35** PluroGel PN (Double Antibiotic) Phase II Results
David G. Armstrong, DPM, MD, PhD
- 9:35 – 9:40** Discussion
- 9:40 – 10:00** Break – Visit Exhibits (South Corridor, 2nd Floor)

SESSION 115 (Gramercy Suites East and West, 2nd Floor)

GREAT DEBATES

Moderators: *Dieter O. Mayer, MD*
Marc A. Brenner, DPM

- 10:00 – 10:07** Dermal Substitutes Outperform Split Skin Grafts In Chronic Wounds: Pro
Lee C. Rogers, DPM
- 10:07 – 10:14** Dermal Substitutes Outperform Split Skin Grafts In Chronic Wounds: Con
Hisham Rashid, MD
- 10:14 – 10:20** Discussion
- 10:20 – 10:27** Dermagraft Or Apligraf: That's The Question
Wayne J. Caputo, DPM
- 10:27 – 10:30** Discussion
- 10:30 – 10:37** Skin Substitutes May Be Nice, But Flaps Are The Only Way To Go: Pro
Peter A. Blume, DPM
- 10:37 – 10:44** Skin Substitutes May Be Nice, But Flaps Are The Only Way To Go: Con
Gary W. Gibbons, MD
- 10:44 – 10:50** Discussion

SESSION 116 (Gramercy Suites East and West, 2nd Floor)

EVIDENCE-BASED MEDICINE IN WOUND CARE

Moderator: *Bauer E. Sumpio, MD, PhD*

- 10:50 – 11:00** An Evidence-Based And Interdisciplinary Guideline For Acute Wound Care
Hester Vermeulen, PhD
- 11:00 – 11:05** Discussion
- 11:05 – 11:15** Predicting Complex Acute Wound Healing In Patients From A Wound Expertise Center
Anne M. Eskes, RN, PhD
- 11:15 – 11:20** Discussion
- 11:20 – 11:25** A Prospective Study On Demographic Characteristics, Genetic Pattern And Association Of Lipidema
Afsaneh Alavi, MD
- 11:25 – 11:30** Discussion
- 11:30 – 11:40** Prospective Randomized Study Evaluating Polymen And Negative Wound Pressure Therapy (NWPT) With NWPT Alone
Afshin Assadian, MD
- 11:40 – 11:45** Discussion
- 11:45 – 12:30** Lunch Break – Visit Exhibits (South Corridor, 2nd Floor)

SESSION 117 (Gramercy Suites East and West, 2nd Floor)

THE DIABETIC FOOT

Moderator: *Giacomo Clerici, MD*

- 12:30 – 12:45** Screening For The High Risk Diabetic Foot: What Is The Return On Investment
R. Gary Sibbald, MD
- 12:45 – 12:55** Discussion
- 12:55 – 1:05** How To Improve Compliance For Offloading In Diabetic Patients
Thomas Boeni, MD
- 1:05 – 1:15** Discussion
- 1:15 – 1:25** Is There A Major Fungal Component Within Diabetic Neurotrophic Ulcerations
Marc A. Brenner, DPM
- 1:25 – 1:35** Discussion

- 1:35 – 1:45** Predictors Of Poor Outcome In Non-Revascularized Patients With A Diabetic Foot Ulcer And Peripheral Arterial Disease
Robert J. Hinchliffe, MD
- 1:45 – 1:55** Discussion

SESSION 118 (Gramercy Suites East and West, 2nd Floor)
VASCULAR INTERVENTIONS IN WOUND CARE
Moderator: Joseph L. Mills, MD

- 1:55 – 2:05** LEAN Principles And Their Application To Vascular Healthcare: What Can Toyota Teach Us In Vascular Healthcare
Tej M. Singh, MD, MBA
- 2:05 – 2:15** Discussion
- 2:15 – 2:25** PTA First For Critical Ischemia And Wound Healing: A Success Story Started 40 Years Ago By Andreas Gruentzig At The University Hospital Of Zurich
Beatrice Amman-Vesti, MD
- 2:25 – 2:35** Discussion
- 2:35 – 2:45** Evaluation Of Feasibility Of Ankle Pressure And Foot Oximetry Values For The Detection Of Critical Limb Ischemia In Diabetic Patients
Giacomo Clerici, MD
- 2:45 – 2:55** Discussion
- 2:55 – 3:05** Perfusion Guided Revascularization Using Tissue Implanted Oxygen Sensors
Miguel F. Montero-Baker, MD
- 3:05 – 3:15** Discussion
- 3:15 – 3:25** New And Better Ways Of Measuring Perfusion: An Unmet Need
Joseph L. Mills, MD
- 3:25 – 3:35** Discussion
- 3:35 – 3:40** Closing Remarks
Dieter O. Mayer, MD
- 3:40** **End of Program Q**

FACULTY

A

- Anne L. Abbott, MD, PhD, FRACP**
Melbourne, Australia
- Dorothy B. Abel, BSBME**
Silver Spring, Maryland
- Apolonia E. Abramowicz, MD**
Bronx, New York
- Christopher J. Abularrage, MD**
Baltimore, Maryland
- Ali F. AbuRahma, MD**
Charleston, West Virginia
- Charles W. Acher, MD**
Madison, Wisconsin
- Mark A. Adelman, MD**
New York, New York
- Sam S. Ahn, MD, MBA, FACS**
Los Angeles, California and Dallas, Texas
- Afsaneh Alavi, MD, FRCPC**
Toronto, Ontario, Canada
- Jose I. Almeida, MD, RVT, RPVI, FACS**
Miami, Florida
- Jean-Marc Alsac, MD, PhD**
Paris, France
- David J. Altschul, MD**
Bronx, New York
- Beatrice R. Amann-Vesti, MD**
Zurich, Switzerland
- Ali Amin, MD, RVT, FACS, FACC**
Reading, Pennsylvania
- Max Amor, MD**
Essey-Lès-Nancy, France
- Frank R. Arko, MD**
Charlotte, North Carolina
- David G. Armstrong, DPM, MD, PhD**
Tucson, Arizona
- Zachary M. Arthurs, MD**
San Antonio, Texas
- John E. Aruny, MD**
New Haven, Connecticut
- Enrico Ascher, MD**
Brooklyn, New York
- Afshin Assadian, MD**
Vienna, Austria
- Martin J. Austermann, MD**
Münster, Germany
- Hamdy Awad, MD**
Columbus, Ohio
- Elizabeth A. Ayello, PhD, RN, ACNS-BC, CWON, MAPWCA, FAAN**
Albany, New York
- Ali Azizzadeh, MD**
Houston, Texas

B

- Martin R. Back, MD**
Tampa, Florida
- Ron Balm, MD, PhD**
Amsterdam, The Netherlands
- Jörn O. Balzer, MD, PhD**
Mainz, Germany
- Dennis F. Bandyk, MD**
La Jolla, California
- Iris Baumgartner, MD**
Bern, Switzerland
- Yvonne Bausback, MD**
Leipzig, Germany
- Jonathan D. Beard, ChM, MEd, FRCS**
London, United Kingdom

- Jean-Pierre Becquemin, MD, FRCS**
Creteil, France
- Daniel Benitti, MD**
São Paulo, Brazil
- Amira Benjelloun, MD**
Rabat, Morocco
- Jeffrey S. Berger, MD, MS, FAHA, FACC**
New York, New York
- Ramon Berguer, MD, PhD**
Ann Arbor, Michigan
- Todd Berland, MD**
New York, New York
- Robert M. Bersin, MD**
Seattle, Washington
- Giancarlo Biamino, MD, PhD**
Impruneta (FI), Italy
- Colin D. Bicknell, MD, FRCS**
London, United Kingdom
- Jean Bismuth, MD**
Houston, Texas
- Martin Bjorck, MD, PhD**
Uppsala, Sweden
- James H. Black III, MD**
Baltimore, Maryland
- Stephen A. Black, MD**
London, United Kingdom
- Jan D. Blankensteijn, MD**
Amsterdam, The Netherlands
- John Blebea, MD, MBA**
Tulsa, Oklahoma
- Francine Blei, MD**
New York, New York
- Peter A. Blume, DPM, FACS**
New Haven, Connecticut
- Dittmar Boeckler, MD**
Heidelberg, Germany
- Thomas Boeni, MD**
Zurich, Switzerland
- Amman Bolia, MD**
Leicester, United Kingdom
- Marc Bosiers, MD**
Dendermonde, Belgium
- Thomas C. Bower, MD**
Rochester, Minnesota
- Jonathan R. Boyle, MD, FRCS**
Cambridge, United Kingdom
- Marc A. Brenner, DPM, FASPD**
Glendale and Manhasset, New York
- Marianne Brodmann, MD**
Austria, Europe
- Allan L. Brook, MD**
Bronx, New York
- Thomas G. Brott, MD**
Jacksonville, Florida
- Deborah Brouwer-Maier, RN, CNN**
Lansdale, Pennsylvania
- Martin M. Brown, MD**
London, United Kingdom
- O. William Brown, MD, JD**
Royal Oak, Michigan
- Elchanan Bruckheimer, MBBS**
Petah-Tikva, Israel
- Jan S. Brunkwall, MD, PhD**
Cologne, Germany
- Clifford J. Buckley, MD**
Temple, Texas
- Richard Bulbulia, MA, MD, FRCS**
Oxford and Cheltenham, United Kingdom

FACULTY

**Nick J. Burfitt, BSc, MB, BChir,
MRCS, FRCR**

London, United Kingdom

Patricia E. Burrows, MD
Milwaukee, Wisconsin

Jacques Busquet, MD
Paris, France

C

Keith D. Calligaro, MD
Philadelphia, Pennsylvania

Richard P. Cambria, MD
Boston, Massachusetts

Ludovic Canaud, MD, PhD
Montpellier, France

Piergiorgio Cao, MD, FRCS
Rome, Italy

Lou R. Caplan, MD
Boston, Massachusetts

Laura Capoccia, MD, PhD
Rome, Italy

Joseph A. Caprini, MD
Skokie, Illinois

Wayne J. Caputo, DPM
*Belleville, New Jersey and
New York, New York*

Jeffrey P. Carpenter, MD
Camden, New Jersey

Kenneth J. Cavanaugh, Jr., PhD
Silver Spring, Maryland

Neal S. Cayne, MD
New York, New York

Rabih A. Chaer, MD
Pittsburgh, Pennsylvania

Elliot L. Chaikof, MD, PhD
Boston, Massachusetts

John B. Chang, MD
Roslyn, New York

Sylvain Chastanet, MD
Nice and Monaco

Eric Chemla, MD
London, United Kingdom

Nicholas J.W. Cheshire, MD
London, United Kingdom

Ian C. Chetter, MD, FRCS
Yorkshire, United Kingdom

Roberto Chiesa, MD
Milano, Italy

Larry Chinitz, MD
New York, New York

Kyung Cho, MD
Ann Arbor, Michigan

Timothy A.M. Chuter, DM
San Francisco, California

Daniel G. Clair, MD
Cleveland, Ohio

Giacomo Clerici, MD
Pavia, Italy

Rachel E. Clough, MD, PhD
London, United Kingdom

**Anthony J. Comerota, MD, FACS,
FACC**
Toledo, Ohio

Mark Conrad, MD, MMSc
Boston, Massachusetts

Michael S. Conte, MD
San Francisco, California

Gioachino Coppi, MD
Modena, Italy

Joseph S. Coselli, MD
Houston, Texas

Hans M.E. Coveliers, MD, MBA
Amsterdam, The Netherlands

Enrique Criado, MD, FACS
Ann Arbor, Michigan

Frank J. Criado, MD, FACS, FSVM
Baltimore, Maryland

Jack L. Cronenwett, MD
Lebanon, New Hampshire

David L. Cull, MD, FACS
Greenville, South Carolina

D

Guilherme Dabus, MD
Miami, Florida

Michael D. Dake, MD
Stanford, California

Ronald L. Dalman, MD
Stanford, California

Alan Dardik, MD, PhD
New Haven, Connecticut

Herbert Dardik, MD
Englewood, New Jersey

R. Clement Darling III, MD
Albany, New York

**Alun H. Davies, MA, DM, FRCS,
FHEA, FEBVS, FACPh**

London, United Kingdom

Mark G. Davies, MD
Houston, Texas

Gerrit J. de Borst, MD
Utrecht, The Netherlands

Rick De Graaf, MD, PhD
Maastricht, The Netherlands

Jean-Paul de Vries, MD, PhD
Nieuwegein, The Netherlands

David H. Deaton, MD
Crownsville, Maryland

Erik E. Debing, MD, PhD
Brussels, Belgium

Sebastian E. Debus, MD, PhD
Hamburg, Germany

Michael J. Denton, FRACS
Melbourne, Australia

Ralph G. DePalma, MD
Washington, District of Columbia

Colin P. Derdeyn, MD
St. Louis, Missouri

Brian G. DeRubertis, MD
Los Angeles, California

Pascal Desgranges, MD, PhD
Creteil, France

David J. Dexter, MD
Norfolk, Virginia

Florian Dick, MD
Berne, Switzerland

Nicolas A. Diehm, MD
Aarau, Switzerland

Edward B. Diethrich, MD
Phoenix, Arizona

Alan M. Dietzek, MD, RPVI, FACS
Danbury, Connecticut

Konstantinos P. Donas, MD
Münster, Germany

Walter Dorigo, MD
Florence, Italy

Matthew J. Dougherty, MD
Philadelphia, Pennsylvania

David M. Dudzinski, MD
Boston, Massachusetts

FACULTY

E

- Matthew J. Eagleton, MD**
Cleveland, Ohio
- Hans-Henning Eckstein, MD, PhD**
Munich, Germany
- John F. Eidt, MD**
Greenville, South Carolina
- Bo G. Eklof, MD, PhD**
Helsingborg, Sweden
- Steve Elias, MD**
Englewood, New Jersey
- Eric Elster, MD**
Bethesda, Maryland
- Tod C. Engelhardt, MD**
New Orleans, Louisiana
- Ignacio Escotto, MD**
Mexico City, Mexico
- Mark K. Eskandari, MD**
Chicago, Illinois
- Anne M. Eskes, RN, PhD**
Amsterdam, The Netherlands
- Mohammad H. Eslami, MD, RVT**
Boston, Massachusetts

F

- Ronald M. Fairman, MD**
Philadelphia, Pennsylvania
- Fabrizio Fanelli, MD, EBIR**
Rome, Italy
- Mark A. Farber, MD**
Chapel Hill, North Carolina
- Peter L. Faries, MD, FACS**
New York, New York
- Ted Feldman, MD**
Evanston, Illinois
- Jose Fernandes e Fernandes, MD,**
PhD, FRCS (Eng), FACS
Lisbon, Portugal
- Roberto Ferraresi, MD**
Bergamo, Italy
- Marcelo Ferreira, MD**
Rio de Janeiro, Brazil
- Mark F. Fillinger, MD**
Lebanon, New Hampshire
- David Fiorella, MD**
Stony Brook, New York
- Eugene S. Flamm, MD**
Bronx, New York
- John P. Fletcher, MD**
Sydney, Australia
- Paul J. Foley III, MD**
Philadelphia, Pennsylvania
- Thomas L. Forbes, MD**
London, Ontario, Canada
- Charles J. Fox, MD, FACS**
Denver, Colorado
- David Fox, MD, FACS**
New York, New York
- Gustav Fraedrich, MD**
Innsbruck, Austria
- Ian J. Franklin, MS, FRCS (Gen. Surg.)**
London, United Kingdom
- Don Frei, MD**
Denver, Colorado
- Julie Ann Freischlag, MD**
Sacramento, California
- Wei Guo Fu, MD**
Shanghai, China
- John H. Furtek, BS, RT(r)**
Charleston, South Carolina

G

- Dennis R. Gable, MD, FACS**
Dallas, Texas
- Vivian Gahtan, MD**
Syracuse, New York
- Pierre Galvagni Silveira, MD, PhD**
Florianopolis, SC, Brazil
- Zsolt Garami, MD**
Houston, Texas
- Lawrence A. Garcia, MD**
Boston, Massachusetts
- Mark J. Garcia, MD**
Newark, Delaware
- Jean Luc Gerard, MD**
Creteil, France
- Gary Giangola, MD**
New Hyde Park, New York
- Athanasios D. Giannoukas, MSc,**
MD, PhD, FEBVS
Larissa, Greece
- Gary W. Gibbons, MD**
Weymouth, Massachusetts
- Richard G.J. Gibbs, FRCS**
London, United Kingdom
- Joseph S. Giglia, MD**
Cincinnati, Ohio
- David L. Gillespie, MD**
Fall River, Massachusetts
- Marc H. Glickman, MD**
Norfolk, Virginia
- Monika L. Gloviczki, MD, PhD**
Rochester, Minnesota
- Peter Gloviczki, MD**
Rochester, Minnesota
- Pierre Gobin, MD**
New York, New York
- Manj S. Gohel, MD, FRCS**
Cambridge, United Kingdom
- Jerry Goldstone, MD**
Cleveland, Ohio
- R. Gilberto Gonzalez, MD, PhD**
Boston, Massachusetts
- Philip P. Goodney, MD, MS**
Lebanon, New Hampshire
- David Gordon, MD**
Bronx, New York
- Peter C.J. Goverde, MD**
Antwerp, Belgium
- Mayank Goyal, MD, FRCPC**
Calgary, Alberta, Canada
- Alan M. Graham, MD**
Upland, Pennsylvania
- William A. Gray, MD**
New York, New York
- Roger M. Greenhalgh, MD**
London, United Kingdom
- Franco Grego, MD**
Padua, Italy
- Marcelo Guimaraes, MD**
Charleston, South Carolina

H

- John (Jeb) W. Hallett, MD**
Charleston, South Carolina
- Alison Halliday, MS, FRCS**
Oxford, United Kingdom
- Mo S. Hamady, MD, FRCR, EBIR**
London, United Kingdom

FACULTY

George Hamilton, MD
London, United Kingdom

Ziv J. Haskal, MD, FACR, FAHA, FSIR
Charlottesville, Virginia

Stephan Haulon, MD
Lille, France

Kem Hawkins, MBA
Bloomington, Indiana

Peter Henke, MD
Ann Arbor, Michigan

Mitchell L. Henry, MD
Columbus, Ohio

Jan M.M. Heyligers, MD, PhD, FEBVS
Tilburg, The Netherlands

Michael D. Hill, MD
Calgary, Alberta, Canada

Robert J. Hinchliffe, MD
London, United Kingdom

Anil P. Hingorani, MD
Brooklyn, New York

Joshua A. Hirsch, MD
Boston, Massachusetts

Kim J. Hodgson, MD
Springfield, Illinois

Andrew Holden, MBChB
Auckland, New Zealand

Larry H. Hollier, MD
New Orleans, Louisiana

L. Nelson Hopkins, MD
Buffalo, New York

Brian R. Hopkinson, ChM, FRCS
Nottingham, United Kingdom

Emmanuel M. Houdart, MD
Paris, France

Karl A. Illig, MD
Tampa, Florida

Jeffrey Indes, MD
New Haven, Connecticut

Luigi Inglese, MD
Milan, Italy

Krassi Ivancev, MD, PhD
London, United Kingdom

Benjamin M. Jackson, MD
Philadelphia, Pennsylvania

Glenn Jacobowitz, MD
New York, New York

Michael J. Jacobs, MD
Maastricht, The Netherlands

Michael R. Jaff, DO
Boston, Massachusetts

Edward C. Jauch, MD, MS
Charleston, South Carolina

**Michael P. Jenkins, MBBS, BSc, MS,
FRCS, FEBVS**
London, United Kingdom

William Jennings, MD
Tulsa, Oklahoma

James W. Jones, MD, PhD, MHA
Houston, Texas

Randolph Todd C. Jones III, MD
New York, New York

William D. Jordan, Jr., MD
Birmingham, Alabama

K

**Lowell S. Kabnick, MD, RPhS,
FACS, FACPh**

New York, New York

Christopher Kabrhel, MD, MPH

Boston, Massachusetts

Susan R. Kahn, MD, MSc

Montreal, Canada

Johannes Kalder, MD

Aachen, Germany

Manju Kalra, MBBS

Rochester, Minnesota

Paul H.L. Kao, MD

Taipei, Taiwan

Vikram S. Kashyap, MD

Cleveland, Ohio

Karthikeshwar Kasirajan, MD

Blackhawk, California

Piotr M. Kasprzak, MD

Regensburg, Germany

**Konstantinos Katsanos, MSc, MD,
PhD, EBIR**

London, United Kingdom

Athanasios Katsargyris, MD

Nuremberg, Germany

Steven G. Katz, MD

Pasadena, California

Barry T. Katzen, MD

Miami, Florida

John A. Kaufman, MD

Portland, Oregon

Patrick W. Kelly, MD

Sioux Falls, South Dakota

K. Craig Kent, MD

Madison, Wisconsin

Neil M. Khilnani, MD

New York, New York

Ali Khojenezhad, MD, PhD

Los Angeles, California

Tilo Koelbel, MD, PhD

Hamburg, Germany

Mark J.W. Koelemay, MD, PhD

Amsterdam, The Netherlands

Raghu Kolluri, MD

Columbus, Ohio

Ralf R. Kolvenbach, MD

Duesseldorf, Germany

Olivier H.J. Koning, MD

's-Hertogenbosch, The Netherlands

Walter Koroshetz, MD

Bethesda, Maryland

Dietmar H. Koschyk, MD

Hamburg, Germany

Larry W. Kraiss, MD

Salt Lake City, Utah

Zvonimir Krajcer, MD, FACC

Houston, Texas

Albrecht H. Krämer, MD

Santiago, Chile

Hans Krankenberg, MD

Bad Bevensen, Germany

Timothy F. Kresowik, MD

Iowa City, Iowa

Boonprasit Kritpracha, MD

Hat Yai, Songkhla, Thailand

Mariana Krutman, MD

São Paulo, Brazil

Toru Kuratani, MD, PhD

Osaka, Japan

Christopher J. Kwolek, MD

Boston, Massachusetts

FACULTY

L

- Daniel L. Labovitz, MD**
Bronx, New York
- Mario Lachat, MD**
Zurich, Switzerland
- John R. Laird, MD**
Sacramento, California
- Brajesh K. Lal, MD**
Baltimore, Maryland
- Johannes Lammer, MD**
Vienna, Austria
- Patrick J. Lamparello, MD**
New York, New York
- Glenn M. LaMuraglia, MD**
Boston, Massachusetts
- Gregg S. Landis, MD**
New Hyde Park, New York
- Werner Lang, MD**
Erlangen, Germany
- David J. Langer, MD**
New York, New York
- Kamphol Laohapensang, MD**
Chiang Mai, Thailand
- Thomas Larzon, MD, PhD**
Örebro, Sweden
- Peter F. Lawrence, MD**
Los Angeles, California
- Jeffrey H. Lawson, MD, PhD**
Durham, North Carolina
- Frank A. Lederle, MD**
Minneapolis, Minnesota
- Byung-Boong Lee, MD**
Washington, District of Columbia
- Jason T. Lee, MD**
Stanford, California
- Luis R. Leon, MD, RVT, FACS**
Tucson, Arizona
- Christos D. Liapis, MD**
Athens, Greece
- David S. Liebeskind, MD**
Los Angeles, California
- Timothy K. Liem, MD**
Portland, Oregon
- Francesco Liistro, MD**
Arezzo, Italy
- Jes S. Lindholt, MD**
Odense, Denmark
- Evan C. Lipsitz, MD**
New York, New York
- Armando C. Lobato, MD, PhD**
São Paulo, Brazil
- Melvin D. Lobo, MBChB, PhD, FRCP**
London, United Kingdom
- Ian Loftus, MD**
London, United Kingdom
- Joann Lohr, MD**
Cincinnati, Ohio
- Charmaine Lok, MD**
Toronto, Ontario, Canada
- Joseph V. Lombardi, MD**
Camden, New Jersey
- Alberto Lomeo, MD**
Catania, Italy
- Lars B. Lönn, MD, PhD**
Copenhagen, Denmark
- Robert A. Lookstein, MD, FSIR, FAHA**
New York, New York
- Qingsheng Lu, MD**
Shanghai, China

- Marzia Lugli, MD**
Modena, Italy
- Alan B. Lumsden, MD, FACS**
Houston, Texas
- Fedor Lurie, MD, PhD**
Toledo, Ohio
- Sean P. Lyden, MD**
Cleveland, Ohio

M

- Sumaira Macdonald, MBChB (Comm), FRCP, FRCR, PhD**
Sunnyvale, California
- Lindsay Machan, MD**
Vancouver, British Columbia, Canada
- Edward G. Mackay, MD**
St. Petersburg, Florida
- Robyn A. Macsata, MD**
Washington, District of Columbia
- Michel Makaroun, MD**
Pittsburgh, Pennsylvania
- Mahmoud B. Malas, MD, MHS**
Baltimore, Maryland
- Thomas S. Maldonado, MD**
New York, New York
- Martin Malina, MD, PhD**
Malmö, Sweden
- Nicola Mangialardi, MD**
Rome, Italy
- Marco G. Manzi, MD**
Vicenza, Italy
- Giustino Marcucci, MD**
Civitavecchia, Rome
- Michael L. Marin, MD**
New York, New York
- Natalie A. Marks, MD, RVT, RPVI**
Brooklyn, New York
- Enrico M. Marone, MD**
Milan, Italy
- William A. Marston, MD**
Chapel Hill, North Carolina
- Tara M. Mastracci, MD**
Cleveland, Ohio
- Elna M. Masuda, MD**
Honolulu, Hawaii
- Klaus D. Mathias, MD**
Hamburg, Germany
- Jon S. Matsumura, MD**
Madison, Wisconsin
- James May, MD, MS, FRACS, FACS**
Sydney, Australia
- Dieter O. Mayer, MD**
Zurich, Switzerland
- James F. McKinsey, MD**
New York, New York
- Robert B. McLafferty, MD**
Portland, Oregon
- David McLain, FEBVS**
Newport, Wales, United Kingdom
- Richard G. McWilliams, FRCR, EBIR**
Liverpool, United Kingdom
- Mollie Meek, MD**
Little Rock, Arkansas
- Barend M.E. Mees, MD, PhD**
Maastricht, The Netherlands
- Manish Mehta, MD, MPH**
Albany, New York
- George H. Meier III, MD**
Cincinnati, Ohio
- Mark H. Meissner, MD**
Seattle, Washington

FACULTY

Germano Melissano, MD

Milano, Italy

Matthew W. Mell, MD, MS

Stanford, California

**Geno J. Merli, MD, MACP, FHM,
FSVM**

Philadelphia, Pennsylvania

D. Christopher Metzger, MD

Kingsport, Tennessee

Philip M. Meyers, MD

New York, New York

Mark W. Mewissen, MD

Milwaukee, Wisconsin

Claude Mialhe, MD

Monaco

Charles C. Miller, PhD

Houston, Texas

Gregg A. Miller, MD

Brooklyn, New York

Todd S. Miller, MD

Bronx, New York

Joseph L. Mills, MD

Tucson, Arizona

Ross Milner, MD

Chicago, Illinois

Erich Minar, MD

Vienna, Austria

David J. Minion, MD

Lexington, Kentucky

J. Mocco, MD, MS

Nashville, Tennessee

**Irwin V. Mohan, MBBS, MD, FRCS,
FEBVS, FRACS**

Sydney, Australia

Frans L. Moll, MD, PhD

Utrecht, The Netherlands

Gregory L. Moneta, MD

Portland, Oregon

Samuel R. Money, MD, MBA

Scottsdale, Arizona

Miguel F. Montero-Baker, MD

Tucson, Arizona

Wesley S. Moore, MD

Los Angeles, California

Robert A. Morgan, MD

London, United Kingdom

Christopher J. Morin, MD

Denver, Colorado

Lee M. Morin, MD, PhD

Houston Texas

Nicholas J. Morrissey, MD

New York, New York

Peter J. Mossop, MBBS

*Melbourne, Australia and
Vancouver, British Columbia*

Albeir Y. Mousa, MD

Charleston, West Virginia

Patrick E. Muck, MD, FACS

Cincinnati, Ohio

Stefan Müller-Hülsbeck, MD

Flensburg, Germany

Bart E. Muhs, MD, PhD

New Haven, Connecticut

Dipankar Mukherjee, MD

Falls Church, Virginia

Firas F. Mussa, MD

New York, New York

Jihad A. Mustapha, MD

Wyoming, Michigan

**Pramook Mutirangura, FRCS
(Edinburgh) Bangkok, Thailand**

B. Patrice Mwapatayi, FRACS

Perth, Western Australia

N

Ross Naylor, MD, FRCS

Leicester, United Kingdom

Peter K. Nelson, MD

New York, New York

Richard F. Neville, MD

Washington, District of Columbia

Andrew N. Nicolaidis, MS

Nicosia, Cyprus

Christoph A. Nienaber, MD, PhD

Rostock, Germany

Sigrid Nikol, MD

Hamburg, Germany

Samy S. Nitecki, MD

Haiifa, Israel

Raul G. Nogueira, MD

Atlanta, Georgia

Katariina M. Noronen, MD

Helsinki, Finland

Furuzan Numan, MD

Istanbul, Turkey

O

Thomas F. O'Donnell, Jr., MD

Boston, Massachusetts

Gerard J. O'Sullivan, MD

Galway, Ireland

Alfred M. Obermayer, MD

Vienna, Austria

Gustavo S. Oderich, MD, FACS

Rochester, Minnesota

Jeffrey W. Olin, DO

New York, New York

Karl H. Orend, MD

Ulm, Germany

John W. Osborn, PhD

Minneapolis, Minnesota

Kenneth Ouriel, MD, MBA

New York, New York

Christopher D. Owens, MD

San Francisco, California

P

Jean M. Panneton, MD

Norfolk, Virginia

Peter J. Pappas, MD

Brooklyn, New York

Rajiv Parakh, MBBS, MS, FRCS

Gurgaon, India

Kosmas I. Paraskevas, MD

Sheffield, United Kingdom

Juan C. Parodi, MD

Buenos Aires, Argentina

Marc A. Passman, MD

Birmingham, Alabama

Aman B. Patel, MD

New York, New York

Patrick Peeters, MD

Bonheiden, Belgium

Constantino Pena, MD

Miami, Florida

Bruce A. Perler, MD, MBA

Baltimore, Maryland

Ivo Petrov, MD, PhD

Sofia, Bulgaria

Gregory Piazza, MD, MS

Boston, Massachusetts

Paul Pittaluga, MD

Monte-Carlo, Monaco

FACULTY

Don Poldermans, MD
Spijkennisse, The Netherlands

Frank B. Pomposelli, MD
Boston, Massachusetts

Janet T. Powell, MD, PhD
London, United Kingdom

Richard J. Powell, MD
Lebanon, New Hampshire

Giovanni Pratesi, MD
Rome, Italy

Hillel Presser, Esq., MBA
Deerfield Beach, Florida

Calogero Presti, MD
São Paulo, Brazil

Ourania Preventza, MD
Houston, Texas

Barrie A. Price, Mr, MD, MS, FRCS
Guildford, England

Robert Provenzano, MD
Detroit, Michigan

Q

William J. Quinones-Baldrich, MD
Los Angeles, California

R

Claudio Rabbia, MD
Torino, Italy

Joseph D. Raffetto, MD
West Roxbury, Massachusetts

Dieter Raithel, MD, PhD
Nuremberg, Germany

Seshadri Raju, MD
Jackson, Mississippi

Zoran Rancic, MD, PhD
Zurich, Switzerland

Hisham Rashid, FRCS, FRCS(Gen)
London, United Kingdom

Peter A. Rasmussen, MD
Cleveland, Ohio

Todd E. Rasmussen, MD, FACS
Fort Detrick, Maryland

John E. Rectenwald, MD, MS
Ann Arbor, Michigan

Amy B. Reed, MD
Hershey, Pennsylvania

Donald B. Reid, MD
Wishaw, Scotland

Michel M.P. Reijnen, MD, PhD
Arnhem, The Netherlands

Erno Remsey-Semmelweis, MD, PhD
Marburg, Germany

Timothy A. Resch, MD, PhD
Malmö, Sweden

Vicente Riambau, MD, PhD
Barcelona, Spain

Jean-Baptiste Ricco, MD, PhD
Poitiers, France

Thierry Richard, MD
Paris, France

Götz M. Richter, MD, PhD
Stuttgart, Germany

John J. Ricotta, MD
Washington, District of Columbia

Joseph J. Ricotta II, MD, MS
Atlanta, Georgia

Howard A. Riina, MD
New York, New York

Thomas S. Riles, MD
New York, New York

Eduardo F. Rocha, MD
Sorocaba, São Paulo, Brazil

Krishna J. Rocha-Singh, MD
Springfield, Illinois

Caron B. Rockman, MD
New York, New York

Sean P. Roddy, MD
Albany, New York

Julio A. Rodriguez-Lopez, MD
Phoenix, Arizona

Lee C. Rogers, DPM
Los Angeles, California

Marco Romanelli, MD, PhD
Pisa, Italy

Sonia Ronchey, MD, PhD
Rome, Italy

Eric E. Roselli, MD
Cleveland, Ohio

Robert J. Rosen, MD
New York, New York

Melvin Rosenblatt, MD
Fairfield, Connecticut

Kenneth Rosenfield, MD
Boston, Massachusetts

David Rosenthal, MD
Atlanta, Georgia

John R. Ross, Sr., MD
Orangeburg, South Carolina

Howard A. Rowley, MD
Madison, Wisconsin

Prabir Roy-Chaudhury, MD, PhD
Cincinnati, Ohio

Steven H. Rudolph, MD
Brooklyn, New York

Maria Antonella Ruffino, MD
Torino, Italy

John H. Rundback, MD, FSIR, FAHA
Teaneck, New Jersey

S

Theodore F. Saad, MD
Newark, Delaware

Carlos Saadeh, MD, FRCSC, FACS
Beirut, Lebanon

Mikel Sadek, MD
New York, New York

Hazim J. Safi, MD
Houston, Texas

Natzi Sakalihasan, MD, PhD
Sart Tilman, Liege, Belgium

Clifford M. Sales, MD, MBA
Summit, New Jersey

Jason T. Salsamendi, MD
Miami, Florida

Peter Samek, MD, PhD
Slovakia, Europe

Russell H. Samson, MD, RVT, FACS
Sarasota, Florida

Luis A. Sanchez, MD
St. Louis, Missouri

Pina C. Sanelli, MD, MPH, FACR
New York, New York

Timur P. Sarac, MD
New Haven, Connecticut

Sudhakar R. Satti, MD
Newark, Delaware

Andres Schanzer, MD
Worcester, Massachusetts

Dierk Scheinert, MD
Leipzig, Germany

FACULTY

Larry A. Scher, MD

Bronx, New York

Marc L. Schermerhorn, MD

Boston, Massachusetts

A. Frederick Schild, MD

Miami, Florida

Jürg Schmidli, MD

Berne, Switzerland

Andrej Schmidt, MD

Leipzig, Germany

Darren B. Schneider, MD

New York, New York

Peter A. Schneider, MD

Honolulu, Hawaii

Claudio J. Schonholz, MD

Charleston, South Carolina

Torben V. Schroeder, MD, DMSc

Copenhagen, Denmark

Geert Willem H. Schurink, MD, PhD

Maastricht, The Netherlands

Bernard J. Segers, MD

Brussels, Belgium

Carlo Setacci, MD

Siena, Italy

Francesco Setacci, MD

Rome, Italy

Murray L. Shames, MD

Tampa, Florida

Palma M. Shaw, MD

Syracuse, New York

David Shemesh, MD, RVT

Jerusalem, Israel

Surendra Shenoy, MD, PhD

St. Louis, Missouri

**Mehdi H. Shishebor, DO, MPH,
PhD**

Cleveland, Ohio

Cynthia K. Shortell, MD

Durham, North Carolina

Chang Shu, MD

ChangSha, Hunan Province, China

R. Gary Sibbald, MD

Toronto, Canada

Anton N. Sidawy, MD, MPH

Washington, District of Columbia

Horst Sievert, MD

Frankfurt, Germany

Henrik Sillesen, MD, DMSc

Copenhagen, Denmark

Michael B. Silva, Jr., MD

Galveston, Texas

Niten Singh, MD

Seattle, Washington

Tej M. Singh, MD, MBA

Palo Alto, California

Björn Sonesson, MD, PhD

Malmö, Sweden

Thomas A. Sos, MD

New York, New York

J. David Spence, MD

London, Canada

E. Brooke Spencer, MD

Denver, Colorado

Lawrence M. Spergel, MD

San Francisco, California

Francesco Spinelli, MD

Rome, Italy

James C. Stanley, MD

Ann Arbor, Michigan

Benjamin W. Starnes, MD

Seattle, Washington

Barry Stein, MD, FSIR, FACR

Hartford, Connecticut

W. Charles Sternbergh III, MD

New Orleans, Louisiana

Scott L. Stevens, MD

Knoxville, Tennessee

Gregg W. Stone, MD

New York, New York

Patrick A. Stone, MD

Charleston, West Virginia

Michael C. Stoner, MD

Rochester, New York

Julianne Stoughton, MD, FACS

Boston, Massachusetts

Timothy M. Sullivan, MD

Minneapolis, Minnesota

**Sherif Sultan, MD, FRCS, EBQS-
VASC**

Galway, Ireland

Bauer E. Sumpio, MD, PhD

New Haven, Connecticut

Thoralf Sundt, MD

Boston, Massachusetts

Gabriel Szendro, MD

Beer Sheva, Israel

T

Gunnar Tepe, MD

Rosenheim, Germany

Matt M. Thompson, MD

London, United Kingdom

Carlos H. Timaran, MD

Dallas, Texas

Giovanni Torsello, MD

Münster, Germany

**Ramesh K. Tripathi, MD, FRCS,
FRACS**

Bangalore, India

Yamume Tshomba, MD

Milan, Italy

Aquilla S. Turk, DO

Charleston, South Carolina

U

Jean Francois Uhl, MD, FACPh

Paris, France

V

Claude D. Vaislic, MD

Le Plessis Roninson, France

**Domenico Valenti, DMChir, PhD,
FRCS, FRCS(Ed), FEBVS**

London, United Kingdom

S. Rao Vallabhaneni, MD, FRCS

Liverpool, United Kingdom

Jos C. van den Berg, MD, PhD

Lugano, Switzerland

Isabelle van Herzeele, MD, PhD

Ghent, Belgium

Marc R.H.M. van Sambeek, MD, PhD

Eindhoven, The Netherlands

Suresh Vedantham, MD

St. Louis, Missouri

Frank J. Veith, MD

Cleveland, Ohio and

New York, New York

Hence J.M. Verhagen, MD, PhD

Rotterdam, The Netherlands

Eric L.G. Verhoeven, MD, PhD

Nuremberg, Germany

FACULTY

Frank E.G. Vermassen, MD, PhD
Ghent, Belgium

Hester Vermeulen, PhD
Amsterdam, The Netherlands

Fabio Verzini, MD, PhD
Perugia, Italy

J. Leonel Villavicencio, MD
*Bethesda, Maryland and
Washington, District of Columbia*

Renu Virmani, MD
Washington, District of Columbia

Todd R. Vogel, MD, MPH
Columbia, Missouri

Robert L. Vogelzang, MD
Chicago, Illinois

Arno von Ristow, MD
Rio de Janeiro, Brazil

W

Thomas W. Wakefield, MD
Ann Arbor, Michigan

Ajay K. Wakhloo, MD, PhD
Worcester, Massachusetts

Ron Waksman, MD
Washington, District of Columbia

Craig M. Walker, MD
Houma, Louisiana

Milton Waner, MD
New York, New York

Jeffrey Y. Wang, MD
Rockville, Maryland

ShenMing Wang, MD, PhD
Guangzhou, China

Anders Wanhainen, MD, PhD
Uppsala, Sweden

**Haimanot (Monnie) Wasse, MD,
MPH, FASN**
Chicago, Illinois

Fred A. Weaver, MD
Los Angeles, California

Ido Weinberg, MD, MSc
Boston, Massachusetts

Michael Werk, MD
Berlin, Germany

Grayson H. Wheatley, MD
Philadelphia, Pennsylvania

Rodney A. White, MD
Los Angeles, California

Mark S. Whiteley, MS, FRCS
Guildford, United Kingdom

Mark H. Wholey, MD
Pittsburgh, Pennsylvania

Arno M. Wiersema, MD
Amsterdam, The Netherlands

David M. Williams, MD
Ann Arbor, Michigan

Mathew Williams, MD
New York, New York

Willem Wisselink, MD
Amsterdam, The Netherlands

Cees H.A. Wittens, MD, PhD
Maastricht, The Netherlands

Edward Y. Woo, MD
Washington, District of Columbia

Jack Work, MD
Atlanta, Georgia

Y

Wayne F. Yakes, MD
Englewood, Colorado

Kak Khee Yeung, MD, PhD
Amsterdam, The Netherlands

Yoshihiko Yokoi, MD
Tokyo, Japan

Z

Osama O. Zaidat, MD
Milwaukee, Wisconsin

Paolo Zamboni, MD
Ferrara, Italy

Christopher K. Zarins, MD
Stanford, California

Hany Zayed, MD
London, United Kingdom

Clark J. Zeebregts, MD, PhD
Groningen, The Netherlands

Max Zegelman, MD
Frankfurt, Germany

Thomas Zeller, MD
Bad Krozingen, Germany

Wayne W. Zhang, MD
Shreveport, Louisiana

Wei Zhou, MD
Stanford, California

Burkhardt Zipfel, MD, PhD
Berlin, Germany

Robert M. Zwolak, MD, PhD
Lebanon, New Hampshire

VEITHSYMPOSIUM ON DEMAND

www.veithondemand.com



VIEW THE
ENTIRE 2014
VEITHSYMPOSIUM
ONLINE

Purchase all the Talks, Slides, and Videos - fully synchronized - and all the Panels.

This Library or Components thereof can be used as an Educational Resource or Teaching Tool.

For more information on how to obtain the VEITHsymposium Online Library, please call 800-987-9314, ext. 300.

This activity has been approved for *AMA PRA Category 1 Credits™*.

REGISTRATION



Tuesday, November 18 – Saturday, November 22, 2014

NEW YORK HILTON - MIDTOWN
1335 Avenue Of The Americas | New York, NY 10019

Meeting Registration

(See Registration Form on reverse side)

Full Registration

Tuition

- Practicing Physicians \$1399
- Practicing Physicians Combination Rate
VEITHsymposium, AIMsymposium and
AVIDsymposium \$1899
- US and Canadian Vascular Surgery Fellows
In Training* Complimentary

US 2nd-Year Fellows in an RRC-approved 2-Year Vascular Fellowship **OR** 5th-Year Vascular Resident in an approved Vascular Surgery Residency as of November 2014, **AND** Canadian Vascular Surgery Fellows in Training (*Tuition is provided through an Educational Grant by W.L. Gore & Associates Inc.*) Letter of verification from Chief of Service must be obtained prior to registration and faxed to (888) 418-7043. The letter must include the start and end dates of Vascular Surgery Fellowship.

- Non-U.S. Fellows Nurse Practitioners
- Physician Assistants \$699
- Residents Nurses Technologists \$650
- Allied Health Care Professionals \$950

Saturday Only Components

Tuition includes access to any Saturday Only Component

- Saturday Only - Endovascular Treatment of Venous Disease \$349
- Saturday Only - Hemodialysis Access \$349
- Saturday Only - Complex Vascular Malformations and Vascular
Tumors: Current Controversies and Therapies \$349
- Saturday Only - WOUNDS \$349
- Saturday Only - WOUNDS (Nurses and Students only) \$149
- Saturday Only - WOUNDS (Residents only) \$199

Refund: There is a \$95 cancellation fee if canceled by October 17, 2014. No refunds will be made thereafter.

Online: <http://www.veithsymposium.org>

Phone: 800-987-9314, Ext. 200 or 718-549-3140 with your payment information.

Fax: the reverse form with your credit card payment to 888-418-7043

Mail: this form with your payment to:
The Cleveland Clinic Educational Foundation
Attn: VEITH 02010218
P.O. Box 931653
Cleveland, OH 44193-1082

Additional Information

VEITHsymposium
4455 Douglas Avenue, Suite 11E
Riverdale, New York 10471

Phone: 800-987-9314 or 718-549-3140

E-mail: registrar@veithsymposium.org or
admin@veithsymposium.org

REGISTRATION



Full Registration

Tuition

- Practicing Physicians \$1399
- Practicing Physicians Combination Rate
VEITHsymposium, AIMsymposium and
AVIDsymposium \$1899
- US and Canadian Vascular Surgery Fellows
In Training* Complimentary

US 2nd-Year Fellows in an RRC-approved 2-Year Vascular Fellowship **OR** 5th-Year Vascular Resident in an approved Vascular Surgery Residency as of November 2014, **AND** Canadian Vascular Surgery Fellows in Training (*Tuition is provided through an Educational Grant by W.L. Gore & Associates Inc.*) Letter of verification from Chief of Service must be obtained prior to registration and faxed to (888) 418-7043. The letter must include the start and end dates of Vascular Surgery Fellowship.

- Non-U.S. Fellows Nurse Practitioners
- Physician Assistants \$699
- Residents Nurses Technologists \$650
- Allied Health Care Professionals \$950

Saturday Only Components

Tuition includes access to any Saturday Only Component

- Saturday Only - Endovascular Treatment of Venous Disease \$349
- Saturday Only - Hemodialysis Access \$349
- Saturday Only - Complex Vascular Malformations and Vascular
Tumors: Current Controversies and Therapies \$349
- Saturday Only - WOUNDS \$349
- Saturday Only - WOUNDS (Nurses and Students only) \$149
- Saturday Only - WOUNDS (Residents only) \$199

First Name: _____

Last Name (Surname) _____

Degree: _____

Specialty: _____

Physician Non-Physician Cleveland Clinic Employee? Yes No

Affiliation: _____

Address Type: Home Other

Address: _____

City: _____ State/Province _____

Zip Code: _____ Country _____

E-mail: _____

(A valid registrant's e-mail address is required for confirmation and CME certificate.)

Phone: _____ Fax _____

Payment Method

Check: Please make checks payable to the Cleveland Clinic Educational Foundation and mail to:
The Cleveland Clinic Educational Foundation
Attn: VEITH 02010218
P.O. Box 931653
Cleveland, OH 44193-1082

Credit Card:

Name on Card: _____

Credit Card Number: _____

Verification Code (3-4 Digit Code on Credit Card): _____ Expiration Date _____

Zip Code: _____ Country _____

Signature: _____

VEITH SYMPOSIUM[®]
Connecting The **Vascular** Community

SAVE THE DATE

Tuesday – Saturday, November 17–21, 2015

VASCULAR ENDOVASCULAR ISSUES TECHNIQUES HORIZONS

Symposium Chairman
Frank J. Veith, MD

Symposium Co-Chairmen
Enrico Ascher, MD
Kenneth Ouriel, MD, MBA
Daniel G. Clair, MD

Sponsored by

 **Cleveland Clinic**


Hilton

www.VEITHsymposium.org



THE CLEVELAND CLINIC EDUCATIONAL FOUNDATION

PO BOX 931653
CLEVELAND, OH 44193-1082



Hilton

New York Hilton-Midtown

Tuesday - Saturday,
November 18 - 22, 2014

Translation to Spanish, Portuguese and Chinese will be available in selected sessions on selected days.

SATURDAY, NOVEMBER 22, 2014 COMPONENT MEETINGS

- Endovascular Treatment of Venous Disease • Hemodialysis Access
- WOUNDS • Complex Vascular Malformations and Vascular Tumors: Current Controversies and Therapies

NEW THIS YEAR

Associate Faculty Podium/Poster Presentations - ISVS, Latin America, Asia, Worldwide

VEITH SYMPOSIUM®

Connecting The Vascular Community
www.veithsymposium.org



Non-profit Org
US Postage

PAID

White Plains, NY
Permit No. 7033